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Abstract 
α-Carbonyl sulfoxonium ylides have recently been gaining attention as alternative 
reagents to α-diazoketones, in part due to the supposed superior safety profile and 
stability of sulfoxonium ylides. However, functionalisation of aryls and heteroaryls 
using sulfoxonium ylides without the help of a directing group has so far remained a 
neglected area. Following on from previous work in the Aїssa group1, this thesis will 
discuss the development of two novel reactions for the functionalisation of aryls and 
heteroaryls. The first reaction allows the synthesis of 2-indanones and does not require 
a metal catalyst. It appears to proceed via a five-centre, 4π electron electrocyclisation, 
with C-S bond cleavage being encouraged by the strong hydrogen bond donating 
ability of the solvent 1,1,1,3,3,3-hexafluoroisopropanol (HFIP). The second reaction 
allows the synthesis of pyrrolizinones and indolizinones from sulfoxonium ylides in 
the presence of an iridium catalyst. It appears to proceed via nucleophilic attack by the 
aromatic ring on an iridium carbene, followed by 1,2-migration and re-aromatisation. 
Significantly, each reaction is chemospecific for a certain class of substrates: phenyl 
rings and benzofurans will cyclise under the HFIP-mediated electrocyclisation, but not 
in the presence of the iridium catalyst. Pyrroles will cyclise in the presence of the 
iridium catalyst, but do not undergo the HFIP-mediated electrocyclisation. Indoles fall 
in between the two, depending on the nature of the substituent on nitrogen. 
 
1. Barday, M.; Janot, C.; Halcovitch, N. R.; Muir, J.; Aїssa, C. Cross Coupling 
of α-Carbonyl Sulfoxonium Ylides with C-H Bonds. Angew. Chem. Int. Ed. 
2017, 56, 13117-13121.  
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1.1 General Introduction to Sulfoxonium Ylides 
1.1.1 Dimethylsulfoxonium methylide 
The simplest sulfoxonium ylide is dimethylsulfoxonium methylide 1, which was first 
generated and used in 1962 by Corey and Chaykovski.1 This ylide could be generated 
by the deprotonation of trimethylsulfoxonium chloride 2 with sodium hydride, and 
subsequently, it could be used for the epoxidation of ketones (Scheme 1).  
 
 
Scheme 1: Epoxidation of ketones with 1 reported by Corey and Chaykovski. 
 
The method allowed access to numerous epoxides derived from aldehydes and ketones 
in moderate to excellent yields. However, α,β-unsaturated ketones tended to undergo 
cyclopropanation, rather than epoxidation. In 2008, the scope of this reaction was 
expanded by Shibasaki and co-workers to include access to chiral expoxides (Scheme 
2)2. The reaction proceeded with a good level of enantioselectivity if both the chiral 
lanthanide catalyst and the phosphine oxide were present.  
 
 
Scheme 2: Shibasaki’s enantioselective epoxidation of ketone 3 using chiral 
lanthanum catalyst 5 
 
Although ylide 1 has been used in a variety of other reactions, including 
cyclopropanation,3,4,5 and ring expansion of epoxides6,7 and oxetanes6 and aziridines8, 
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it has recently been more commonly used for the synthesis of more complex 
sulfoxonium ylides. This is largely accomplished by treatment of a suspension of 1 
with an activated carboxylic acid or ester. For example, the process chemistry group 
at Bristol-Meyers Squibb (BMS) needed to synthesise chiral α-amino epoxides 6 
(Scheme 3),9,10 which are intermediates in the synthesis of HIV protease inhibitors. 
These can be accessed via reduction and ring closure of the corresponding α-
chloroketone 7. Traditionally, these have been made by hydrolysis of corresponding 
diazoketones 8, however due to safety concerns about large scale synthesis of such 
compounds, they decided to make the corresponding sulfoxonium ylides (e.g. 11) 
instead. These can be made from nitrophenyl esters such as 10, and 11 was synthesised 
in 99% yield and without loss of stereochemical integrity. The stereogenic centre was 
also maintained in the conversion of ylide 11 into α-chloroketone 12. 
 
  
Scheme 3: The synthesis of α-chloroketone 12 through the acid hydrolysis of 
sulfoxonium ylides 11. 
 
Other carboxylic acid derivatives, including acid chlorides11 and methyl esters9, and 
isocyanates12 have been used to synthesise sulfoxonium ylides by addition of the 
respective reagent to a suspension of 1 in THF at 0 oC (Scheme 4). Although in some 
instances, methyl and ethyl esters can be used to synthesise sulfoxonium ylides , 4-
nitrophenyl esters remain the most reliable precursors.10 Moreover, cyclic 
sulfoxonium ylides such as 20 can be accessed via rhodium catalysed cyclisation of 
diazosulfoxides.13  
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Scheme 4: The use of acid chlorides, methyl esters, isocyanates and sulfoxides to 
synthesise sulfoxonium ylides. 
 
Heteroaromatic rings that are prone to undergo nucleophilic aromatic substitution can 
also be used to generate bis-substituted sulfoxonium ylides.14 For example, 2-
chloropyrimidine 20 underwent nucleophilic attack by 1 to make sulfoxonium ylide 
21, which could then be further functionalised by treatment with other electrophiles 
such as phenyl isocyanate or acetyl chloride (Scheme 5). Other notable examples of 
the synthesis of bis-substituted sulfoxonium ylides include Burtoloso’s 2018 report on 
the coupling of sulfoxonium ylides with arynes,11 Aissa’s 2019 report on the 
palladium-catalysed cross coupling of sulfoxonium ylides with aryl bromides15 and 
Vaitla’s 2017 report on the synthesis of sulfoxonium ylides via in situ generated 
iodonium ylides16 (Scheme 6).  
 
N
N
Cl
1, 2 equiv
THF, rt N
N
S
O
21 2270%
AcCl (0.5 equiv)
or
PhNCO (1 equiv)
1,4-dioxane, 0 oC-rt
N
N
S
O
R
R = Ac, 23, 73%
R = NH(CO)Ph, 24, 95%  
Scheme 5: Synthesis of sulfoxonium ylides 22 and 23 from 2-chloropyrimidine 21 
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O
S
O
24
1 equiv
+
TMS
TfO
25
1.5 equiv
CsF (4 equiv)
MS (4 A)
MeCN (0.13 M)
65 oC, 3 h
O
S
O
26
70%
Br CN +
EtO
O
S
O
27
1 equiv
28
2.5 equiv
Pd(PPh3)4 (10 mol%)
Cs2CO3 (1.1 equiv)
MeCN (0.1 M)
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EtO
O
S
O
CN
29
90%
O
OEt
O
PhI(OAc)2 (1.2 equiv)
Rh2(OAc)4 (2 mol%)
MgO (2 equiv)
DMSO (0.5 M)
100 oC, MW, 5 min
30
1 equiv
O
OEt
O
S
O
31
76%  
Scheme 6: Top: Burtoloso’s coupling of sulfoxonium ylides and arynes. Middle: 
Aissa’s palladium catalysed cross coupling between aryl bromides and sulfoxonium 
ylides. Bottom: Vaitla’s synthesis of sulfoxonium ylides via in situ generated 
iodonium ylides. MS = Molecular sieves 
 
1.1.2 Applications of Complex Sulfoxonium Ylides 
1.1.2.1 Metal Free Reactions 
1.1.2.1.1 Hydrolysis 
Complex sulfoxonium ylides have been used in various metal and non-metal catalysed 
reactions. Perhaps the simplest non-metal catalysed process is hydrolysis, and one 
example of this was described in the previous section (Scheme 3).9 In 1965, Metzger 
and Konig also used acid hydrolysis of sulfoxonium ylide 18 to generate α-chloro 
amide 32 in nearly quantitative yield (Scheme 7).12  
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Scheme 7: Acid hydrolysis of 18 to give α-chloroamide 32 
 
1.1.2.1.2 S-H Insertion 
Metzger and Konig also showed that sulfoxonium ylides coud undergo S-H insertion 
for the synthesis of  β-keto thioethers. In 2016, Burtoloso and co-workers re-visited 
this earlier work, and showed that sulfoxonium ylides such as 24 were able to undergo 
S-H insertion for the synthesis of β-keto thioethers 26 (Scheme 8).17 They found that 
a range of aromatic thiols were able to undergo the reaction the smoothly, without any 
additional additive, or a metal catalyst. The reaction was also selective for the thiol 
group, as when the thiol contained other nucleophilic groups, such as -OH, -NH2, or -
CO2H, only the thioether could be detected (Scheme 8, top). However, when an alkyl 
thiol was used, no reaction took place. The authors reasoned that this was because 
protonation of the ylide plays an important role in the mechanism of the reaction, with 
aromatic thiols (pKa ~10 in DMSO) being more acidic than alkyl thiols (pKa ~17 in 
DMSO). The addition of diphenyl phosphate 34 as an organocatalyst proved to be 
sufficient to protonate the ylide and allow the reaction to take place in good yield 
(Scheme 8, bottom). 
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Scheme 8: Top: Synthesis of β-keto thioethers 33 from sulfoxonium ylide 24 and aryl 
thiols. Bottom: Synthesis of β-keto thioethers 35 from 24 and alkyl thiols catalysed by 
phosphate 34. 
 
Burtoloso’s group also showed that di-functionalisation of sulfoxonium ylides is 
possible,18 again building on the earlier work by Metzger and Konig. Simply by 
treating sulfoxonium ylides such as 24 with an alkyl halide, Burtoloso and co-workers 
were able to synthesise α-alkyl-α-haloketones in one step, avoiding enolate chemistry 
and the use of reactive reagents such as Br2 or NBS (Scheme 9). The method also 
provided an easy way to access α,α-dihaloketones by replacing the alkyl iodide with 
an “X+” source (Selectfluor, NBS) and a “Y-“ source (NaI, NaBr, TBAC), thus 
providing access to dihaloketones in one step in moderate to good yield (Scheme 9).  
 
 
Scheme 9: Difunctionalisation of sulfoxonium ylide 24. NBS = N-bromosuccinimide. 
TBAC = Tetrabutylammonium bromide 
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1.1.2.2 Metal Catalysed Reactions 
1.1.2.2.1 Carbon-Heteroatom Bond Formation 
Sulfoxonium ylides have also been used in metal catalysed reactions. The first such 
report was by Baldwin in 1993,19 who reported the metal catalysed intramolecular N-
H insertion of sulfoxonium ylide 38 for the synthesis of 3-oxopyrrolidine 39 (Scheme 
10). They found that rhodium (II) trifluoroacetate was the best catalyst for this 
reaction, and although rhodium (II) acetate also promoted the reaction in reasonable 
yield, a variety of copper catalysts were completely inactive, or led to uncontrolled 
decomposition of the sulfoxonium ylide. 
 
 
Scheme 10: Metal catalysed intramolecular N-H insertion of sulfoxonium ylide 38 to 
give 3-oxopyrrolidine 39. 
 
This type of reactivity suggested the presence of a carbene intermediate, and later on, 
Mangion and co-workers at Merck re-visited this work and decided to develop a more 
general method for inter- and intramolecular X-H insertion reaction of sulfoxonium 
ylides (X = O, NH, NR, S, Scheme 11)20. A screening of possible catalysts showed 
that [Ir(cod)Cl]2 was a better catalyst for this reaction than either of the rhodium (II) 
catalysts reported by Baldwin for the intramolecular N-H insertion (Scheme 11).  
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Scheme 11: Ir catalysed intermolecular X-H (X = O, N, S) insertion reaction of 
sulfoxonium ylide 40. a: At 70 oC in 1,2-DCE. b: Conducted at 35 oC with EtOH as 
solvent. 
 
The iridium catalysed reaction worked well at room temperature for primary amines 
(Scheme 11, entry 1), however, when secondary amines were used, the temperature 
had to be increased to 70 oC and the solvent thus changed to 1,2-DCE (entry 2). O-H 
insertion could also be carried out if the alcohol was used as the solvent (entry 3), and 
S-H insertion was carried out in good yield (entry 4). Mangion also found that 
sulfoxonium ylides such as 41 could undergo intramolecular iridium catalysed N-H 
insertion, giving access to cyclic 3-oxo amines such as 42 (Scheme 12). 
 
 
Scheme 12: Ir catalysed intramolecular N-H insertion of 41 to give cyclic 3-oxo 
amine 42 
 
A year later, the same authors reported21 a gold (I) catalysed X-H insertion reaction of 
sulfoxonium ylides. In conducting further catalyst screening, the authors found that 
AuCl(SMe2) provided a minor improvement in the yield as compared to the previously 
reported reaction with [Ir(cod)Cl]2 (table 1, entry 1 vs entry 2). They also discovered 
that a variety of platinum (II) and gold (III) catalysts were able to efficiently carry out 
the reaction, though with a lower yield of product as compared to the gold (I) complex 
 Page | 10  
 
(table 1, entries 3 and 4 vs entry 1). A silver (I) salt was also examined, but it proved 
to be significantly less active than AuCl(SMe2).  
 
 
Table 1 
 
The gold (I) catalyst provided an improvement to the scope of the intermolecular X-
H insertion reaction with respect to both sulfoxonium ylide and nucleophile, being 
efficient for the reaction of both bis-substituted sulfoxonium ylides such as 40 and 
carrying out the X-H insertion reaction of a variety of sulfoxonium ylides derived from 
protected amino acids such as 11, derived from Boc-protected phenylalanine (Scheme 
13).  
 
 
Scheme 13: Gold (I) catalysed N-H insertion of aniline 44 into ylide 11. 
 
Sulfoxonium ylide 11 was synthesised following the method described by Nugent9 
without loss of stereochemical integrity, and were able to undergo N-H and O-H 
insertion, again without loss of stereochemical integrity, for example with electron 
deficient aniline 44. Interestingly, AuCl(SMe2) proved to be far inferior than 
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[Ir(cod)Cl]2 as a catalyst in the intramolecular N-H insertion (Scheme 14), perhaps 
because carbamates are much poorer nucleophiles than anilines or alcohols. 
 
 
Scheme 14: Comparison between [Ir(cod)Cl]2 and AuCl(SMe2) for the intramolecular 
N-H insertion of sulfoxonium ylide 41. 
 
The previous two methods developed by Merck were able to be applied in the large-
scale manufacture of two candidate drug molecules, MK724622 and MK765523. The 
synthesis of MK7246 (Scheme 15), a treatment for asthma, required the synthesis of 
ketone 48. They decided to make this compound from sulfoxonium ylide 47, which 
was synthesised by treating diester 46 with dimethylsulfoxonium methylide 1. An 
iridium catalysed intramolecular N-H insertion reaction then followed, which 
proceeded smoothly in 86% yield. Gratifyingly, this reaction proved to be significantly 
higher yielding than an alternative rhodium catalysed N-H insertion of diazoketone 
49, which was used during earlier development of MK724624 (Scheme 15, bottom). 
Significantly, they were able to carry out the sulfoxonium ylide process on more than 
100 kg of starting material. The sulfoxonium ylide process was therefore favoured 
over the N-H insertion reaction involving 49 due to the higher yield, and significant 
safety concerns over the large scale synthesis and storage of 49. 
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Scheme 15: Large scale synthesis of MK-7246 using an Ir catalysed intramolecular 
N-H insertion of sulfoxonium ylide 44 
 
In 2018, Hopmann and co-workers published25 an iron catalysed reaction between 
vinyl sulfoxonium ylides such as 51 and substituted pyridines such as 52.  This 
reaction uses the simple iron (II) salt, FeBr2, and can be used for the synthesis of 
indolizines  such as 53 (Scheme 16). 
 
 
Scheme 16: Synthesis of indolizinone 53 from 51 and 52. 
 
When vinyl sulfoxonium ylides such as 51 was treated with FeBr2 in the presence of 
a pyridine, for example 52, indolizidine 53 was synthesised in 72% yield. In this case, 
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a sterically hindered 2-substituted pyridine was very well tolerated. The reaction was 
also able to tolerate electron deficient and electron rich aromatic rings well. In order 
to elucidate the mechanism of this reaction, DFT calculations suggested that the active 
catalyst is a complex between pyridine and FeBr2, which attacks the sulfoxonium ylide 
to form complex 54, and enter the catalytic cycle. Intermediate 54 can easily lose 
DMSO (the activation barrier is 35.15 kJ mol-1) to form iron carbene 55, which can 
then undergo intermolecular attack by another molecule of pyridine to form 56. 
Although the activation barrier for this step is high, 56 is predicted to be much lower 
in energy than 55 (56 is -53.56 kJ mol-1 more stable than 55), making the conversion 
of 55 into 56 irreversible. Intermediate 56 can then undergo very fast C-C bond 
formation (barrier 10.46 kJ mol-1) to release 57. Intermediate 57 can then undergo re-
aromatisation to form the indolizine products such as 53.  Attack of another molecule 
each of pyridine and sulfoxonium ylide 51 on 56 regenerates complex 54 which can 
then re-enter the catalytic cycle. 
 
 
MeO
O
Ph S
O
Fe
Pyr
Br
Br
54
MeO
O
Ph
Fe
PyrDMSO
Br Br
55
MeO
O
Fe
56
51 + 52
N
Ph
Ph
CO2Me
57
N
Ph
CO2Me
53
DMSO
Br
Br
NPh Ph
 
Scheme 17: Proposed mechanism of FeBr2 catalysed formation of indolizidines from 
vinyl sulfoxonium ylides 51 and pyridines. Pyr = 2-benzylpyridine 
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1.1.2.2.2 Carbon-Carbon Bond Formation Without a Directing 
Group 
In 2012, a patent was published26 in which the iridium (I) catalysed cyclisation of 
sulfoxonium ylide 58 was disclosed. Substituted pyrrole 58, with an alkyl chain 
bearing the sulfoxonium ylide moiety, undergoes cyclisation in moderate yield when 
treated with with 10 mol% [Ir(cod)Cl]2 in 1,2-DCE to give the seven membered ring 
59 (Scheme 18). 
 
 
Scheme 18: Iridium catalysed intramolecular cyclisation of sulfoxonium ylide 58 
 
In 2017, the group of Hopmann published27 an iridium catalysed reaction between β-
enamino esters and sulfoxonium ylides for the synthesis of 3,5-substituted pyrroles 
(Scheme 19).  
 
Scheme 19: Selected scope of the iridium catalysed C-H insertion reaction between 
β-enamino esters and sulfoxonium ylides. 
 
The reaction afforded highly substituted N-alkylated and N-H pyrroles, and halides 
were tolerated in the reaction, for example with sulfoxonium ylide 61, which 
underwent reaction with 60 to afford p-methoxybenzyl (PMB) protected pyrrole 62 in 
64% yield. The reaction could also be extended to bis-substituted sulfoxonium ylides, 
and was applied to the synthesis of the important statin atorvastatin/Lipitor. The 
mechanism of the reaction is shown in Scheme 20. Insertion of the sulfoxonium ylide 
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into [Ir(cod)Cl]2 produces iridium carbene 63. This undergoes attack by the β-enamino 
esters to form complex 64, which then undergoes protonolysis to release enamine 65. 
It is noteworthy that these β-enamino esters selectively undergo formal C-H, rather 
than N-H insertion. This is most likely due to the highly nucleophilic nature of the 
substrate. Intermediate 65 can then undergo acid catalysed cyclisation to give the 
observed pyrrole products such as 62. 
 
[Ir(cod)Cl]2
Ar
O
[Ir]
Ar
O
S
O
DMSO MeO2C
H NHR
Me
Ar
O
[Ir]
MeO2C
NH2R
Me
Ar
O
MeO2C
NHR
Me
p-TSA
N
RAr
CO2Me
Me
63
64
6562  
Scheme 20: Proposed mechanism for the formation of pyrroles from sulfoxonium 
ylides and β-enamino esters. 
 
1.1.2.2.3 Carbon-Carbon Bond Formation with a Directing Group 
Later on in 2017, further reports of metal catalysed C-H activation for carbon-carbon 
bond formation were published by the groups of Aїssa28 and Li.29  Li’s group reported 
a rhodium (III) catalysed C-H activation reaction between 1-(pyrimidin-2-yl)-1H-
indole 66 and α-ketosulfoxonium ylide 24 to give ketone 67 in 96% yield. (Scheme 
21). 
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Scheme 21: Li’s reported Rh (III) catalysed C-H activation reaction between 66 and 
24 to give 67.  
 
Aїssa and co-workers disclosed a similar rhodium (III) catalysed directed C-H 
insertion reaction between 2-phenylpyridine 68 and sulfoxonium ylide 69, in the 
presence of the solvent 1,1,1,3,3,3-hexafluoroisopropanol (HFIP, Scheme 22).  
 
 
Scheme 22: Reaction reported by Aissa and co-workers between 2-phenylpyridine 68 
and sulfoxonium ylide 69 to give ketone 70. 
 
Through extensive optimisation of the conditions, a crucial factor to the success of this 
reaction was the choice of solvent, HFIP, as all attempts to use other protic or aprotic 
solvents failed. Mechanistically, the reactions reported by Aїssa and Li are similar 
(Scheme 23). Cyclometallation of the active catalyst species with 66 or 68 occurs to 
give complex 74. Coordination of sulfoxonium ylide 24 or 69 with 74 gives rhodium 
(III) alkyl species 75. Complex 75 undergoes α-elimination of DMSO to give rhodium 
carbene species 76. Migratory insertion of the rhodium-aryl bond into the carbene 
generates rhodium (III) alkyl species 77, which undergoes protonolysis by a molecule 
of HX to release products 67 or 70 and regenerate the active catalyst. In the reaction 
described by Aїssa, HFIP is promoting protonolysis of complex 77, whereas for Li’s 
reaction, it is pivalic acid. However, the authors could not rule out the possibility of 
an SN2-type displacement of DMSO by the aryl group of complex 75.  
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Scheme 23: Proposed catalytic cycle for the reactions reported by Li and Aїssa. HX = 
HFIP or PivOH. 
 
Since the publication of these two reactions, many more metal catalysed C-H 
activation reactions have been disclosed, notably for the synthesis of heterocycles, 
such as Wu’s report on the synthesis of 2-sustituted indoles,30 Cheng’s reported 
synthesis of 5-arylimidazo[2,1-a]isoquinolines31 and Fan’s synthesis of carbazoles32 
(Scheme 24). 
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Scheme 24: A: Wu’s synthesis of 2-alkylindoles. B: Cheng’s reported synthesis of 5-
arylimidazo[2,1-a]isoquinolines. C: Fan’s synthesis of carbazoles. 
 
During efforts to expand the scope of the rhodium (III) catalysed reaction reported by 
Aissa28 and co-workers, sulfoxonium ylide 85 was synthesised and subjected to the 
optimised reaction conditions (Scheme 25). 
 
 
Scheme 25: Unexpected synthesis of indanone 87 from sulfoxonium ylide 85 under 
the optimised reaction conditions 
 
The major product of this reaction was in fact 2-indanone 87, which was isolated in 
57% yield. Sulfoxonium ylide 85 thus appears to have undergone an intramolecular, 
Friedel-Crafts type reaction, rather than the desired intermolecular C-H activation 
reaction. To the best of our knowledge, the synthesis of 2-indanones in this manner 
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has not been reported from sulfoxonium ylides. However, it is a well-studied reaction 
of other ylides, most notably α-diazoketones, but also iodonium ylides, and gold 
carbenes formed in situ from alkynes, which we will briefly review in the next section. 
 
1.2 Friedel Crafts Reactions of Ylides 
1.2.1 Friedel Crafts Reactions of α-Diazoketones 
1.2.1.1 Metal Catalysed Reactions of α-Diazoketones 
1.2.1.1.1 C-C Bond Formation on Phenyl Rings 
The first example of a metal-catalysed Friedel-Crafts reaction of α-diazoketones was 
reported by Taylor and Davies in 198633. They reported the rhodium (II) catalysed 
conversion of diazoketone 88 into naphthol 89 (Scheme 26) which proceeded in 99% 
yield. 
 
 
Scheme 26: Taylor and Davies’ report on the Rh (II) catalysed reaction of diazoketone 
85 
 
The following year, Saba reported34 the copper catalysed synthesis of benzopyranone 
91 from α-diazoketone 90. The catalyst in this case is copper (II) 
hexafluoroacetylacetonate (catalyst A).Using these conditions, 91 could be isolated in 
86% yield (Scheme 27). 
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Scheme 27: The synthesis of benzopyranones reported by Saba 
  
Also in 1990, McKervey and co-workers reported35 the synthesis of 2-tetralone 94 
from diazoketone 92 (Scheme 28). This reaction is an intramolecular Buchner 
reaction, and proceeds via the intermediate azulenone 93, which can be isolated. 
However, the group discovered that, on prolonged exposure to silica gel, 93 would 
be converted to the 2-tetralone 94. Further investigation of this reactivity led to the 
one pot procedure shown whereby treatment of 92 with catalytic amounts of rhodium 
(II) acetate followed by 1 drop of TFA leads exclusively to the 2-tetralone 94.  
 
Scheme 28: Synthesis of 2-tetralone 94 from diazoketone 92 via azulenone 93. 
 
The regioselectivity of the reaction was affected by substituents in the ortho and 
para positions (Schemes 29 and 30). Diazoketone 95 (Scheme 29), with an ortho-
methyl group, afforded 2-tetralone 97, indicating that cyclisation had occurred away 
from the substituent, likely to minimize steric hindrance. However, diazketone 98, 
with an ortho-OMe group afforded 2-tetralone 100, indicating that the cyclisation 
occurred in the proximity of the substituent. The authors speculate that this could be 
explained by co-ordination of the carbenoid intermediate to the oxygen atom of the 
methoxy group, which would direct the cyclisation.  
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Scheme 29: The reaction of ortho-substituted diazoketones 95 and 98. 
 
Having at least one substituent in the meta position of the diazoketone again changed 
the regioselectivity (Scheme 30). When diazoketone 101 was subject to the rhodium 
(II) catalysed conditions, tetralone 102 was isolated without the addition of TFA, and 
none of the corresponding azulenone could be detected. Diazoketone 103 also by-
passed the azulenone intermediate and gave an 80:20 mixture of regioisomeric 
tetralones 104 and 105 in 96% overall yield. 
 
 
Scheme 30: The reaction of diazoketones 101 and 103. 
 
Related to this work, in 1997, Sudrik and co-workers published36 a synthesis of 2-
tetralones and 2-benzosuberones as part of their total synthesis of (±)-ar-
himachalene 106 (Scheme 31), an important terpenoid natural product. This work 
demonstrated that seven membered rings could be synthesised by this method, as 
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diazoketone 107 underwent rhodium-catalysed Buchner reaction to give azulenone 
108, which was converted to the 2-benzosuberone 109 by addition of the Lewis acid 
BF3•OEt2 in 94% yield from 107. This reaction allowed the authors to synthesise 106 
in 3 steps from diazoketone 107. 
 
 
Scheme 31: Reaction of diazoketone 107 via azulenone 108. 
 
In 1990, Nakatani further developed this rhodium catalysed reaction when he 
investigated the competition between aromatic C-H insertion for the synthesis of 2-
indanones, secondary aliphatic C-H insertion for the synthesis of cyclopentanones, 
and intramolecular cyclopropanation of alkene C=C bonds37 (Scheme 32). When 
diazoketone 110 underwent rhodium catalysed decomposition, 2-indanone 111 was 
the major product, but cyclopentanone 112 was also isolated in 18% yield. This 
product comes from insertion of the rhodium carbenoid into the secondary aliphatic 
C-H bond of the n-propyl group. In the case of diazoketone 113, aromatic C-H 
insertion was only the minor product, 2-indanone 114 being isolated in 26% yield. 
The major product in this case was cyclopropane 115, which derives from reaction of 
the carbenoid with the C=C double bond of the allyl group. No trace of insertion of 
the carbenoid into the secondary aliphatic C-H bond was observed. From these 
results, it appears that cyclopropanation is the most favoured process, followed by 
aromatic C-H insertion, then secondary aliphatic C-H insertion, at least with 
Rh2(OAc)4 as the catalyst. 
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Scheme 32: Reaction of diazoketones 110 and 113. 
 
The effect of changing the carboxylate ligand has also been investigated extensively 
by Moody and Padwa.38,39,40 They have discovered that using fluorinated carboxylate 
ligands on the rhodium (II) centre, such as in rhodium (II) perfluorobutyrate 
(Rh2(pfb)4) or rhodium (II) trifluoroacetate (Rh2(tfa)4), or using amidate ligands such 
as in rhodium (II) caprolactamate (Rh2(cap)4),  tends to favour aromatic C-H 
insertion, even when other pathways are possible. For example, in 1993, Padwa 
reported39 the rhodium (II) catalysed reaction of diazoketone 113 (Scheme 33). 
Using Rh2(OAc)4 as the catalyst, overall isolated yield of indanone 114 and 
cyclopropane 115 was 99%, but the selectivity was poor. Using Rh2(pfb)4 “switched 
off” the cyclopropanation pathway, and indanone 114 was isolated in 95% yield as 
the sole product. In contrast, Rh2(cap)4 produced the opposite selectivity, and 115 
was isolated in 72% yield as the sole product. Similar results were reported in 
competition reactions between aliphatic C-H insertion and cyclopropanation (not 
shown in Scheme). 
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Scheme 33: Reaction of diazoketone 113 with different rhodium (II) carboxylates. 
 
The authors rationalised this by speculating that the change from a highly 
electrophilic metal centre in Rh2(pfb)4 to a weakly electrophilic metal centre 
(Rh2(cap)4) accounts for the selectivity, as the less stable (and therefore more 
reactive) carbenoid arising from Rh2(pfb)4 would prefer to use the less entropically 
demanding pathway, i.e., aromatic substitution. The following year, Moody and 
Padwa reported38 their investigations into the rhodium catalysed reactions of 
diazoamides for the synthesis of oxindoles (Scheme 34). They discovered that the 
reaction of diazoamide 116 is controlled by the choice of ligand on the rhodium, in a 
similar manner to that described above. Rhodium (II) perfluorocarboxylates such as 
Rh2(pfb)4 or Rh2(tfa)4 produced exclusively oxindole 117 (i.e. the rhodium carbenoid 
underwent aromatic C-H insertion as opposed to aliphatic C-H insertion), but with 
impractical reaction times (entries 2 and 3 respectively). Switching to 
trifluoroacetamide or perfluorobutyramide ligands led to a dramatic decrease in the 
reaction time, but with no loss in selectivity, with 117 being the only detectable 
product (entries 4 and 5). Once again, this remarkable selectivity is attributed to the 
strongly electrophilic metal centre in carbenoids derived from rhodium (II) 
perfluorocarboxylates or perfluoroamidates.  
 
 
Scheme 34: Selectivity of different rhodium (II) catalysts for aliphatic or aromatic 
C-H insertion. 
 
Another study of the effect of ligands on the selectivity of the rhodium (II) catalysed 
reaction was published in 1992 by Ikegami and co-workers41 (Scheme 35). They 
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looked at the competition between aliphatic and aromatic C-H insertion in 
diazoketone 119 to give either cyclopentanone 120 or indanone 121. Like Moody 
and Padwa, they found that using Rh2(OAc)4 gave them a high yield (86%) but poor 
selectivity (Scheme 35, entry 1). However, by switching the catalyst to rhodium (II) 
diphenylacetate (Rh2(dpa)4, entry 2), they were able to maintain the high yield, but 
increase selectivity for indanone 121 dramatically, and rhodium (II) triphenylacetate 
(Rh2(tpa)4, entry 3), improved on this again, giving a 92% overall yield and a 4:96 
ratio of 120/121. This suggests that using ligands with steric bulk also switches the 
selectivity of the reaction towards aromatic C-H insertion. 
 
 
Scheme 35: Reaction of diazoketone 119 with different Rh (II) carboxylates. 
Rh2(dpa)4: Rhodium (II) diphenylacetate. Rh2(tpa)4: Rhodium (II) triphenylacetate. 
Despite many reports of the metal catalysed Friedel-Crafts cyclisation of diazo 
compounds, there was no definitive mechanistic study until 2009, when Jung and co-
workers reported42 the synthesis of isoquinolinone derivatives such as 123 from 
phenylsulfonyl substituted diazoketones such as 122 (Scheme 36), using Rh2(pfb)4 as 
the catalyst. They showed that this reaction is not a simple C-H insertion (a σ-bond 
metathesis) as the case of aliphatic C-H bonds, but is more like electrophilic 
aromatic substitution (SEAr). They examined the effects of the substituent on the 
aromatic ring on the regioselectivity of the reaction (Scheme 36), and found that 
substituent effects match well with what would be expected from an SEAr reaction. 
For example, a methoxy group in the meta (R2) position as in 122 yielded 
isoquinolinone 123 in 96% yield in only 2 hours. However, with a trifluoromethyl 
group instead of a methoxy, as in 124, isoquinolinone 125 was isolated in only 27% 
yield after 48 hours. 
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Scheme 36: Substituent effects in the intramolecular Rh (II) catalysed reaction of 
diazoketones 122 and 124. Rh2(pfb)4: Rhodium (II) perfluorobutyrate. 
 
With substituent effects established, the team then decided to investigate deuterium 
kinetic isotope effects (Scheme 37).  They synthesised mono-deuterated diazoketone 
126 and subjected it to the standard conditions to obtain 127 and 128 in 46.1% and 
53.9% yield respectively. This gave them kH/kD = 0.855, thus implying that there is 
no primary kinetic isotope effect and thus direct C-H activation could be ruled out. 
The observation of the inverse secondary deuterium kinetic isotope effect is 
consistent with an sp2 to sp3 hybridisation change during the addition of a rhodium 
carbenoid to the aromatic ring to form a σ-complex as the rate determining step. This 
unambiguously warrants an SEAr mechanism rather than direct C-H activation. The 
final proposed mechanism is shown in the bottom half of Scheme 35. Addition of the 
catalyst to the diazoketone and extrusion of nitrogen gas forms the rhodium 
carbenoid 130 irreversibly. Attack of the aromatic ring onto 130 generates Wheland 
intermediate 131. Intermediate 131 can then be re-aromatised by hydrogen transfer 
from the ring to the former carbenoid carbon. 
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Scheme 37: Top: Experiments to determine the primary kinetic isotope effects. 
Bottom: Proposed mechanism of the rhodium (II) catalysed reaction of diazoketone 
129. 
 
1.2.1.1.2 C-C Bond Formation on Pyrroles 
In addition to the intramolecular C-C bond forming reactions on phenyl rings 
described in the previous section, there are also reports of intramolecular C-C bond 
formation reactions using metal catalysed reactions of diazoketones on heterocyclic 
rings. These include pyrroles, furans and thiophenes. 
 
In 1986, Jefford and co-workers needed to synthesise dihydroindolizinone 137  as 
part of their total synthesis of ipalbidine (Scheme 38)43. To accomplish this, they 
decided to synthesise diazoketone 132, and use an intramolecular rhodium (II) 
catalysed cyclisation. In this reaction, two products, dihydroindolizinone 137 and 
indanone 142 are possible. The major product was 137, giving a 36:1 ratio of 
indolzinone/indanone, and an 89% overall yield. They decided to test the selectivity 
of the reaction by varying the electronics of the phenyl ring, and so diazoketones 
133-136 were synthesised (Scheme 38). As expected, the pyrrole ring proved more 
reactive in all cases, even when the phenyl ring carried an electron donating group 
(134 and 135). An electon poor ring as in 136 (R = NO2) led to almost complete 
selectivity for the indolizinone, with no indanone detected. Using acetoxy-
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substituted dihydroindolizinone 132, the authors were able to synthesise (±)-
ipalbidine in 4 steps from 132. 
 
 
Scheme 38: Intramolecular reaction of diazoketones 132-136. 
 
1.2.1.1.3 C-C Bond Formation on Furans  
Furanyl diazoketones have also been reported to undergo metal-catalysed 
decomposition. However, unlike phenyl or pyrrole rings, the furan rings prefer to 
undergo cyclopropanation followed by electrocyclic ring opening to an unsaturated 
aldehyde.  The first report of this reaction was by Nwaji and Onyiriuka, when they 
reported44 the reaction of diazoketone 147 to give cyclic unsaturated aldehyde 149 
(Scheme 39), catalysed by copper (II) sulfate. The reaction was presumed to proceed 
via cyclopropane intermediate 148, followed by electrocyclic ring opening to give 
the observed aldehyde. Intermediate 148 could not be detected or isolated, even on 
early quenching of the reaction. 
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Scheme 39: Intramolecular Cu (II) catalysed reaction of furanyl diazoketone 147. 
 
This reaction has been re-visited several times over the years,45,46,47,48 most notably 
by the groups of Padwa45 and Wenkert.47 A change of catalyst to Rh2(OAc)4 allowed 
Padwa and co-workers to confirm the identity of the product, and confirm that the 
geometry of the exocyclic double bond as Z, rather than E as initially reported by 
Onyiriuka (Scheme 40). They were also able to isolate cyclopropane 153 under 
identical reaction conditions, thus confirming, in the authors’ eyes at least, the 
mechanism of the reaction. Cyclopropane 153 was able to undergo acid catalysed 
ring opening to give dihydrobenzofuranone 154 in 85% yield, showing that it is 
possible to obtain formal C-H insertion products from furanyl diazoketones. 
 
 
Scheme 40: Rh (II) catalysed reactions of diazoketones 150 and 152, and acid-
catalysed ring opening of 153 to give 154. 
 
Although Wenkert and co-workers were further able to expand the scope (Scheme 
41), for example with the synthesis of tran fused unsaturated aldehyde 156, 
synthesised from diazoketone 155, they were unable to detect or isolate any 
cyclopropane intermediates.  
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Scheme 41: The reaction of diazoketone 155. 
 
1.2.1.1.4 C-C Bond Formation on Thiophenes 
Intramolecular reaction of thienyl diazoketone 157 was reported by Capretta and co-
workers49 to give tetrahydrobenzothiophenone 159 (Scheme 42), and, like the 
analogous furanyl  diazoketones described above, the reaction is assumed to proceed 
via cyclopropane intermediate 158. Unlike the reaction of the furanyl derivatives, 158 
undergoes ring opening to give 159, leaving the thiophene ring intact. The difference 
in reactivity of the two cyclopropane intermediates has been attributed to the formation 
of a stronger C=O bond in the opening of the furan ring. 
 
 
Scheme 42: Contrasting reactions of furanyl and thienyl diazoketones 
 
1.2.1.2 Acid Catalysed Reactions of α-Diazoketones 
Friedel-Crafts alkylation of phenyl rings with diazoketones has also been 
accomplished in the absence of a transition metal catalyst. In these cases, Lewis and 
Brnsted acids are the catalysts. The first report of an acid catalysed Friedel-Crafts 
alkylation came in 1945, when Cook and Schoental reported50 the synthesis of 2-
chrysenol 161 from the diazoketone 160 (Scheme 43) using a 10% solution of 
concentrated sulfuric acid in acetic acid.  
 
 
Scheme 43: Acid catalysed reaction of diazoketone 160. 
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Then, in 1960, Wilds reported51 the synthesis of indanone 163 from diazoketone 162, 
this time using a Lewis acid, BF3•OEt2 (Scheme 44), although more forcing 
conditions were required in this case.  
 
 
Scheme 44: BF3•OEt2 catalysed reaction of diazoketone 163. 
Mander and co-workers then published a series of papers52,53,54,55,56 which investigated 
the reactions of a series of phenolic and methoxy-substituted phenyl diazoketones. For 
instance, diazoketone 164 (Scheme 45) undergoes TFA-mediated cyclisation to give 
dienone 165. The reaction is thought to proceed via formation of cyclobutanone 167, 
which results from the attack of the diazoketone at the para position to the methoxy 
group. Intermediate 167 can then undergo rearrangement to 165 via cyclobutanone 
ring opening and demethylation. 
 
Scheme 45: Acid promoted cyclisation of diazoketone 164. 
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This methodology has been applied to the total synthesis of natural products, for 
example by Mander in his synthesis of (±)-gibberellin A, and by Chatterjee and Pandit 
in their synthesis of deserpidine57. The methodology has also been extended to the 
intermolecular Friedel-Crafts alkylation of diazoketones for the synthesis of 
substituted oxindoles58.  
 
1.2.2 Friedel-Crafts Reactions of Iodonium Ylides 
In contrast with the many examples of Friedel-Crafts type reactions of diazoketones, 
only one example has been described for iodonium ylides59. The advantage of using 
iodonium ylides over diazoketones is that iodonium ylides are much less hazardous 
and do not require reagents such as diazomethane for their synthesis. In 1997, 
Moriarty and co-workers reported the synthesis of 2-tetralones 175-176 and 179 
from β-dicarbonyl iodonium ylides 169-170 and 177 (Schemes 46 and 47), mediated 
by stoichiometric amounts of copper (I) chloride. Like the reactions of the 
diazoketones reported by McKervey35 and diazoketone 107 reported by Sudrik36, the 
reactions of o- and p-OMe substituted iodonium ylides 169 and 170 (Scheme 46) 
appear to proceed via cyclopropanation, to give intermediates 171 and 172. These 
appeared to be in equilibrium with azulenones 173 and 174, as these could both be 
detected by both 1H NMR and TLC. After column chromatography though, the only 
products isolated were tetralones 175 and 176, in 75% and 85% yield respectively. 
Scheme 46: Reaction of iodonium ylides 169 and 170. 
In contrast to 169 and 170, meta-methoxy iodonium ylide 177 appeared to undergo 
direct Friedel-Crafts alkylation with participation of the methoxy group (Scheme 47) 
to give Wheland intermediate 178, which would then rearomatize to give 179 in 90% 
yield. Direct alkylation is suspected in this case as no azulenone intermediate such as 
171 or 172 could be detected by either 1H NMR or TLC. 
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Scheme 47: Reaction of iodonium ylide 177 via direct alkylation 
The authors also attempted to extend this methodology to the synthesis of indanones 
from iodonium ylides (Scheme 48). However, only meta-methoxy substituted ylide 
180 proceeded to give indanone 181 in 65% yield. Iodonium ylides 182 and 183, o- 
and p-methoxy substituted respectively, only produced dimers 184 and 185. 
Presumably this is because if intramolecular cyclopropanation were to occur, the result 
would be a highly strained tricyclic butanone, whereas for m-methoxy iodonium ylide 
180, direct alkylation with participation of the methoxy group is possible. Curiously, 
the role of CuCl is unknown in this reaction, and the formation of a copper carbene 
was not suspected.  
 
Scheme 48: Reactions of iodonium ylides 180, 182 and 183. 
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1.2.3 Alkynes as Diazo Surrogates 
1.2.3.1 Reactions with an Internal Oxidant 
There are also numerous reports of alkynes and an oxidant being used as diazo 
surrogates to access gold or platinum carbenes. These could then undergo Friedel-
Crafts type cyclisation if aryl alkynes are used. Like the use of iodonium ylides, this 
is an attractive method for accessing metal carbenoids without the drawbacks of 
diazoketones. For example, in 2007, the groups of Toste60 and Zhang61 reported the 
synthesis of benzothiazepinones such as 188 and 190 from alkynyl sulfoxides 186 and 
189 (Scheme 49) using gold (III) and gold (I) catalysts.  
 
Scheme 49: Cyclisation of alkynes 186 and 189. 
In these cases, no external oxidant is required as the sulfoxide oxygen can attack the 
alkyne as it is complexed to the metal, forming intermediate 192 (Scheme 50). In this 
case, Zhang showed62 that an α-oxo gold carbene is not involved in the reaction. 
Instead, intermediate 192 can undergo a [3,3] sigmatropic rearrangement to form 
intermediate 193. Re-aromatisation and protodeauration then gives the product 188. 
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Scheme 50: Proposed mechanism for gold catalysed cyclisation of alkynes 186 and 
189. 
Since then, numerous examples of the intramolecular cyclisation of aryl alkynes using 
an internal oxidant have been reported,63 62 64 65 extending the scope to include five 
and six membered rings, and using nitrones rather than sulfoxides as the internal 
oxidant.  
 
1.2.3.2 Reactions with an External Oxidant 
Numerous examples have also been reported of the in-situ generation of gold carbenes 
from alkynes using an external oxidant, mostly pyridine N-oxides. For example, in 
2013, Gagosz and co-workers reported66 the synthesis of 2-indanones from propargyl 
arenes catalysed by a bisarylphosphonite gold (I) complex, and later on in the same 
year, Li reported67 the synthesis of oxindoles via the gold catalysed oxidative 
cyclisation of N-arylynamides (Scheme 51). 
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Scheme 51: Gold catalysed oxidative cyclisation of N-arylynamides with pyridine-N-
oxide as the external oxidant 
 
Gold (I) catalyst Ph3PAuCl was chosen as the optimum catalyst for this reaction, and 
yields were generally reasonably poor, however, halogens, electron rich and electron 
poor aryl groups were tolerated in the reaction. For example, ynamide 194 gave 
oxindole 195 in 42% yield. Meta-substituted ynamide 196 gave a mixture of  
regioisomers 197 and 198 in 55% yield and a 1:0.7 ratio. The mechanism of this 
reaction does seem to involve the formation of a gold carbene (Scheme 52).  
 
 
Scheme 52: Proposed mechanism of the gold catalysed oxidative cyclisation of 
ynamides with pyridine N-oxide as the external oxidant. 
 
Deuterium kinetic isotope effect experiments indicated that C-H cleavage was unlikely 
to be involved in the rate determining step, thus an electrophilic aromatic substitution 
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mechanism was proposed. This is thought to involve attack of pyridine N-oxide on the 
alkyne as it co-ordinates to the catalyst to generate intermediate 199. Electrophilic 
aromatic substitution can then occur to form Wheland intermediate 200, which can 
then re-aromatise to give intermediate 201. Intermediate 201 can then undergo 
protodeauration to release the final products. Many more such examples have been 
published using a gold (I) or (III) catalyst with an external oxidant, such as Yang’s 
synthesis of 1H-pyrrolo[1,2-a]indol-2(3-H)-ones,68 Ye’s synthesis of isoquinolines 
and β-carbolines69 and Hashmi’s synthesis of benz[a]fluorenones using a combination 
of oxidative gold catalysis and photochemistry.70 
 
1.2.2.3 Reactions without a metal catalyst 
Interestingly, it is also possible to carry out this reaction without a metal catalyst: in 
1975, Utawanit and Katzellenbogen reported71 the synthesis of indanone 205 from 
alkyne 202, simply by heating 202 to 90 oC either neat, or in CCl4 solution (Scheme 
53). 
 
 
Scheme 53: Metal free cyclisation of alkyne 202 to indanone 203. 
 
The reaction appears to proceed via a Claisen-type rearrangement from 203 to form 
ketene 204, which can rapidly cyclise and rearomatize to form 205. 
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2.1 Aims 
As described in the previous section, in 2017 the group published1 a paper describing 
the functionalisation of aromatic C-H bonds (Scheme 54) with α-ketosulfoxonium 
ylides. While the scope of the reaction was broad, sulfoxonium ylide 85 did not react 
in the expected manner, producing ketone 86 in only 10% yield. Instead, the major 
product was 2-indanone 87. As previously described, one of the major methods to 
synthesise 2-indanones is to start from the parent α-diazoketone.  
 
 
Scheme 54: Top: previous work within the Aїssa group on Rh (II) catalysed C-H 
insertion reaction of sulfoxonium ylides. Bottom: Unpublished result with 
sulfoxonium ylide 85, in which the major product was indanone 87. 
Further investigation of the reaction described in Scheme 54 (bottom) found that the 
yield of 87 improved from 57% to 77% in the absence of [Cp*RhCl2]2, AgSbF6 and 
phenylpyridine. The initial aims of this thesis were therefore: 
i) to optimise the reaction with respect to the base and the solvent 
ii) to expand the scope of the reaction to heterocycles 
iii) to study the mechanism of the reaction. 
 
Furthermore, one motivation for exploring the chemistry of sulfoxonium ylides is to 
provide an alternative reagent to α-diazoketones, which are often considered to be 
highly unstable and explosive compounds. However, barring a few relatively limited 
examples2–5, quantitative data on the thermal stability of diazoketones is not widely 
available. For sulfoxonium ylides, only one example of the thermal stability of a 
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sulfoxonium ylide has been described6. Therefore, one additional aim of the project 
was to collect some quantitative data on the thermal stability of sulfoxonium ylide 85, 
and compare it with the equivalent diazoketone. 
 
Diazketone 208 was synthesised (Scheme 55), and differential scanning calorimetry 
(DSC) data was collected on both it and sulfoxonium ylide 85. A DSC experiment 
would reveal at exactly what temperature decomposition of each compound occurred, 
whether decomposition was endothermic or exothermic, and the magnitude of any 
endotherms or exotherms. 
 
 
Scheme 55: Synthesis of diazoketone 208 from carboxylic acid 206. 
 
Compound 206 was treated with SOCl2 and DMF to synthesise the acid chloride 207, 
and then, after the DCM and excess SOCl2 had been removed, the acid chloride was 
dissolved in dry diethyl ether and treated with a solution of trimethylsilyl 
diazomethane in hexane to afford the diazoketone 208 in 38% yield as a bright orange 
solid. Compound 208 was then shipped to AstraZeneca’s Macclesfield Campus, and 
subject to the DSC experiment (chart 1). The DSC experiments were carried out by 
Benjamin Dobson. 
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Chart 1: Result of DSC experiment with diazoketone 208. Blue = endotherm, red = 
exotherm 
 
10.4 mg of 208 was weighed out and sealed in a crucible, then heated slowly from 
room temperature to 500 oC. Firstly, there is an endotherm (chart 1, blue peak) 
beginning at around 34 oC and peaking 60 oC. The size of this endotherm is -73 J•g-1, 
and is likely to be related to the melting of 208. Then, there is a large exotherm (red 
peak) beginning at 73 oC, and continuing up to 244 oC, releasing a total of 866 J•g-1. 
According to United Nations guidelines7, a substance cannot be explosive if the 
decomposition energy released between 0 and 500 oC is less than 800 J•g-1. With a 
decomposition energy of 866 J•g-1, 208 is squarely above this limit, and thus must be 
considered an explosive. Also likely to be of concern is the relatively low temperature 
(~73 oC) that this exotherm begins at, as this could be close to the temperature a 
reaction is being conducted at, thereby increasing the risk of an incident. Chart 1 can 
be contrasted with the DSC data of sulfoxonium ylide 85 (chart 2).  
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Chart 2: DSC data of sulfoxonium ylide 85 
 
This experiment was conducted according to the same procedure as for 208, using 5.7 
mg of 85. This compound also has a small endotherm (-15 J•g-1) beginning at 134 oC, 
and then there is an exotherm beginning at 145 oC, and continuing up to 172 oC. The 
decomposition energy released during this event is 264 J•g-1, which is well below the 
limit set by the United Nations guidelines, thus, 85 cannot be considered as an 
explosive material. Furthermore, this exotherm has a much smaller range than 208 (27 
oC for 85, vs 171 oC for 208), and it occurs at a much higher temperature. There are 
then two smaller exotherms, beginning at 179 oC and 412 oC, which are likely to be 
related to the decomposition of DMSO. Taking these into account, the total exotherm 
released is 650 J•g-1, still well below the United Nations limit for a compound to be 
considered explosive. 
 
2.2 Optimisation of the Reaction 
2.2.1 Variation of the solvent 
As it had already been established that the reaction proceeds in the absence of 
phenylpyridine, [Cp*RhCl2]2 and AgSbF6, it was decided to next vary the solvent. A 
variety of solvents were tested, both protic and aprotic, and spanning a range of 
polarities (table 2).  
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Table 2: Variation of the solvent. Conditions: 85 (50 mg, 0.17 mmol), NaOAc (14 
mg, 1 equiv) dissolved in solvent (0.9 mL, 0.2 M) and heated at 60 oC for 16 h. a: 
Isolated yield of 87. b: No base, 5 equiv A. c: No base, 5 equiv B. 
 
Simply changing the solvent from HFIP to TFE (2,2,2-trifluoroethanol) (entry 1 vs 
entry 2) led to no reaction, and  the starting material was recovered unchanged. 
Moving away from fluorinated alcohols, 1,2-DCE did not promote the reaction at all 
(entry 3), not even upon the addition of additives with a similar pKa to that of HFIP 
(entries 4 and 5; HFIP pKa: 9.2, A pKa ~10.99; B pKa ~10.28) . Isopropanol, tert-
butanol or ethanol did not promote the reaction either (entries 6-8). It is worth noting 
that in entries 2, 5 and 6-8, the starting material was recovered intact, with no traces 
of any O-H or N-H insertion products. Aprotic solvents such as THF (entry 9), toluene 
(entry 10) and ethyl acetate (entry 11) did nothing to promote the reaction. However, 
upon the use of HFIP as a co-solvent, the reactivity was recovered (entries 12-14), and 
the yields were virtually unchanged from the initial conditions in entry 1. These 
results, particularly entries 2, 4-5 and 6-8, suggest that the role of HFIP must be more 
than to simply act as a proton source, and the implications of this will be discussed 
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further in a later section. Given the results in table 2, it was decided to use HFIP as the 
solvent for the rest of the screening reactions.  
 
2.2.2 Variation of the base 
Next, it was decided to vary the base to see if what, if any, effect this would have on 
the reaction (table 3). 
 
Table 3: Variation of the base. Conditions: 85 (50 mg, 0.17 mmol), base (1 equiv), 
dissolved in HFIP (0.9 mL, 0.2 M) and heated at 60 oC for 16 h. a: Isolated yield of 
87. b: With 2 equiv base. c: Reaction conducted using 200 mg 85. 
 
Changing the base to KOPiv did not result in a significant increase in the yield (entry 
1 vs entry 2), and neither did using 2 equivalents of base (entries 3 and 4 vs entries 1 
and 2). Neither K2CO3 nor K3PO4 caused any significant increase in the yield of 87 
(entries 5 and 6). NaHCO3 and NaH both caused significant drops in yield (entries 7 
and 8), perhaps surprisingly given their different pKa values. Next, a series of amine 
bases were attempted (entries 9-14). Triethylamine, DIPEA and DABCO did not cause 
a significant increase in yield of 87 (entries 9, 10 and 12 respectively), however, DBU, 
pyridine and DMAP caused significant drops in the yield of 87 (entries 11, 13 and 14 
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respectively). Next, the rest of the alkali metal carbonates were tried (entries 15-17), 
which all resulted in similar yields of 87. However, it is also noteworthy that the 
reaction worked to some extent in the complete absence of base (entry 18), albeit with 
a lower yield. Since potassium carbonate is cheap and abundant, it was decided to use 
it in all subsequent reactions to expand the scope of the reaction, particularly after the 
reaction was scaled up from initial 50 mg scale to 200 mg (entry 5, 91% isolated yield).  
 
2.3 Synthesis of Sulfoxonium Ylides 
As there are many literature reports of sulfoxonium ylides being synthesised from 
methyl or ethyl esters, the synthesis of sulfoxonium ylide 85 was first attempted from 
methyl ester 209 and 1 derived from trimethylsulfoxonium iodide 210 and KOtBu 
(Scheme 56), proved to be problematic. 
 
 
Scheme 56: The synthesis of sulfoxonium ylide 85 from ester 209. 
 
Compound 210 was suspended in dry THF, KOtBu was added and the mixture was 
heated at reflux in the dark for 2 hours, before being cooled to room temperature. Neat 
209 was then added in one portion, and the reaction was heated to reflux for 16 h. The 
conversion of ester 209 by this procedure was low, as was the yield of 85 (31%). The 
purity of the isolated material also proved to be poor, as observed by 1H NMR, even 
after chromatography. Perhaps more seriously, the results were not reproducible and 
further attempts to the synthesise 85 from methyl ester 209 were unsuccessful. Given 
Nugent’s reports8,9 of the synthesis of sulfoxonium ylides from 4-nitrophenyl esters in 
high yield, and the reported synthesis of sulfoxonium ylides from acid chlorides, these 
methods were next investigated (Scheme 57). 
 
 Page | 53  
 
 
Scheme 57: Top: Synthesis of sulfoxonium ylide 85 from 4-nitrophenyl ester 212. 
Bottom: synthesis of 85 via acid chloride 207. 
 
Firstly, 4-nitrophenyl ester 212 was synthesised from commercially available acid 206 
and 4-nitrophenol 211 in 91% isolated yield after column chromatography. Compound 
212 was then used to synthesise 85. For this reaction, the experimental procedure was 
modified: compound 210 and KOtBu were refluxed for 2 hours in the dark in THF as 
before, however, the suspension was then cooled to 0 oC. A solution of ester 212 in 
THF was added dropwise, then the mixture was stirred at room temperature. This 
procedure led to full conversion of 212 in 30 mins. Compound 85 could be isolated in 
48% yield after column chromatography and re-crystallisation from ethyl acetate, and 
in satisfactory purity. Importantly, this proved to be reproducible, with a further batch 
of 85 being synthesised in 50% yield from 212. An attempt to synthesise 85 from acid 
chloride 207 was made in an attempt to further improve the yield. The acid chloride 
207 was synthesised from the acid 206 and SOCl2, however, no attempt was made to 
isolate or characterise it. DCM and excess SOCl2 were evaporated on the Schlenck 
line, and a THF solution of acid chloride 207 was added dropwise at 0 oC. Full 
conversion was achieved in just 15 minutes, and 85 was isolated in 62% yield after re-
crystallisation of the crude material from ethyl acetate. Importantly, this also proved 
to be reproducible, with a further batch of 85 being synthesised via acid chloride 207 
in 58% yield over two steps from acid 206. Because of the higher yield, and the shorter 
reaction time from acid 206, all further batches of 85 were synthesised via the acid 
chloride. However, it is noteworthy that, although the acid chloride method proved to 
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be the best way of synthesising some sulfoxonium ylides in this chapter (Scheme 58), 
the more reliable method for most was found to be the nitrophenyl ester (Scheme 60). 
This variability was attributed to the presence of small amounts of SOCl2 and HCl, 
even after evaporation on the Schlenck line for several hours. 
 
 
Scheme 58: Sulfoxonium ylides discussed in this chapter which were synthesised via 
the acid chloride 
 
Compound 213 was synthesised in 67% yield, whereas a series of 4-substituted 
sulfoxonium ylides 214-218 were synthesised from the corresponding carboxylic 
acids in 40-62% yield. In the case of 214, the corresponding carboxylic acid is 
ibuprofen, the common non-steroidal anti-inflammatory drug (NSAID), and therefore 
commercially available. However, corresponding carboxylic acids for 215-218 were 
synthesised by deprotonation of commercially available methyl esters with LDA, 
followed by addition of MeI. Subsequent saponification of the resulting ester resulted 
in the carboxylic acids. Gem-dimethyl sulfoxonium ylide 219 was synthesised in 94% 
yield from the commercially available carboxylic acid. Allyl, benzyl and cyclohexyl 
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substituted sulfoxonium ylides 220, 221 and 222 were synthesised in 58%, 25% and 
36% yields respectively. Carboxylic acids for 220 and 221 were synthesised by a 
similar method described for 215-218, except that the enolate was quenched with allyl 
bromide and benzyl bromide respectively. The carboxylic acid leading to 222 was 
commercially available. As discussed, severe reductions in yield could be due to the 
presence of small amounts of HCl or SOCl2 present, even after evaporation under high 
vacuum. Compound 223 was synthesised in 37% yield. In this case, the carboxylic 
acid was not commercially available, and so was synthesised via the palladium 
catalysed cross coupling of bromobenzene 224 with an enolate derived from ester 225 
(Scheme 59). 
 
 
Scheme 59: Palladium catalysed cross coupling of bromobenzene 224 with ester 225. 
 
Compound 226 could be isolated in 62% yield after column chromatography, and 
saponification of 226 with NaOH led to the carboxylic acid. The majority of 
sulfoxonium ylides were synthesised from the corresponding 4-nitrophenyl esters, for 
example 227 and 228 (Scheme 60).   
 
 
Scheme 60: Sulfoxonium ylides synthesised from the corresponding 4-nitrophenyl 
esters. 
 
In the case of both 227 and 228, the corresponding carboxylic acids were purchased 
from Sigma Aldrich and Fluorochem respectively and used as received. Compound 
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227 was isolated in 81% yield from the corresponding 4-nitrophenyl ester, whereas 
228 was isolated in 64% yield from the corresponding nitrophenyl ester. The synthesis 
and structures of further sulfoxonium ylides will be discussed at the beginning of the 
relevant sections. 
 
2.4 Scope of the HFIP-mediated reaction 
2.4.1 Variation of the substituents on the phenyl ring 
With both the optimum synthesis of sulfoxonium ylides, and the optimum conditions 
for the HFIP mediated reaction established, attention was next turned to expanding the 
scope. Firstly, variation of the substituent in the para position of the phenyl ring was 
attempted (Scheme 61). Variation in this position was attempted first as a single 
regioisomer of product would be formed, thus simplifying analysis and purification. 
 
 
Scheme 61: Reaction of sulfoxonium ylides 213-218. Conditions: Sulfoxonium ylide 
(0.66 mmol), K2CO3 (0.66 mmol) in HFIP (3.3 mL, 0.2 M) at 60 oC for 16 h. a: At 80 
oC in the microwave for 2 h. b: At 90 oC 
 
Compound 213 (R1 = H) was subjected to the optimised reaction conditions, and 
indanone 229 was isolated in 46% yield, with the remainder of the mass balance 
consisting of unreacted starting material. Compound 214 (R1 = iBu) led to indanone 
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230 in 77% yield, whereas compound 215, with an aromatic ring bearing a strongly 
electron-donating group, led to only 65% yield of indanone 231, with the remainder 
of the mass balance consisting of solvolysis product 232, which was isolated in 25% 
yield. Halogen substituents were well tolerated, with compound 216 (R1 = Cl) leading 
to 51% yield of 233 under the optimised conditions. This yield could be increased to 
81% by heating the reaction at 80 oC in the microwave for 2 h. Compound 217 (R1 = 
Br) led to 34% yield of indanone 234 under the optimised conditions, however this 
yield could also be increased, this time by simply increasing the temperature to 90 oC. 
Compound 218, with an aromatic ring bearing a strong electron-withdrawing group, 
also needed the temperature to be increased to 90 oC, and these conditions led to 61% 
yield of indanone 235. Attention was then turned to sulfoxonium ylides 227 and 228, 
desmethyl analogues of 212 and 215 respectively (Scheme 62). 
 
 
 
Scheme 62: Reaction of compounds 227 and 228 under the HFIP mediated conditions.  
 
In the case of 227, indanone 236 could not be detected. Instead, the product of the 
reaction was ketone 237, which was isolated in 54% yield. This is compared to 
compound 212, where the indanone 228 was the major product (65% yield), and 
ketone 229 was only isolated in 25% yield. In the case of 228, indanone 241 also could 
not be detected, and the only product of the reaction was HFIP ester 239. These results 
led us to consider that substitution at the benzylic carbon was important, and that the 
Thorpe-Ingold effect was therefore playing an important role in governing the 
 Page | 58  
 
reactivity of each sulfoxonium ylide towards cyclisation. Attention was then turned to 
gem-dimethyl substituted sulfoxonium ylide 219 (Scheme 63).  
 
 
 
Scheme 63: Reaction of sulfoxonium ylide 219 under the HFIP mediated conditions. 
 
According to the Thorpe-Ingold effect, a gem-dimethyl group ought to have made 219 
very reactive towards cyclisation, however, indanone 240 could not be detected, and 
219 was recovered unchanged. This result meant that the Thorpe-Ingold effect could 
be discounted when considering the difference in reactivity between 215 and 227, and 
between 218 and 228. Attention was next turned to proposing a mechanism for the 
reaction to account for these observations, as well as the fact that HFIP appears to play 
a crucial role in facilitating the reaction. 
 
2.4.2 Proposed Mechanism 
2.4.2.1 Properties of HFIP 
HFIP has several unique properties which might explain its role in the reaction (table 
4), and which TFE and iPrOH do not share to the same extent10. 
 
 
Table 4: Properties of HFIP, TFE and iPrOH. 
 Page | 59  
 
When compared with TFE and iPrOH, HFIP has a lower viscosity, lower boiling point 
and lower entropy of vaporisation, which indicates that the degree of intermolecular 
hydrogen bonding in neat HFIP is lower than in TFE or iPrOH. This is because HFIP 
is a poor hydrogen bond acceptor, but as a hydrogen bond donor, it is uniquely strong 
(table 5).  
 
 
Table 5: Strengths (-ΔH/kJ  mol-1) of hydrogen bonds between HFIP, TFE and EtOH, 
and selected hydrogen bond acceptors. Measured in CCl4, NA = not available. 
 
According to table 5,10,11 the strength of the hydrogen bond between HFIP and a 
hydrogen bond acceptor is much stronger than the bond between TFE or EtOH and an 
acceptor. Most relevantly for the reaction of sulfoxonium ylides, the hydrogen bond 
between HFIP and DMSO is much stronger (ΔH = -36.4 kJ mol-1) than the hydrogen 
bond between  TFE and DMSO (ΔH = -23.4 kJ mol-1). This is significant, as it could 
mean that hydrogen bonding between the sulfoxonium moiety of the ylide and HFIP 
could increase the ability of DMSO to act as a leaving group. Indeed, there is ample 
literature precedent where the hydrogen bond donating ability of  HFIP is used to 
activate a leaving group, for example Paquin and co-worker’s report of a Friedel-
Crafts reaction of benzyl fluorides12 (Scheme 64). 
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Scheme 64: Top: Friedel-Crafts reaction of benzyl fluoride 241 with p-xylene 242. 
Bottom: Proposed mechanism for the reaction 
 
Benzyl fluoride 241 was reported to undergo a Friedel-Crafts arylation reaction in the 
presence of 5 equivalents of p-xylene 242 in HFIP/DCM (1:9), to give diarylmethane 
243 in 90% yield. Given that the reaction would not proceed in the absence of HFIP, 
the presence of a base, or the presence of the methyl ether of HFIP instead of HFIP, a 
mechanism was proposed whereby the benzyl fluoride would form a hydrogen bond 
with HFIP to form complex 244. Cleavage of the C-F bond would then take place, via 
TS1, to form carbocation 245 and a fluoride ion hydrogen bonded to HFIP. Cation 
245 can then undergo electrophilic aromatic substitution with Ar2H to generate the 
diarylmethane and a proton, which would combine with fluoride to generate HF. Since 
HF is itself a very strong hydrogen bond donor, it could then enter the reaction as the 
active catalyst, turning over more benzyl fluoride and generating more HF. The overall 
driving force of the reaction is proposed to be the generation of strong hydrogen bonds 
along the reaction pathway. Other reported examples of HFIP allowing a reaction to 
take place by forming hydrogen bonds with a leaving group include Moran’s report of 
Friedel-Crafts reactions of highly electronically deactivated benzyl alcohols,13 Aubé’s 
reports on the inter- and intramolecular Friedel-Crafts acylation of arenes,14,15 Zhu’s 
report of the use of HFIP in combination with LiCl for Friedel-Crafts reactions,16 and 
Adrio’s report on the dramatic acceleration in rate of olefin epoxidation in HFIP.17  
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Another possible explanation of the crucial role HFIP plays in promoting the 
cyclisation reaction is its ability to stabilise carbocations. For instance, HFIP has been 
reported to arrest certain electrophilic aromatic substitutions, increasing the half-life 
of radical cations enough to allow their study by EPR spectroscopy10. Moreover, the 
use of fluorinated alcohols such as HFIP and TFE has been reported to generate oxy- 
or hydroxyallyl cations from a variety of ketones with leaving groups in α-position. 
For instance, Tang and co-workers reported18 the reaction between 2-
chlorocyclohexanone 246 and 2-naphthol 247 to give 249 (Scheme 65). 
 
 
Scheme 65: Reaction between 246 and 247 in the presence of HFIP and a base. a: 
Yield determined by 1H NMR. 
 
The reaction was proposed to proceed via oxyallyl cation 248, which is trapped by 
naphthol 246. The absolute requirement for the presence of HFIP or TFE is 
demonstrated by all attempts to conduct the reaction in alternative solvents. DMF, 
DMSO, toluene, DCM and acetonitrile all failed to promote the reaction, with only 
traces of product being detected by 1H NMR. This concept is also illustrated by 
MacMillan’s reported19 generation of oxyallyl cations from α-tosyloxyketones in the 
presence of fluorinated alcohols. Thanks to these observations, an initial mechanism 
was proposed where an oxyallyl cation was formed from the sulfoxonium ylide, which 
would then be attacked by the aromatic ring via an SEAr mechanism. Attention was 
then turned to gathering experimental evidence for this mechanism.  
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2.4.2.2 Proposed Mechanism 
The reaction of compound 85 under the standard conditions was followed by 1H NMR, 
and the concentration of starting material was plotted as a function of time (chart 3). 
1H NMR data was collected at AstraZeneca by David Whittaker. 
 
 
Chart 3: Plot of ln ([85]) vs time 
 
The graph of ln([SM]) vs time is  linear, with a good correlation (R2 = 0.99). This 
suggests that the reaction is first order with respect to 85, and should allow the natural 
logarithm to be used when calculating kobs for the Hammett plot. After ~5.5 hours, the 
concentration of starting material had dropped to below 5%, and thus calculations of 
concentration became unreliable. Therefore, these points have been excluded from 
chart 3.                                                              
 
2.4.2.3 Hammett Plots 
As sulfoxonium ylides 214-218 contain para-substituted aryl rings and ylide 213 
contains an unsubstituted ring, it was reasoned that it should be possible to analyse 
each reaction using the Hammett equation, and thus obtain the reaction constant, ρ. 
Generation of an oxyallyl cation followed by Friedel-Crafts attack of the aromatic ring 
would be expected generate a strongly negative (≤ -2.5)20–22 ρ value, as electron 
density would be leaving the aromatic ring during the rate determining step.  
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Experiments were conducted on 213-218 in order to measure the initial rate constant, 
kobs. Each reaction was stopped after 15 mins, and the temperature was increased to 
90 oC in order to have sufficient conversion into product. 
 
Table 6: Conversions of ylides 213-218. [SMt] = concentration of starting material 
after 15 mins. a: Conversions determined by 1H NMR spectroscopy. 
 
Using 213 (R = H, entry 1) led to 28% conversion. 214 had 32% conversion after 15 
mins, whereas the more electron rich 215 (entry 3, R = OMe) led only to slightly 
increased conversion (35%). 216 (entry 4, R = Cl) led to 19% conversion after 15 
mins, and 218 led to 18% conversion. Conversions established, equation 1 was then 
used to obtain kobs for each sulfoxonium ylide (table 7). 
 
                                       kobs =  ln([SM]0 – [SM]t)/t                                                   (1) 
where [SM]0 = initial concentration of starting material 
[SM]t = concentration of starting material at time t (15 mins). 
 
Table 7: Initial rate constants (kobs) of sulfoxonium ylides 213-218. a: The σp value 
for a methyl group was used. 
 
Entry Ylide R1 Product %conversiona [SMt] (M) 
1 213 H 229 28 0.144 
2 214 iBu 230 32 0.136 
3 215 OMe 231 35 0.130 
4 216 Cl 233 19 0.162 
5 218 CF3 235 18 0.156 
Entry Ylide R1 Product kobs 
(min-1) 
Log(kobs(X)/kobs(H)) σp 
1 213 H 229 0.022 0 0.00 
2 214 iBu 230 0.026 0.07 -0.17a 
3 215 OMe 231 0.029 0.12 -0.27 
4 216 Cl 233 0.014 -0.19 0.23 
5 218 CF3 235 0.017 -0.12 0.54 
 Page | 64  
 
Initial rate constants in hand, the Hammett plot could now be obtained (chart 4). The 
Hammett σp constants were used, and were plotted against log((kobs(X))/(kobs(H))), 
where kobs(X) is the initial rate constant for 214-216, and kobs(H) is the initial rate 
constant for 213. 
                                 log (௞(௢௕௦)௑
௞(௢௕௦)ு
)            (2) 
 
 
Chart 4: Plot of log (k(obs)X/k(obs)H) vs Hammett σp constants. 
 
Taking the gradient of chart 3 gives a ρ value of -0.6 (R2 = 0.97). This does not support 
a mechanism where positive charge is put onto the aromatic ring during the rate 
determining step, however, it does suggest a mechanism where electron density is 
leaving the aromatic ring. An identical plot using the Hammett σ+ values led to a ρ 
value of -0.3, but with a poorer correlation (R2 = 0.70, chart 5).  
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Chart 5: Plot of log (kX/kH) vs Hammett σ+ values. 
 
A ρ value of -0.6 is in fact consistent with ρ values reported for a 5-centre, 4π electron 
antarafacial electrocyclisation reaction to form the indanone ring.23–25 For instance, in 
2012, Antonchick and co-workers reported24 a synthesis of carbazoles 251 from 
acetanilides 250, mediated by hypervalent iodine in HFIP (Scheme 66, top).  
 
 
Scheme 66: Synthesis of carbazoles 251 and 252 from acetanilides 250. 
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A series of para substituted acetanilides 250 were synthesised, subject to the optimised 
reaction conditions, and the product ratios were correlated with Hammett σp values. 
Using this method, Antonchick and co-workers were able to obtain a ρ value of -0.501, 
with a good correlation (R2 = 0.99). Having obtained a negative ρ value, they 
concluded that electron density was flowing away from the aromatic ring in the rate 
determining step. Using this, and experiments to determine the primary kinetic isotope 
effect, they were able to propose a mechanism for the reaction (Scheme 66, bottom). 
Oxidation of 250 with hypervalent iodine leads to intermediate 253, which leads to the 
formation of 254. Intermediate 254 can then undergo a 5-centre, antarafacial, 4π 
electron electrocyclic ring closure to form intermediate 255, which re-aromatises to 
give products 251.  
 
Having obtained a plausible mechanism for the key C-C bond forming step, one 
further observation was important in enabling a full mechanism to be proposed. During 
the characterisation of all sulfoxonium ylides utilised in this chapter, it was noted that 
the carbonyl C=O stretch in the infrared spectra was not where it was expected, around 
1750 cm-1. Instead, in all cases it was observed at ~1560 cm-1, e.g., for 85, it was at 
1559 cm-1 (Scheme 67). This suggests that the predominant resonance form of the 
sulfoxonium ylide is not as a ketone, but as an enolate 256 (Scheme 67). 
 
 
Scheme 67: C=O stretch in the infrared spectrum of 85. 
 
Using these data, a full mechanism for the reaction has been proposed (Scheme 68). 
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Scheme 68: Proposed mechanism of formation of indanones from sulfoxonium ylides 
under the HFIP mediated conditions. 
 
Starting from the enolate resonance form of the sulfoxonium ylides, protonation by 
HFIP leads to intermediate 257 (the keto resonance form). Base promoted formation 
of intermediate 258, followed by C-S bond cleavage and loss of DMSO would lead to 
key intermediate 259. The formation of 259 from 258 is thought to be the step in which 
HFIP is indispensable, as its strong hydrogen bond donating abilities would allow it 
to form a hydrogen bonding network with DMSO, promoting C-S bond cleavage. 
Intermediate 259 could then under a 5-centre, 4π electron antarafacial 
electrocyclisation to give intermediate 260, which could then undergo a facile re-
aromatisation to give the indanone products. This mechanism, particularly the 
formation of intermediate 259, can also explain the formation of solvolysis products 
229 and 237 and Favorskii rearrangement product 239 (Scheme 69). 
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Scheme 69: Top: Formation of solvolysis products 229 and 237 from intermediate 
259. Bottom: Formation of Favorskii rearrangement product 239 from intermediate 
259. 
 
If R1 = OMe, then an equilibrium between 259 and 261 led to attack by HFIP on 262, 
a resonance form of 261, to give the solvolysis products 229 and 237. If R2 = H, then 
nucleophilic attack of HFIP is unhindered, and presumably proceeded faster than the 
electrocyclisation. However, if R2 is a more sterically bulky Me group, then the carbon 
atom is more hindered, and nucleophilic attack is slower. That would allow the base 
to convert 261 back to 259 and the electrocyclisation to take place. Conversely, if R1 
= CF3 and R2 = H, then 259 can undergo the Favorskii rearrangement to form 
intermediate 263, which can then undergo ring opening by attack of HFIP on the 
cyclopropananone to form 239. With a satisfactory mechanism proposed, attention 
then turned to further expanding the scope of the reaction. 
 
2.4.3 α-Carbon Substitution 
The next thing that was explored was substitution at the α-carbon atom (Scheme 70). 
This was conducted in order to challenge the system with more sterically demanding 
substituents (e.g. cyclohexyl), and to test the regioselectivity of the reaction. 
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Scheme 70: Variation of the substituent at the α-carbon. a: Reaction conducted at 90 
oC. 
 
Compound 220 (R = allyl) reacted smoothly to give indanone 114 in 88% yield, 
whereas compound 221 (R = benzyl) reacted to give indanone 264 in 67% yield, 
although this required the temperature to be increased to 90 oC. It is noteworthy that 
compound 264 was the sole product of this reaction, with no trace of cyclisation with 
the benzyl group. A more sterically hindered cyclohexyl group in compound 222 led 
to a correspondingly reduced yield, with 265 being isolated in just 8% yield. Next, 
attention was turned to sulfoxonium ylides that would further challenge the 
regioselectivity of the reaction 
 
2.4.4 Regioselectivity 
Sulfoxonium ylide 223 was synthesised via the acid chloride, and subject to the 
optimised reaction conditions. Compound 223 was a desirable compound as it contain 
two aryl rings which have the potential for cyclisation to occur, with one being more 
electron rich than the other (Scheme 71). 
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Scheme 71: Reaction of sulfoxonium ylide 223 under the HFIP mediated 
electrocyclisation. 
 
Compound 220 gave a mixture of regioisomers 263 and 264 in 74% yield and in a 6:1 
ratio. As expected, the major regioisomer resulted from cyclisation occurring on the 
more electron rich ring. Unfortunately, the two regioisomers could not be separated 
by column chromatography. To further test the regioselectivity of the reaction, 
sulfoxonium ylides 268-271 were synthesised (Scheme 72). 
 
 
Scheme 72: Synthesis of sulfoxonium ylides 268-271 via the 4-nitrophenyl esters 
 
Compound 268 was isolated in quantitative yield from the corresponding 4-
nitrophenyl ester. Compounds 269-271 are derived from the NSAIDs naproxen, 
carprofen and zaltoprofen respectively, so the carboxylic acids were commercially 
available. In the case of naproxen and zaltoprofen, the acids were used as received in 
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the DCC mediated coupling, whereas carprofen had to first undergo N-methylation by 
deprotonation with excess NaH followed by quenching with MeI. The resulting acid 
was then used in the DCC mediated coupling. Compound 269 was isolated in 85% 
yield, compound 270 in 77% yield and compound 271 in 45% yield. The results of 
compounds 268-271 under the HFIP mediated electrocyclisation reaction are shown 
in Scheme 73. 
 
 
Scheme 73: Reaction of 268-271 in the HFIP mediated electrocyclisation. a: After 48 
h at 60 oC. 
 
Compound 268 gave indanone 272 in 85% yield as a single regioisomer. The 
regioselectivity can be explained by a desire to avoid steric clash with the methoxy 
groups, as would happen it the other regioisomer was formed. Compound 269 gave 
compound 273 in 91% yield, again as a single regioisomer, although it required an 
extended reaction time to achieve this yield. Compound 270 gave compound 277 in 
68% yield, again as a single regioisomer, and again requiring an extended reaction 
time. However, compound 271 gave 1:1 ratio of both regioisomers 278 and 276 in 
51% yield. Unfortunately, the regioisomers could not be separated by column 
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chromatography. To further expand the scope of the reaction, compounds 277 and 278 
were synthesised (Scheme 74). 
 
 
Scheme 74: Synthesis of sulfoxonium ylides 277 and 278 
 
In both cases, the sulfoxonium ylides were synthesised from the 4-nitrophenyl esters. 
In this case, the carboxylic acids were not commercially available, and required multi-
step syntheses. For instance, in the case of 277, the first step was the palladium 
catalysed cross-coupling between 4-bromoindole 279 and tert-butyl acetate to give 
ester 286 (Scheme 75). Enolate formation and subsequent quenching with MeI led to 
ester 287, followed by trimethylsilyliodide mediated hydrolysis to give acid 285. This 
was a common intermediate in the synthesis of 277 and 278. For 277, it could be used 
directly in the synthesis of the 4-nitrophenyl ester. For 278, tosyl deprotection with 
refluxing KOH, followed by N-methylation gave the relevant carboxylic acid, which 
was then used in the synthesis of the nitrophenyl ester. For full details on the synthesis 
of all intermediates and sulfoxonium ylides, see chapter 3. 
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Scheme 75: Synthesis of carboxylic acid 285. 
 
With 277 and 278 in hand, both were subjected to the HFIP mediated 
electrocyclisation reaction (Scheme 76). Tosyl was chosen as the protecting group due 
to literature precedent suggesting that carbamates, particularly tert-butoxycarbonyl 
(Boc) groups can be deprotected using HFIP.26 
 
 
Scheme 76: Reaction of 277 and 278 in the HFIP mediated electrocyclisation. 
 
Compound 277 reacted smoothly to produce indanone 286 in 65% yield, with the Ts 
group remaining intact throughout the reaction. Compound 278 also reacted smoothly 
to produce indanone 287 in 64% yield. The electronic nature of the nitrogen 
substituents in 277 and 278 is very different, yet the yield  remained virtually 
unchanged for both. Therefore, it was assumed that the electronic nature of the 
nitrogen substituent had not had any effect on the reactivity of either 277 or 278. 
Encouraged by these results, further expansion of the scope was conducted with the 
synthesis of sulfoxonium ylides 285-290 (Scheme 77). These were synthesised in 
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order to challenge the system further, as an alternative reaction with the pyrrole rings 
is also theoretically possible. 
 
Scheme 77: Synthesis of sulfoxonium ylides 285-287. 
 
Sulfoxonium ylides 285-287 were synthesised via the 4-nitrophenyl esters in moderate 
yields. However, since the carboxylic acids were not commercially available, they also 
required multi-step syntheses. For instance, carboxylic acid 290, leading to 285, was 
synthesised in 2 steps (Scheme 78), by first treating ester 288 with K2CO3 and 
paraformaldehyde to synthesise acrylate 289 in 16% yield. Tandem Michael 
addition/saponification led to acid 290, which could be used directly in the synthesis 
of the nitrophenyl ester.  
 
 
 Page | 75  
 
Scheme 78: Synthesis of carboxylic acid 290. 
 
In the case of 286 and 287, synthesis of the carboxylic acids was accomplished by 
deprotonation of 288 and methyl phenylacetate respectively with LDA in a similar 
manner to that described for 277 and 278 (Scheme 75), followed by addition of the 
relevant alkylating agent. Saponification of the resulting methyl ester led to the 
carboxylic acids. Alkyl iodide 292 and alkyl bromide 295 (Scheme 79) were found to 
be the best alkylating agents for the synthesis of 286 and 287 respectively, and they 
were synthesised using the methods outlined in Scheme 79. For full details of the 
synthesis of intermediate carboxylic acids, see chapter 3. 
 
 
Scheme 79: Synthesis of 292 and 295. 
 
With sulfoxonium ylides 285-287 in hand, each was subjected to the HFIP mediated 
electrocyclisation reaction (Scheme 80). 
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Scheme 80: Reaction of sulfoxonium ylides 285-287. 
 
Contrary to expectations, compounds 285 and 287 proved to be unreactive. Neither 
indanones 296 and 298, nor 6- and 8-membered rings 297 or 299 were detected, and 
the starting materials were recovered unchanged. In contrast, compound 286 proved 
to be very reactive indeed, as tetracycle 300 was isolated in 85% yield, with azepinone 
301 being isolated in 15% yield. The formation of 300 is presumed to proceed via the 
4π electron electrocyclisation to give the indanone 302, which then undergoes 
intramolecular nucleophilic attack by the pyrrole (Scheme 81, top) to give tertiary 
alcohol 303. Base mediated E2 elimination would then take place to form 300. 
Compound 301 is likely formed by an SEAr-type mechanism involving nucleophilic 
attack of the pyrrole on the protonated ylide (Scheme 81, bottom). All attempts to 
prevent intramolecular nucleophilic attack of the pyrrole, including addition of 1-10 
equivalents of water or DMSO, and lowering the reaction time or temperature to 
prevent the elimination, simply resulted in lower yields of 300 and 301.  
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Scheme 81: Top: Reaction of 286 via indanone 302. Bottom: Formation of 301 from 
286. 
 
To check whether compound 301 was an intermediate in the conversion of 286 into 
300 or indanone 302, it was subjected to the standard reaction conditions (Scheme 85). 
However, no reaction was observed and compound 301 was recovered unchanged. 
 
 
Scheme 85: Attempted conversion of 301 into indanone 302 or tetracycle 300. 
 
2.4.5 Heterocycles 
Encouraged by the isolation of azepinone 301, which proved that under some 
circumstances, pyrrole could undergo cyclisation under the HFIP mediated conditions, 
attention was next turned to the synthesis of sulfoxonium ylides 306-311 (Scheme 86). 
 Page | 78  
 
 
Scheme 86: Synthesis of sulfoxonium ylides 306-311. 
 
Sulfoxonium ylides 306-311 were synthesised via the corresponding 4-nitrophenyl 
esters in moderate to excellent yields. Again, carboxylic acids were not commercially 
available, so were synthesised in house. For instance, carboxylic acids leading to 307 
and 309-311 were synthesised in one step from alanine, phenylglycine, phenylalanine 
and homophenylalanine respectively, using a similar method to that shown for alkyl 
bromide 295 (Scheme 79, bottom). Full details on the synthesis of all intermediates is 
available in chapter 3. With sulfoxonium ylides in hand, 306-308 were first subjected 
to the HFIP mediated electrocyclisation (Scheme 90). 
 
 
Scheme 90: Reaction of 306-308 under the HFIP mediated electrocyclisation 
conditions. 
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Unlike compound 286, compounds 306-308 did not appear to undergo cyclisation, as 
solvolysis products 312-314, were the only detectable products. Yields were uniformly 
poor, with the remainder of the mass balance being unreacted starting material. 
Compounds 309 and 310 were next subject to the HFIP mediated electrocyclisation 
reaction (Scheme 85). 
 
 
Scheme 85: Reaction of 309 and 310 under the HFIP mediated electrocyclisation 
conditions. 
 
In the case of 309, solvolysis product 315 was isolated in 56% yield. In contrast, 310 
proved to be unreactive, with no traces of solvolysis product 316 detected, and the 
starting material was recovered unchanged. To account for these observations, a 
mechanism was proposed (Scheme 86) which involved the formation of intermediate 
319, where the carbocation could be stabilised by its proximity to the electron rich 
pyrrole ring. Intermediate 319 could then be attacked by HFIP to form 320, 
protonation of which would form the observed products 312-315.  
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Scheme 86: Proposed mechanism for formation of 312-315. 
 
Undeterred, it was next decided to synthesise sulfoxonium ylides 321-325, to see if 
heterocycles other than pyrrole would react under the HFIP mediated 
electrocyclisation conditions (Scheme 90). 
 
 
Scheme 90: Synthesis of 321-325. 
 
Compounds 321-325 were synthesised from the 4-nitrophenyl esters in moderate 
yields. Carboxylic acids again required multi-step syntheses. For example, 321 and 
322 required Wittig reactions between 2- and 3-coumaranones 326 and 329 and 
commercially available phosphonium ylide 327 (Scheme 88) to give esters 328 and 
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330. Saponification of 328 and 330 led to the carboxylic acids which could then be 
used directly in the synthesis of the 4-nitrophenyl esters.  
 
 
Scheme 88: Synthesis of esters 329 and 331. 
 
Compound 324 was synthesised from ester 331 by treating it with 10 equivalents of 
NaOH and 10 equivalents of TsCl in DCM at -20 oC (Scheme 89) which gave tosyl 
protected ester 332. Methylation of 332 with LDA/MeI using methods described 
previously followed by saponification led to the carboxylic acid. For full details, see 
chapter 3. 
 
 
Scheme 89: Synthesis of 332, an intermediate in the synthesis of 323. 
 
Sulfoxonium ylides in hand, compounds 321 and 322 were first subjected to the HFIP 
mediated electrocyclisation (Scheme 90). 
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Scheme 90: Reaction of 321 and 322. 
 
Compound 321 reacted smoothly produce indanone 333 in 87% yield, and compound 
322 also underwent clean conversion to indanone 334 and isomer 335 in 13% and 75% 
yield respectively. In neither case could any solvolysis product be detected. 
Interestingly, 335 proved to be an intermediate in the reaction, as 28% conversion to 
334 by 1H NMR was observed when 335 was subjected to the standard conditions. 
This perhaps suggests that reaction of 322 is slower than 321. Compounds 323 and 
324 were then subjected to the electrocyclisation conditions (Scheme 91). 
 
 
Scheme 91: Reaction of compounds 323 and 324. 
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Compound 323 proved to be less reactive than either compound 321 or 322, with 
indanone 336 being isolated in only 30% yield, with 8% yield of methyl ketone 337. 
Ketone 337 and indanone 336 could not be separated by column chromatography. 
Compound 337 is likely to be formed by protonation of reaction intermediates such as 
259. Interestingly, compound 324 proved to be much more reactive, with indanone 
338 being isolated in 50% yield, alongside compound 339 in 31% yield. Compounds 
338 and 339 were easily separable by column chromatography, and, like compound 
335, compound 339 proved to be an intermediate in the reaction, as evidenced by its 
conversion into indanone 338 when placed under the standard conditions. Next, 
compound 325 was subjected the electrocyclisation reaction (Scheme 92). 
 
 
Scheme 92: Reaction of 325. 
 
Compounds 340 was not detected, and compound 325 was recovered unchanged. 
Attention was then turned back to compounds 305 and 306 as well as 325, and attempts 
were made to carry out cyclisation of these compounds. 
 
2.5 Iridium Catalysed Cyclisation of  Heteroaryl Sulfoxonium 
Ylides 
2.5.1 Introduction 
Exploration of the intramolecular metal catalysed cyclisation of sulfoxonium ylides 
was begun in order to achieve cyclisation on heteroaromatic rings such as pyrroles 
305 and 306, or indole 322, none of which underwent HFIP mediated 
electocyclisation. Inspired by the apparent intramolecular C-H functionalisation on a 
pyrrole using [Ir(cod)Cl]227, and Hopmann’s 2017 report on the synthesis of pyrroles 
by C-H functionalisation of β-enamino esters28, cyclisation of 305 into 340 and 306 
into 342 was accomplished using 10 mol% [Ir(codCl]2 (Scheme 93).  
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Scheme 93: Iridium catalysed cyclisations of 305 and 306. 
 
2.5.2 Optimisation of Conditions 
 
Scheme 94: Optimisation of the catalyst. a: Microwave heating used. tfa: 
Trifluoroacetate. tht: Tetrahydrothiophene 
 
Firstly, attempts were made at changing the catalyst. Treating 306 with 10 mol% 
[Ir(cod)Cl]2 in 1,2-DCE at 80 oC for 10 mins resulted in only 18% yield of 342 (entry 
1). Increasing the reaction time to 16 h led to  60% yield of 342 (entry 2), and the 
catalyst loading and reaction time could both be lowered by switching to microwave 
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heating (entry 3), which resulted in a 64% yield of 342. Switching to 305 (R = H) with 
10 mol% [Ir(cod)Cl]2 for 10 mins resulted in 74% yield of 341 (entry 4). Switching to 
10 mol% [Rh(cod)Cl]2 resulted in no reaction under identical conditions (entry 5), and 
the starting material was recovered unchanged. Using 10 mol% [Cp*IrCl2]2 (entry 6) 
resulted in 65% yield of 341, whereas [Cp*RhCl2]2 also resulted in no reaction (entry 
7). Since rhodium (II) carboxylates are used for the intramolecular cyclisation of α-
diazoketones (chapter 1), it was decided to test Rh2(OAc)4 and Rh2(tfa)4 (tfa = 
trifluoroacetate) for the intramolecular cyclisation of 306 (entries 6-8). When 10 mol% 
Rh2(OAc)4 was used, after 10 mins there was no reaction (entry 8). Even when 
microwave heating was used, no reaction was observed (entry 3 vs entry 9). Only when 
the reaction time was extended to 16 h (entry 10) did the yield of 342 increase to a 
comparable level to that obtained using [Ir(cod)Cl]2 (entry 10 vs entries 2 and 3), 
however, using 5 mol% of Rh2(tfa)4 resulted in no reaction (entry 11). Simple iron (II) 
salt FeBr2 was reported by Hopmann’s group29 for the synthesis of indolizines from 
vinyl sulfoxonium ylides and pyridines, so it was decided to try this salt for the 
intramolecular cyclisation of 306. However, using 5 mol% FeBr2 resulted in no 
reaction (entry 12). Gold (I) catalysts have been reported by Merck30 for the X-H 
insertion of sulfoxonium ylides, however, gold (I) complex AuCl(tht) (tht = 
tetrahydrothiophene) showed no reactivity towards the intramolecular cyclisation of 
306 (entry 13). Since no catalyst had shown improvement over [Ir(cod)Cl]2, it was 
chosen to examine the reaction of compound 325 under metal catalysis (Scheme 95). 
 
 
Scheme 95: Reaction of 325 under iridium catalysis. 
 
To our delight, compound 325 underwent smooth cyclisation into 340 with 10 mol% 
[Ir(cod)Cl]2 in 58% yield after 10 mins. Noting that, in the case of compound 305, 
microwave irradiation had allowed reduction of the catalyst loading to 1 mol% whilst 
maintaining the yield of 341 (Scheme 94, entry 3), it was decided to examine the effect 
of microwave irradiation much more closely (Scheme 96). 
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Scheme 96: Effect of microwave irradiation and catalyst loading on reaction time and 
yield. MW = microwave. 
 
With 10 mol% [Ir(cod)Cl]2, after 10 minutes in the microwave, the reaction had gone 
to completion and 89% yield of 340 was obtained (entry 1). Lowering the catalyst 
loading to 5 mol% lowered the yield to 66% (entry 2). Therefore, when the catalyst 
loading was lowered to 1 mol% (entry 3), the reaction time was increased to 1 h, and 
this resulted in 80% yield of 340. Increasing the reaction time to 2 h (entry 4) increased 
the yield to 85%. Optimised conditions in hand (Scheme 95, entry 4), attention was 
next turned to the expansion of the scope of the reaction. 
 
2.5.3 Scope 
2.5.3.1 Regioselectivity  
Firstly, the reaction of compounds 308-310 under iridium catalysis was examined 
(Scheme 97). Compounds 308-310 would challenge the system as all three contain 
alternative aromatic rings or C-H bonds that have been reported to undergo rhodium 
(II) catalysed reaction with α-diazoketones (chapter 1). 
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Scheme 97: Reaction of 308-310 under iridium catalysis 
 
Compound 308 contains an alternative aromatic C-H bond that could be functionalised 
to synthesise indanone 343. However, 343 was not detected, and pyrrolizinone 344 
was isolated in 90% yield. Compound 309 could undergo a Buchner reaction to 
synthesise azulenone 345. However, 345 was not detected, and pyrrolizinone 346 was 
isolated in 95% yield. Compound 310 could undergo either secondary aliphatic C-H 
insertion to give cyclopentanone 347, or heteroaromatic C-H insertion to give 
compound 348. However, compound 347 was not detected, and pyrrolizinone 348 was 
isolated in 79% yield, albeit with an increased catalyst loading. Next, compounds 285-
287 were subjected to iridium catalysis, to further examine the regioselectivity of the 
reaction (Scheme 98). 
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Scheme 98: Reaction of 285-287 under iridium catalysis.  
 
Compound 285 underwent smooth reaction to give indolizinone 297 in 94% yield, 
with no trace of indanone 296. Similarly, 286 underwent smooth reaction to give 
azepinone 301 in 90% yield, with no trace of indanone 302. This is a much higher 
yield and greater selectivity compared with the HFIP mediated electrocyclisation of 
compound 286, which gave tetracycle 300 in 85% yield, with 15% yield of 301. 
Compound 287 underwent smooth reaction to give azocinone 299 in 56% yield, again 
with no trace of indanone 298, although this reaction required higher catalyst loading 
and temperature, and longer reaction time. In each case, reaction has occurred on the 
more nucleophilic aromatic ring, even though it is the less entropically favoured 
pathway.  
 
2.5.3.2 Substituted Pyrrole 
In order to test the impact of an electron withdrawing substituent on the pyrrole, 
compound 351 was synthesised (Scheme 99). A piperazine amide was chosen as 
saturated heterocycles and amide groups are common motifs in biologically active 
molecules. 
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Scheme 99: Synthesis of compound 351. 
 
Compound 351 was synthesised from acid 349 via 4-nitrophenyl ester 350 in 78% 
yield. Acid 349 was synthesised in 3 steps (Scheme 100) from commercially 
available 1-Boc-piperazine 352 and acid 353, utilising an amide coupling with 
PyBOP as the coupling agent to give compound 354. Compound 354 was then 
deprotonated using NaH, then quenched with ethyl bromoacetate. The resulting ester 
underwent saponification to give compound 349. 
 
Scheme 100: Synthesis of acid 346. 
 
With compound 351 in hand, it was subjected to iridium catalysis to synthesise 
compound 355 (Scheme 101). 
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Scheme 101: Reaction of compound 351 under iridium catalysis 
 
With 1 mol% [Ir(cod)Cl]2 at 80 oC for 2 h, only 26% yield of 355 was observed (entry 
1). When the reaction time was increased from 2 h to 3 h (entry 2), the yield improved 
to 42%. When the catalyst loading was increased to 5 mol% (entry 3), the yield 
improved still further to 61%, and when the temperature was increased to 100 oC (entry 
4), the yield was a moderate 53% with 2.5 mol% catalyst. The reduced reactivity of 
351 is presumably due to the electron withdrawing nature of the amide group, thus 
making the pyrrole less nucleophilic.  
 
2.5.3.3 Indoles 
In order to further expand the scope of the reaction, compound 358 was synthesised 
(Scheme 102). 
 
 
Scheme 101: Synthesis of compounds 357 and 358. Enantiomeric excess determined 
by chiral chromatography, by comparison with racemic 358. 
 
Compound 358 was synthesised via the corresponding 4-nitrophenyl ester, and was 
isolated in moderate yields. Compound 358 was derived from L-tryptophan, which 
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underwent N-methylation to synthesise acid 356. It is worth noting that the 
stereocentre survived the ylide formation without significant degradation, as reported 
by Nugent and co-workers for the synthesis of sulfoxonium ylides derived from chiral 
amino acids8,9. With compound 358 in hand, it, along with compounds 323-324 were 
subjected to iridium catalysis (Schemes 103 and 104).  
 
 
Scheme 103: Reaction of compound 358. MW = microwave.  
 
Compound 358, underwent smooth cyclisation to afford compound 359 in 85% yield, 
but with significant erosion of stereochemical integrity, with the e.e. dropping from 
92% to 57%. The origin of this loss of e.e. is unknown. Compounds 323 and 324 were 
then subjected to iridium catalysis (Scheme 104). 
 
 
Scheme 104: Reaction of 323 and 324 under iridium catalysis.  
 
Compound 323 underwent smooth cyclisation to afford compound 336 in 80% yield, 
which was isolated cleanly by column chromatography. Compound 337, produced in 
8% yield during the HFIP mediated electrocyclisation reaction, was not detected. On 
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the other hand, compound 324 produced a complex mixture of products, from which, 
compound 339 could be isolated in 5% yield. No other product could be isolated or 
identified, and it appears that compound 324 underwent uncontrolled decomposition 
under the iridium catalysed conditions. Compounds 277 and 278 were next subjected 
to iridium catalysis (Scheme 105). 
 
 
Scheme 105: Reaction of compounds 277 and 278 under iridium catalysis. 
 
Compounds 277 and 278 did not undergo cyclisation. In both cases, a complex mixture 
of products was obtained, from which neither indanones 283 or 284, nor compounds 
360 or 361 could be detected. It appeared that, like compound 324, compounds 277 
and 278 also underwent uncontrolled decomposition under the iridium catalysed 
conditions. 
 
2.5.3.4 Benzofurans 
Compounds 321 and 322 were next subjected to iridium catalysis, to further broaden 
the scope of the reaction to include other heterocycles (Scheme 106). 
 
 
Scheme 106: Reaction of compounds 321 and 322 under iridium catalysis. 
 Page | 93  
 
Compound 321 did not cyclise smoothly, and a complex mixture of products was 
obtained, in which compound 333 could not be detected. Similarly, compound 322 did 
not undergo cyclisation, and neither compound 334 nor compound 335 could be 
detected in the complex mixture of products that was obtained.  
 
2.5.3.5 Amides 
In order to further broaden the scope of the reaction, amide sulfoxonium ylides 367 
and 368 were synthesised (Scheme 107). Synthesis and full characterisation of 
compound 365-368 was carried out by undergraduate students Pierre Palamini and 
Isobel Jobson.  
 
 
Scheme 107: Synthesis of compounds 366 and 367. Synthesis carried out by Pierre 
Palamini and Isobel Jobson. CDI: carbonyldiimidazole. 
 
A THF solution of N-methyl anilines 362 and 363 was added slowly to a refluxing 
solution of carbonyldiimidazole (CDI) to afford imidazole 1-carboxamides 364 and 
365. Compounds 364 and 365 were converted into 366 and 367 by treatment with 
dimethylsulfoxonium methylide 1 at 0 oC. With compound 366 and 367 in hand, both 
were subjected to iridium catalysis for the synthesis of oxindoles. Oxindoles have 
previously been synthesised from diazoketones (Scheme 108), and are structural 
motifs found in many natural products and biologically active compounds.  
 
 
Scheme 108: Synthesis of oxindoles from diazoacetamides 
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Various transition metal catalysts have been used for the Friedel-Crafts type 
cyclisation of the aromatic ring onto the corresponding metal carbenoids, including 
rhodium (II) carboxylates31–33, copper (II) salts34–36, and palladium (0)37. These 
reactions were generally high yielding, and by careful choice of ligand, selectivity for 
aromatic C-H insertion over competing secondary aliphatic C-H insertion or N-H 
insertion could be achieved. This transformation has also been achieved through none-
metal catalysed reactions, including with the Bronsted-acidic resin Nafion-H32,38, N-
halosuccinimides39,40, and the electrophilic fluorine source NFSI41. However, this 
transformation has not been achieved using an iridium (I) catalyst, nor has it been 
reported for sulfoxonium ylides. Thus, 366 and 367 were synthesised and subjected to 
the optimised reaction conditions (Scheme 109). Reaction of 367 was carried out by 
Isobel Jobson. 
 
 
 
Scheme 109: Reaction of compounds 366 and 367 under iridium catalysis.  
 
Compound 366 reacted smoothly with 2.5 mol% [Ir(cod)Cl]2 at 80 oC for 2 h, giving 
oxindole 368 in 51% isolated yield. However, when 367 was subjected to the iridium 
catalysis, oxindole 370 was isolated in only 21% yield, with 16% yield of dimer 369. 
The remainder of the mass balance in this case was unreacted 367. The lower reactivity 
and presence of dimer 369 can be explained by the low solubility of 367 in 1,2-DCE, 
forcing molecules of 367 into close proximity, thus promoting dimerisation. In order 
to suppress dimerisation, the use of DMF as a co-solvent was investigated (Scheme 
110). 
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Scheme 110: O’Shea’s reported synthesis of 48 from 47 using [Ir(cod)Cl]2 in 
toluene/DMF as part of the synthesis of MK-7246. Bottom: Use of DMF as a co-
solvent in the iridium catalysed reaction of 368. This reaction was carried out by me. 
 
The choice of DMF as a co-solvent was inspired by O’Shea’s report of the large-scale 
synthesis of MK-724642, in which 48 was synthesised from 47 using [Ir(cod)Cl]2 in a 
toluene/DMF mixture. This was necessary due to the low solubility of 47 in toluene. 
Thus, when 367 was treated with 2.5 mol% [Ir(cod)Cl]2 in an 8.5:1 mixture of 1,2-
DCE and DMF, compound 369 could not be detected, and oxindole 370 was isolated 
in 41% yield, with the remainder of the mass balance being unreacted 367. This 
reaction was carried out by me. The solubility of 367 appeared to be increased in the 
DCE/DMF mixture, and the absence of dimer 369 suggests that low solubility was 
indeed the reason for its formation in 1,2-DCE alone. Investigation of other polar 
aprotic solvents such as NMP or DMSO, either as co-solvents with DCE, or alone, 
was not investigated, but would be useful in order to increase the yield of 370, and to 
further increase the scope of oxindoles accessible from sulfoxonium ylides such as 
367. 
 
2.5.4 Cyclopropanation vs Formal Aromatic C-H Insertion 
α-Diazoketones have been reported to undergo cyclopropanation catalysed by 
rhodium (II) carboxylates (chapter 1). Good selectivity could be achieved for aromatic 
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C-H insertion over cyclopropanation by changing to very electron withdrawing 
carboxylate ligand, e.g. perfluorobutyrate (Rh2(pfb)4). This was rationalised by 
considering that the more electrophilic metal centre in Rh2(pfb)4 preferred to undergo 
the least entropically demanding pathway i.e. C-H insertion. In order to compare these 
results with the iridium catalysed reaction of sulfoxonium ylide, compounds 220 and 
308 were subjected to iridium catalysis (Scheme 111). 
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Scheme 111: Reaction of compounds 220 and 308 under iridium catalysis. 
 
When 220 was subjected to the optimised reaction conditions, 100% selectivity was 
achieved for cyclopropanation, and 115 was isolated in 85% yield. None of the 
indanone 114 could be detected. The presence of 115 when starting from compound 
220 is strong evidence that an iridium carbene is indeed present in this reaction. The 
selectivity of the iridium catalysed reaction is comparable to the reaction of 
diazoketone 113 with Rh2(cap)4, so it could be inferred that the iridium carbene 
generated from 220 and the rhodium carbene generated from 113 and Rh2(cap)4 have 
similar electrophilicity. The iridium catalysed reaction and HFIP mediated 
electrocyclisation of 220 are therefore regiodivergent: the HFIP mediated 
electrocyclisation results in indanone 114 in 88% yield, whereas the iridium catalysed 
reaction results in exclusively cyclopropane 115 in 85% yield. Improvement of the 
diastereoselectivity of the reaction by addition of a chiral ligand was not attempted, 
but would be useful way to develop this reaction further. In contrast, the selectivity of 
the iridium catalysed reaction with 308 is poor, with pyrrolizinone 371 being the major 
product, and cyclopropane 372 being isolated in only 39% yield, but with a similar 
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d.r. to 115. The poorer selectivity could be due to the more nucleophilic nature of the 
pyrrole ring compared with the phenyl ring of 220: the more nucleophilic pyrrole could 
favour the less entropically demanding reaction pathway (i.e. formal C-H insertion), 
whereas the less nucleophilic phenyl ring allows the more entropically demanding 
cyclopropanation reaction to take place. Next, compound 376 was synthesised 
(Scheme 112). Synthesis and full characterisation of compound 374-375 was carried 
out by Isobel Jobson. 
 
 
Scheme 112: Synthesis of compound 375. 
 
Compound 374 was synthesised from N-allylaniline 373 using the same route 
described for compounds 365 and 366. Compound 375 in hand, it was subjected to 
iridium catalysis (Scheme 115). This reaction was carried out by Isobel Jobson. 
 
N
O
S
O
375
[Ir(cod)Cl]2 (2.5 mol%)
1,2-DCE (0.02 M)
80 oC, MW, 2 h
N
O
+ N
O
Ph
376
26%
377
74%  
Scheme 113: Reaction of compound 375 under iridium catalysis. 
 
Compound 375 reacted smoothly to give oxindole 376 in 26% yield and cyclopropane 
377 in 74% yield. In this case, the selectivity is the reverse of that seen for compound 
308. This result could be explained in the context of 220 and 308 by considering the 
relative nucleophilicity of each aromatic ring. The very electron rich pyrrole in 308 
favours formal C-H insertion, and thus 371 is the major product. A slightly less 
electron rich aromatic system in 375 means that although both possible products are 
formed, cyclopropane 377 is the major one. An even less electron aromatic system in 
220 means that formal aromatic C-H insertion does not occur, and cyclopropane 115 
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is the only product. The trend of less electron rich aromatic rings favouring 
cyclopropanation suggests that the reaction does not proceed via formal insertion of 
the carbene into the aromatic C-H bond. 
 
2.5.5 Mechanistic Study 
Attention was next turned to the elution of a potential mechanism for the reaction. 
Compounds 381 and d-381 (Scheme 114) were synthesised in order to study the 
deuterium kinetic isotope effect to see if C-H cleavage was likely to be involved in the 
rate determining step. 
 
Scheme 114: Top: synthesis of compound 386 and d-386. 
 
Compound 381 and d-381 were synthesised from carboxylic acids 379 and d-379 
respectively, via the 4-nitrophenyl esters 380 and d-380 in 70% and 62% yield. 
Compound 379 was synthesised in two steps from indole 385 (Scheme 115). 
Compound 385 was deprotonated with NaH, and the resulting anion was quenched 
with methyl bromoacetate to afford ester 386, which was saponified with NaOH to 
afford acid 379 (Scheme 115, top). Acid d-379 was synthesised from deuterated indole 
d-385. Compound d-385 was synthesised from 385 (Scheme 115, bottom), first by 
protection with benzenesulfonyl chloride to afford compound 390, then by directed 
ortho-lithiation with nBuLi followed by quenching with D2O to give compound d-390. 
Removal of the benzenesulfonyl group with NaOH gave d-385. Compound d-385 was 
then subject to the same sequence of reactions as 385 to afford compound d-381. For 
full details, see chapter 3. 
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Scheme 115: Top: Synthesis of carboxylic acid 379. Bottom: Synthesis of d-385. 
 
With compound 381 and d-381 in hand, both were subjected to iridium catalysis 
(Scheme 116). 
 
 
Scheme 115: Reaction of 386 and d-386. MW = microwave 
 
Compound 381 reacted smoothly to afford compound 385 in 85% yield. A catalyst 
loading of 2.5 mol% was required in order to achieve this yield, and attempts to lower 
the catalyst loading to 1 mol% resulted in both lower conversion of 381 and lower 
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isolated yield of 385. Compound d-381, which was found to be 100% deuterated using 
1H and deuterium NMR, was then subjected to identical conditions, which led to a 
78% isolated yield of 385. However, 1H and deuterium NMR of 385 isolated after 
column chromatography showed that no deuterium incorporation had occurred, 
despite d-381 being 100% deuterated. The reaction with d-381 was therefore repeated, 
and 1H and deuterium NMR were recorded on the crude product (Scheme 117). 
 
 
Scheme 117: Reaction of d-381 and deuterium incorporation into the product 
 
After 30 mins at 100 oC, crude 1H NMR showed that there was full conversion of d-
381 into 385, and deuterium NMR confirmed that 385 had been 60% deuterated at 3-
position of the indole, with smaller levels of deuteration either side of the ketone. It 
was assumed that the deuterium had been lost during column chromatography. Parallel 
reactions of 381 and d-381 were then carried out, with the conversion being measured 
by 1H NMR of the crude residue after evaporation of the solvent. To allow 
measurement of the initial rate, the catalyst loading was reduced to 1 mol% and the 
temperature was lowered to 80 oC (Scheme 118). 
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Scheme 118: Parallel reactions of 381 and d-381. MW = microwave. 
 
Reaction of compound 381 under these conditions resulted in 30.02% conversion to 
385, whereas compound d-381 resulted in 30.00% conversion to d-385, giving a 
deuterium kinetic isotope effect kH/kD = 1.00. This result means that there is no 
deuterium kinetic isotope effect, therefore C-H cleavage is not involved in the rate 
determining step. The proposed mechanism that explains the observed deuterium 
labelling and lack of kinetic isotope effect is shown in Scheme 119. 
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Scheme 119: Proposed mechanism of the iridium catalysed cyclisation. 
 
Iridium carbene 386 would be formed from 381 or d-381, and this would undergo a 
nucleophilic attack by the aromatic ring to give intermediate 390. Intermediate 390 
could then undergo a 1,2-migration to give intermediate 388. Elimination of the 
iridium from 388 would give 389, which could undergo a facile re-aromatisation to 
give 385 and d-385. Alternatively, intermediate 386 could undergo cyclopropanation 
to give intermediate 390. Collapse of 390 would give intermediate 391, which is also 
capable of undergoing a 1,2-migration to give intermediate 389. This mechanism 
would explain the observed deuterium labelling, as deuterium would be transferred to 
the 3-position during the 1,2-migration.  
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2.5.6 Chemospecificity  
During the optimisation of the HFIP-mediated electrocyclisation, a variety of metal 
catalysts were tested in the reaction (Scheme 120). This work was carried out to check 
if any metal catalyst could give a comparable yield to the metal free, HFIP-mediated 
electrocyclisation.  
 
 
Scheme 120: Reactivity of 85 towards different metal catalysts. 
 
However, 85 proved to be unreactive towards iridium (I), rhodium (I), iridium (III), 
rhodium (III) and copper (II) catalysts, both in the presence and absence of 2 
equivalents of AgBF4 as an additive. This was the case even when 10 mol% 
[Ir(cod)Cl]2 was used in conjunction with microwave heating (entry 2), with 85 being 
recovered unchanged. This contrasts with 305 and 306, which both reacted smoothly 
under microwave irradiation. Since rhodium (II) carboxylates have been reported to 
undergo aromatic C-H insertion with aryl α-diazoketones, it was decided to test 
Rh2(OAc)4 and Rh2(tfa)4, alongside FeBr2 and AuCl(tht) (Scheme 121). 
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Scheme 121: Reaction of 85 with rhodium (II), gold (I) and iron (II) catalysts 
 
Using 10 mol% of Rh2(OAc)4 (entry 1) resulted in no reaction, and even under 
microwave irradiation, there was no reaction with this catalyst (entry 2). Rh2(tfa)4 also 
proved to be unreactive (entry 3), as did AuCl(tht) and FeBr2 (entries 4 and 5). Finally, 
a selection of sulfoxonium ylides that had shown reactivity under the HFIP mediated 
conditions (Scheme 122). 
 
 
Scheme 122: Examples of sulfoxonium ylides which did not undergo the iridium 
catalysed reaction 
 
Compound 270, which had cyclised smoothly to give indanone 271 under the HFIP 
mediated electrocyclisation, showed no reactivity under the iridium catalysed 
conditions. Compound 227 was similarly unreactive, as no indanone could be 
detected, and 227 was recovered unchanged. Compound 216, which under the HFIP 
mediated conditions gave 233 in 81% yield with microwave irradiation was unreactive 
under the iridium catalysed conditions, with no 233 being detected. Compound 269, 
which had produced 273 in 91% yield under the HFIP mediated electrocyclisation, 
also did not react under the iridium catalysed conditions, with neither 273 nor its 
regioisomer being detected.  
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2.6 Future Work 
2.6.1 HFIP Mediated Electrocyclisation 
2.6.1.1 Further Investigation of the Regioselectivity 
Although the regioselectivity of the reaction has already been examined somewhat, 
examination of 3-substituted aromatic rings was desired in order to test the effect of 
sterics on the reaction. To that end, a preliminary investigation using sulfoxonium 
ylide 394 was synthesised, (Scheme 123), and preliminary investigations were carried 
out (Scheme 124). 
 
 
Scheme 122: Synthesis of ylide 394. 
 
Compound 394 was synthesised in 27% yield via 4-nitrophenyl ester 393. Since this 
compound was synthesised for preliminary results only, it was characterised by 1H 
NMR only. Compound 392 was synthesised in 2 steps from 2-phenylpyridine and 
methyl 2-bromopropanate (Scheme 123). 
 
 
Scheme 123: Synthesis of acid 392. 
 
A ruthenium (II) catalysed alkylation of 2-phenylpyridine with methyl 2-
bromopropanoate gave ester 395 in 68% yield. Saponification of 395 led to acid 392. 
With compound 394 in hand, it was subjected to the HFIP mediated electrocyclisation 
(Scheme 124). 
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Scheme 124: Reaction of sulfoxonium ylide 394. 
 
If 394 undergoes cyclisastion, two regioisomers are possible, 396 if H1 is lost, and 397 
if H2 is lost. Since H1 is much more sterically hindered than H2, it might be expected 
that 397 would be the dominant isomer. A total yield of 52% was observed for this 
reaction, with a 1:2.7 regioisomeric ratio. It is notable in this case that the two 
regioisomers were separable by flash column chromatography, and it was assumed 
that 397 was the dominant regioisomer for the steric reasons outlined previously. With 
these preliminary results in hand, it would be desirable to synthesise a range of 3-
phenyl, 3-methyl and 3-isopropyl phenyl sulfoxonium ylides, and test the effect on the 
regioselectivity of the HFIP-mediated electrocyclisation (Scheme 125). 
 
 
Scheme 125: Potential future work testing the steric effects of substituents in the 3-
position. 
 
Furthermore, the rhodium (III) catalysed reaction disclosed previously by the Aїssa 
group was also carried out on compound 394 (Scheme 126). 
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Scheme 126: Rhodium (III) catalysed reaction of compound 394. 
 
In this case, it may be expected that compound 396 would be the dominant 
regioisomer. However, both isomers were isolated in 31% total yield in a 1:1 ratio. 
Further investigation of the reasons for this, and attempts to modify the reaction 
conditions to improve the yield and regioselectivity, would be worthwhile. 
 
2.6.1.2 Application to a Biologically Active Molecule 
It may also be desirable to show that a reaction works on multi-gram scale, and to 
show its application in the synthesis of biologically active molecules. In 2012, Abbott 
disclosed43 398 (Scheme 127) as a potent inhibitor of GlyT1 for the treatment of 
neurological and psychiatric disorders, and this compound offers the opportunity to 
demonstrate both scale up, and application of the HFIP-mediated electocyclisation. 
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Scheme 127: Top: Potential retrosynthesis of compound 398 to sulfoxonium ylide 
401. Bottom: Proposed forward synthesis of 398 from 401. Dashed arrows: reactions 
planned, but not carried out. 
 
A functional group interconversion of the amine to the ketone reveals indanone 399. 
Disconnection of the C-O bond and formation of a methyl ether gives 400, which can 
then be disconnected back to sulfoxonium ylide 401. For the forward synthesis, a 
multi-gram scale HFIP mediated cyclisation of 401 would give 400, and a reductive 
amination with azetidine would give amine 402. Demethylation of the methyl ether 
with BBr3 would give phenol 403, and alkylation of this with 404 would give the final 
product in 4 steps from the sulfoxonium ylide.  
 
2.6.1.3 Intermolecular Reactions 
Given the postulated mechanism outlined in Scheme 68, it would be desirable to see 
if intermediate 259 can trapped with nucleophiles other than HFIP. To that end, 
sulfoxonium ylide 227 was reacted with aniline 405 in HFIP, both in the presence of 
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K2CO3, and in its absence (Scheme 128). This reaction was carried out by Sarah 
Livesley. 
 
 
Scheme 128: Intermolecular reaction of sulfoxonium ylide 227 with aniline 405 to 
give 406. 
 
Methyl ketone 406 was isolated in 34% yield under the optimised reaction conditions 
for intramolecular cyclisation. These preliminary results suggest that intermolecular 
trapping of intermediate 256 is possible, and it would be desirable to optimise the 
reaction further and build a scope with a variety of C-, N-, O-, and S-based 
nucleophiles for the synthesis of substituted methyl ketones. 
 
2.6.2 Iridium Catalysed Cyclisation 
To further investigate the regioselectivity of the iridium catalysed cyclisation, 
compound 412 was next synthesised (Scheme 129) via the nitrophenyl ester. This 
compound was synthesised via 4-nitrophenyl ester 411. The carboxylic acid was 
synthesised from 2-vinylpyridine 407 and TOSMIC to give pyrrole 408. Alkylation of 
the pyrrole with methyl bromoacetate gave ester 409, and saponification of 409 gave 
the acid 410. 
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Scheme 129: Synthesis of sulfoxonium ylide 412. 
 
With compound 412 in hand, it was subjected to the iridium catalysed reaction 
(Scheme 130). In this case, it might be expected that compound 413 would be the 
dominant regioisomer, as the pyridine would co-ordinate to the iridium during the 
course of the reaction.  
 
 
Scheme 130: Reaction of ylide 412 under the iridium catalysed conditions. 
 
Regioisomers 413 and 414 were both produced in this reaction, in low overall yield, 
and poor regioselectivity (1.5:1 ratio). Once again, 413 and 414 were separable by 
column chromatography. It would be desirable to try to increase both the yield and 
regioisomeric ratio of this reaction, and to synthesise sulfoxonium ylides with a phenyl 
ring in the 3-position, to compare yields and selectivities (Scheme 131). 
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Scheme 131: Future development of the reaction in Scheme 130. 
 
2.7 Conclusion 
In conclusion, we have developed a chemospecific cyclisation reaction of sulfoxonium 
ylides on aryl and heteroaryl rings. Firstly, quantitative suggestions of the superior 
safety of sulfoxonium ylides have been obtained through the collection of differential 
scanning calorimetry (DSC) data, with sulfoxonium ylide 85 giving a much lower 
exotherm than its equivalent diazoketone. 
 
Secondly, the synthesis of keto sulfoxonium ylides from p-nitrophenyl esters and acid 
chlorides has been accomplished, although the former was preferred in most cases due 
to the difficulty in removing excess SOCl2 and HCl from synthesised acid chlorides. 
Thirdly, the HFIP mediated electrocyclisation was optimised and the crucial role of 
HFIP in the cyclisation was established, with no other solvent promoting the reaction 
to any degree. HFIP could be used as a co-solvent with toluene or 1,2-DCE, but its 
presence was always required. Fourthly, the scope of the HFIP mediated 
electrocyclisation reaction was established, with 15 different indanones being 
successfully synthesised in yields ranging from 42%-92%. It was also established that 
particularly electron rich (hetero)aromatic rings e.g. pyrroles produced solvolysis 
products, as either the sole product, or as a minor side product with cyclisation being 
the major reaction pathway. Electron poor rings could undergo a Favorskii 
rearrangement to obtain an HFIP ester. Through the observation of first-order kinetics 
with respect to the sulfoxonium ylide, and the construction of a Hammett plot, it was 
determined that the reaction proceeded via a 5-centre, 4π electron antarafacial 
electrocyclisation of key intermediate 259. The presence of key intermediate 259 
could also explain the formation of solvolysis and Favorskii side products.  
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The iridium catalysed cyclisation of heteroaromatic rings was also developed in 
tandem. The catalyst loading was lowered to 1 mol% and the reaction time decreased 
through the introduction of microwave heating. The scope of the reaction was 
developed for the synthesis of pyrrolizinones, indolizinones, azepinones and 
acocinones. 2- and 3-subsituted indoles were also able to undergo cyclisation, and the 
method was also applied to the synthesis of oxindoles and cyclopropanes.  
 
Finally, the striking chemospecificity of the reaction was demonstrated, as aryl 
sulfoxonium ylides 85, 216, 227, 269 and 270 and benzofuranyl sulfoxonium ylides 
321 and 322 were unreactive under the iridium catalysed conditions, whereas pyrrole 
sulfoxonium ylides 305-310 did not cyclise in the HFIP mediated electrocyclisation. 
This chemospecificity has not previously been observed for α-diazoketones or other 
ylides. 
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Chapter 3: Experimental Section 
3.1 Synthesis of Compound 205 
 
 
 
In a flame dried 2-neck RB flask under N2, compound 206 (1 g, 4.71 mmol, 1.0 equiv) 
was dissolved in dry DCM (3 mL, 1.4 M) and cooled to 0 oC using an ice/water bath. 
SOCl2 (0.5 mL, 7.07 mmol, 1.5 equiv) was added dropwise, followed by dry DMF (1 
drop). The reaction was stirred at room temperature for 30 mins, after which a small 
aliquot was taken and quenched carefully with MeOH. TLC showed full conversion 
of 206, and so all volatiles were evaporated using Schlenck techniques. The residue 
was re-dissolved in dry diethyl ether (17 mL, 0.28 M) and TMS-diazomethane (2 M 
in hexanes, 5 mL, 9.89 mmol, 2.1 equiv) was added carefully. The reaction was stirred 
at room temperature overnight, then quenched with water, and extracted three times 
with ethyl acetate. The combined organic layers were washed with saturated aqueous 
NaHCO3 solution, then brine, then dried (MgSO4), filtered and concentrated in vacuo. 
The residue was purified by FCC (9:1 petroleum ether:ethyl acetate) to afford 
compound 205 as a bright orange gum (0.42 g, 1.78 mmol, 38%)/ 
 
Compound 208. 1H NMR (500 MHz, CDCl3): δ 7.32 (m, 10H), 5.25 (s, 1H), 4.93 (s, 
1H), in agreement with previously reported data1.  
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3.2 Synthesis of Compounds 82 and 210-220 
 
Representative Procedure A: In a flame dried 2-neck RB flask under N2, compound 
206 (10 g, 47.12 mmol, 1.0 equiv) was dissolved in DCM (34 mL, 1.4 M), and the 
solution was cooled to 0 oC. SOCl2 (5.2 mL, 70.67 mmol, 1.5 equiv) was added 
dropwise, followed by dry DMF (1 drop). The reaction was stirred for 30 mins at rt, 
and a small aliquot was taken and quenched with MeOH. If this showed full 
conversion of the acid, then all volatiles were evaporated using Schlenck techniques. 
The acid chloride was then re-dissolved in dry THF (94 mL). Meanwhile, in a flame 
dried, 3-neck 500 mL RB flask under N2, trimethylsulfoxonium iodide (21 g, 94.24 
mmol, 3 equiv) was suspended in THF (168 mL) and KOtBu (11 g, 94.24 mmol, 3 
equiv) was added in one portion. The suspension was protected from light using 
aluminium foil and heated at reflux for 2 h, before being cooled to 0 oC using an 
ice/water bath. The THF solution of acid chloride was added dropwise, and then the 
reaction was allowed to warm up to rt over 30 mins. The reaction mixture was the 
filtered through Celite, the Celite pad was washed thoroughly with DCM, and the 
filtrate was concentrated in vacuo. The residue was recrystallised from EtOAc to 
afford compound 82 as a white powder (7.73 g, 27.01 mmol, 57%). 
 
Compound 85. m.p.: 123–126 °C; 1H NMR (500 MHz, CDCl3): δ 7.30-7.29 (m, 8H), 
7.23-7.20 (m, 2H), 4.85 (s, 1H), 4.38 (s, 1H), 3.38 (s, 6H); 13C NMR 
(125 MHz, CDCl3): δ 188.9 (e), 141.0 (e, 2C), 129.0 (o, 4C), 128.3 
(o, 4C), 126.5 (o, 2C), 71.2 (o), 62.2 (o), 42.0 (e, 2C); IR (neat): ~ 
= 3098 (w), 3083 (w), 3053 (w) 3005 (w), 2972 (w, 2918 (w, 1596 
(w), 1559 (s), 1493 (m), 1458 (w), 1448 (w), 1431 (w), 1374 (s), 1322 (w), 1300 (w), 
1257 (w), 1231 (w), 1167 (s), 1119 (s), 1071 (w), 1030 (s), 989 (w), 948 (w), 929 (w), 
909 (w), 861 (s), 818 (w), 789 (w), 758 (w), 743 (s), 724 (s), 695 (s) cm-1; HRMS 
(ESI): m/z calcd for C17H18O2S+H+: 287.1100 [M+H]+; found 287.1103. 
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Representative Procedure B: To a flame dried 2-neck RB flask under N2 was added 
iPr2NH (2.5 mL, 17.98 mmol, 1.8 equiv) followed by THF (14 mL). The reaction was 
cooled to -10 oC using an ice/brine bath, and nBuLi (2.5 M in hexanes, 6 mL, 15.98 
mmol, 1.6 equiv) was added dropwise. The reaction was stirred at -10 oC for 15 min, 
before a solution of methyl phenylacetate (1.4 mL, 9.99 mmol, 1.0 equiv) in THF (28 
mL) was added dropwise. The reaction was then stirred at -10 oC for 30 mins, before 
a solution of methyl iodide (1.2 mL, 19.98 mmol, 2.0 equiv) in THF (14 mL) was 
added slowly. The reaction was allowed to warm up to rt over 1 h, then quenched with 
H2O. The layers were separated and the aqueous washed with EtOAc (x3), and the 
combined organic layers were dried (MgSO4), filtered and concentrated in vacuo to 
afford a brown oil which was used in the next step without further purification (1.8 g, 
10.96 mmol, quant). 
 
Compound 415. 1H NMR (500 MHz, CDCl3): δ 7.35-7.28 (m, 4H), 7.27-7.22 (m, 
1H), 3.72 (q, J = 7.5 Hz, 1H), 3.66 (s, 3H), 1.50 (d, J = 7.2 Hz, 3H), in 
agreement with previously reported data2. 
 
 
Representative Procedure C: Compound 415 (1.80 g, 10.96 mmol, 1.0 equiv) was 
dissolved in THF/H2O (1:1, 44 mL, 0.25 M) and powdered NaOH (2.2 g, 54.81 mmol, 
5.0 equiv) was added. The reaction was heated at reflux for 4 h, then cooled to rt and 
carefully acidified to pH 1 with concentrated HCl, then extracted three times with 
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DCM. The combined organic layers were dried (MgSO4), filtered and concentrated in 
vacuo to afford a sticky brown gum that was used without further purification (0.96 g, 
6.39 mmol, 58%). 
 
 Compound 416. 1H NMR (500 MHz, CDCl3): δ 7.36-7.31 (m, 4H), 7.29-7.25 (m, 
1H), 3.74 (q, J = 7.2 Hz, 1H), 1.52 (d, J = 7.2 Hz, 3H), in agreement 
with previously reported data3. 
 
 
Compound 213: Synthesised according to representative procedure A, except that 
crude compound was purified by FCC (9:1 EtOAc:MeOH), from acid 
416 (0.96 g, 6.39 mmol) to afford compound 213 as a cream powder 
(0.96 g, 4.29 mmol, 67%). m.p. = 68-70 oC; 1H NMR (400 MHz, 
CDCl3): δ 7.30-7.29 (m, 4H), 7.24-7.19 (m, 1H), 4.27 (s, 1H), 3.53 (q, 
J= 7.2 Hz, 1H), 3.36 (s, 3H), 3.32 (s, 3H), 1.45 (d, J= 7.2 Hz, 3H); 13C NMR (100 
MHz, CDCl3): δ 191.8 (e), 143.3 (e), 128.3 (o, 2C), 127.6 (o, 2C), 126.4 (o), 68.7 (o), 
50.4 (o), 42.2 (o), 42.1 (o), 18.3 (o, 2C); IR (neat): ~ = 3076 (w), 3012 (w), 2998 (w), 
2980 (w), 2959 (w), 2923 (w), 2867 (w), 1601 (w), 1556 (s), 1490 (w), 1453 (m), 1429 
(w), 1376 (s), 1362 (s), 1328 (m), 1304 (m), 1291 (m), 1267 (w), 1247 (w), 1184 (s), 
1161 (s), 1127 (s), 1089 (w), 1052 (w), 1030 (s), 993 (m), 946 (m), 916 (w), 889 (w), 
854 (s), 802 (w), 771 (s), 754 (m), 724 (s), 703 (s), 673 (w) cm-1; HRMS (ESI): m/z 
calcd for C12H16O2S+H [M+H]+ 225.0944; found 225.0947. 
 
Compound 214. Synthesised according to representative procedure A, except that 
crude compound was purified by FCC (93:7 DCM:MeOH) 
followed by trituration in Et2O, from 2-(4-
isobutylphenyl)propanoic acid (Ibuprofen, 1.09 g, 4.85 mmol) 
to afford compound 214 as white plates (766 mg, 2.73 mmol, 56%). m.p. = 105-108 
oC; 1H NMR (500 MHz, CDCl3): δ 7.18 (d, J= 8.1 Hz, 2H), 7.06 (d, J= 8.2 Hz, 2H), 
4.27 (s, 1H), 3.49 (q, J= 7.2 Hz, 1H), 3.33 (d, J= 18.7 Hz, 6H), 2.43 (d, J= 7.2 Hz, 2H), 
1.84 (sept, J= 7.0 Hz, 1H); 0.89 (d, J= 6.7 Hz, 6H); 13C NMR (100 MHz, CDCl3): δ 
192.2 (e), 140.3 (e), 139.6 (e), 129.0 (o, 2C), 127.2 (o, 2C), 68.9 (o), 49.9 (o), 44.9 (e), 
42.0 (o), 41.9 (o), 30.1 (o), 22.3 (o), 18.3 (o, 2C); IR (neat): ~ = 3119 (w), 3081 (w), 
3013 (w), 2958 (w), 2923 (w), 2867 (w), 2844 (w), 1562 (s), 1508 (w), 1463 (w), 1384 
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(s), 1332 (w), 1310 (m), 1252 (w), 1178 (s), 1164 (s), 1140 (s), 1086 (w), 1055 (w), 
1033 (m), 999 (w), 947 (w), 930 (w), 892 (w), 861 (m), 844 (m), 811 (w), 772 (w), 
754 (w), 746 (w), 707 (w), 674 (w), 664 (w) cm-1; HRMS (ESI): m/z calcd for 
C16H24O2S+Na+ [M+Na]+ 303.1395; found: 303.1391. 
 
Compound 417. Synthesised according to representative procedure B from methyl 
(4-methoxyphenyl)acetate (1.5 g, 8.32 mmol) to afford compound 
417 as a pale brown oil that was used without further purification 
(1.84 g, 9.47 mmol, quant). 1H NMR (500 MHz, CDCl3): δ 7.22 (d, 
J = 8.6 Hz, 2H), 6.86 (d, J = 8.8 Hz, 2H), 3.79 (s, 3H), 3.68 (q, J = 7.1 Hz, 1H), 3.65 
(s, 3H), 1.47 (d, J = 7.2 Hz, 3H), in agreement with previously reported data4. 
 
Compound 215. Compound 417 (1.84 g, 9.47 mmol) was used in representative 
procedure C to afford acid 418 (1.49 g, 8.27 mmol, 87%), whose 
identity was verified by 1H NMR (500 MHz, CDCl3): δ 7.24 (d, 
J = 8.7 Hz, 2H), 6.86 (d, J = 8.8 Hz, 2H), 3.79 (s, 3H), 3.69 (q, 
J = 7.3 Hz, 1H), 1.49 (d, J = 7.2 Hz, 3H), in agreement with previously reported data5. 
Acid 418 was then used according to representative procedure A, except that crude 
compound was purified by FCC (98:2 DCM:MeOH) followed by recrystallisation 
from EtOAc, to afford compound 215 as a white powder (1.08 g, 4.25 mmol, 51%). 
m.p. = 90-92 oC; 1H NMR (500 MHz, CDCl3): δ 7.24 (d, J = 8.6 Hz, 2H), 6.86 (d, J = 
8.6 Hz, 2H), 4.28 (s, 1H), 3.81 (s, 3H), 3.50 (q, J = 7.2 Hz, 1H), 3.38 (s, 3H), 3.34 (s, 
3H), 1.45 (d, J = 7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ 194.4 (e), 158.2 (e), 
135.5 (e), 128.6 (o, 2C), 113.8 (o, 2C), 68.6 (o), 55.2 (o), 49.6 (o), 42.3 (o), 42.2 (o), 
18.5 (o); IR (neat): ~ = 3068 (w), 3016 (w), 2968 (w), 2927 (w), 2834 (w), 1611 (w), 
1563 (s), 1509 (s), 1462 (m), 1443 (w), 1428 (w), 1414 (w), 1374 (s), 1334 (m), 1303 
(m), 1263 (m), 1247 (s), 1169 (s), 1158 (s), 1132 (s), 1113 (m), 1073 (w), 1060 (w), 
1027 (s), 994 (m), 951 (w), 891 (w), 854 (s), 838 (m), 824 (w), 812 (m), 761 (s), 758 
(w), 729 (m), 694 (w), 671 (w) cm-1; HRMS (ESI): m/z calcd for C13H18O3S+H+ 
[M+H]+ 255.1049; found 255.1055. 
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Compound 419. Methyl (4-chlorophenyl)acetate (1.5 g, 8.12 mmol) was used 
according to representative procedure B to give 1.46 g of a brown 
oil which was used according to representative procedure C to give 
compound 419 as a sticky brown gum (1.13 g, 6.12 mmol, 75%). 
1H NMR (400 MHz, CDCl3): δ 7.30 (dt, J = 8.6, 2.0 Hz, 2H), 7.25 (dt, J = 8.6, 2.2 Hz, 
2H), 3.72 (q, J = 7.2 Hz, 1H), 1.50 (d, J = 7.1 Hz, 3H), in agreement with previously 
reported data.6 
 
Compound 216. Synthesised according to representative procedure A, except that 
crude compound was purified by FCC (98:2 DCM:MeOH) 
followed by recrystallisation from EtOAc, from 419 (1.81 g, 
9.83 mmol) to afford compound 216 as a white powder (1.30 
g, 5.04 mmol, 51%). m.p. = 106-110 oC; 1H NMR (400 MHz, CDCl3): δ 7.29–7.22 
(m, 4H), 4.27 (s, 1H), 3.50 (q, J = 7.1 Hz, 1H), 3.36 (s, 3H), 3.32 (s, 3H), 1.42 (d, J = 
7.2 Hz, 3H); 13C NMR (125 MHz, CDCl3): δ 191.1 (e), 141.7 (e), 132.1 (e), 129.0 (o, 
2C), 128.4 (o, 2C), 68.9 (o), 49.6 (o), 42.2 (o), 42.0 (o), 18.3 (o); IR (neat): ~ = 3068 
(w); 3016 (w); 2968 (w); 2927 (w); 2834 (w); 1611 (w); 1563 (s); 1509 (s); 1462 (m); 
1443 (w); 1428 (w); 1414 (w); 1374 (s); 1334 (m); 1303 (m); 1263 (m); 1247 (s); 1169 
(s); 1158 (s); 1132 (s); 1113 (m); 1073 (w); 1060 (w); 1027 (s); 994 (m); 951 (w); 891 
(w); 854 (s); 838 (m); 824 (w); 812 (m); 761 (s); 758 (w); 729 (m); 694 (w); 671 (w) 
cm-1; HRMS (ESI): m/z calcd for C12H1535ClO2S+Na+: 281.0379 [M+Na]+; found: 
281.0370; elemental analysis calcd (%) for C12H15ClO2S: C 55.70, H 5.84, S 12.39; 
found: C 55.89, H 5.92, S 12.35.. 
 
Compound 217. Synthesised according to representative procedure A, except that 
crude compound was purified by FCC (98 :2 DCM/MeOH), 
from 2-(4-bromophenyl)propanoic acid (3.49 g, 9.97 mmol) to 
afford compound 217 as white powder (1.21 g, 3.39 mmol, 
40%). m.p.: 133–135 °C; 1H NMR (500 MHz, CDCl3): δ 7.41 (d, J = 8.2 Hz, 2H), 7.18 
(d, J = 8.2 Hz, 2H), 4.27 (s, 1H), 3.49 (q, J = 7.2 Hz, 1H), 3.36 (s, 3H), 3.31 (s, 3H), 
1.42 (d, J = 7.2 Hz, 3H); 13C NMR (125 MHz, CDCl3): δ 191.0 (e), 142.2 (e), 131.4 
(o, 2C), 129.4 (o, 2C), 120.2 (e), 68.9 (o), 49.7 (o), 42.2 (o), 42.1 (o), 18.3 (o); IR 
(neat): ~ = 3072 (w), 3018 (w), 3009 (w), 2982 (w), 2963 (w), 2923 (w), 2872 (w), 
1564 (s), 1486 (m), 1460 (m), 1449 (w), 1421 (w), 1408 (m), 1376 (s), 1359 (s), 1337 
Br
O
S
O
217
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(w), 1327 (w), 1303 (m), 1288 (w), 1267 (w), 1199 (w), 1164 (s), 1121 (s), 1074 (s), 
1056 (m), 1023 (s), 1007 (s), 993 (m), 982 (m), 940 (m), 892 (w), 855 (s), 835 (s), 790 
(m), 757 (m), 746 (m), 722 (m), 691 (w), 677 (m) cm-1; HRMS (ESI): m/z calcd for 
C12H1579BrO2S+Na+: 303.0049 [M+Na]+; found: 303.0054; elemental analysis calcd 
(%) for C12H15BrO2S: C 47.53, H 4.99, S 10.57; found: C 47.59, H 4.89, S 10.31. 
 
Compound 420. Methyl (4-trifluoromethyl)phenylacetate (2.7 g, 11.63 mmol) was 
used according to representative procedure B to afford a brown 
oil (3.82 g), which was used according to representative 
procedure C to afford compound 420 as a sticky brown gum (2.19 
g, 10.04 mmol, 81%). 1H NMR (400 MHz, CDCl3): δ 7.60 (d, J = 8.1 Hz, 2H), 7.44 
(d, J = 8.2 Hz, 2H), 3.82 (q, J = 7.3 Hz, 1H), 1.55 (d, J = 7.3 Hz, 3H), in agreement 
with previously reported data7. 
 
Compound 218. Synthesised according to representative procedure A, except that 
crude compound was purified by FCC (98:2 DCM:MeOH) 
followed by trituration in Et2O, from compound 420 (2.19 g, 
10.04 mmol) to afford compound 218 as an off-white powder 
(837 mg, 2.86 mmol, 29%) m.p. = 73-76 oC; 1H NMR (400 MHz, CDCl3): δ 7.55 (d, 
J = 8.1 Hz, 2H), 7.42 (d, J = 8.2 Hz, 2H), 4.31 (s, 1H), 3.59 (q, J = 7.2 Hz, 1H), 3.37 
(s, 3H), 3.32 (s, 3H), 1.46 (d, J = 7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ 190.4 
(e), 147.2 (e), 128.6 (e, q, J = 32.4 Hz), 127.9 (o, 2C), 126.6 (e), 125.2 (o, q, J = 3.6 
Hz, 2C), 124.9 (e, q, J = 273 Hz), 69.2 (o), 50.1 (o), 42.1 (o), 42.0 (o), 18.3 (o); 19F 
NMR (376.5 MHz, CDCl3): δ -62.33 (s, 3F); IR (neat): ~ = 3069 (w), 2991 (w), 2928 
(w), 1617 (w), 1566 (s), 1463 (w), 1418 (w), 1376 (s), 1362 (m), 1322 (s), 1256 (w), 
1161 (s), 1106 (s), 1069 (s), 1031 (s), 1017 (s), 988 (m), 953 (m), 857 (s), 846 (s), 804 
(m), 777 (w), 760 (w), 747 (w), 715 (w), 695 (w), 675 (w) cm-1; HRMS (ESI): m/z 
calcd for C13H15F3O2S+H+: 293.0823 [M+H]+; found: 293.0822; elemental analysis 
calcd (%) for C13H15F3O2S: C 53.42, H 5.17; found: C 53.57, H 5.18. 
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Compound 219. Synthesised according to representative procedure A, except that 
crude compound was purified by FCC (98:2 DCM:MeOH), from 
commercially available 2-methyl-2-phenylpropanoic acid (1.11 g, 
6.08 mmol) to afford compound 219 as fine white flakes (1.37 g, 
5.75 mmol, 94%). m.p. = 92-93 oC; 1H NMR (500 MHz, CDCl3): δ 7.37-7.35 (m, 2H), 
7.31-7.28 (m, 2H), 7.22-7.18 (m, 1H), 4.12 (s, 1H), 3.33 (s, 6H), 1.50 (s, 6H); 13C 
NMR (100 MHz, CDCl3): δ 195.6 (e), 147.1 (e), 128.0 (o, 2C), 126.2 (o, 2C), 125.9 
(o), 63.4 (o), 48.8 (o), 41.9 (o, 2C), 26.8 (o, 2C); IR (neat): ~ = 3094 (w), 3059 (w), 
3001 (w), 2974 (w), 2963 (w), 2968 (w), 2926 (w), 2909 (w), 1572 (s), 1498 (m), 1471 
(m), 1435 (w), 1412 (w), 1380 (m), 1351 (m), 1324 (m), 1306 (m), 1237 (w), 1191 
(w), 1149 (s), 1115 (s), 1096 (s), 1071 (m), 1031 (s), 1004 (m), 982 (m), 946 (m), 912 
(w), 875 (m), 857 (m), 847 (m), 779 (m), 765 (m), 748 (m), 730 (m), 696 (s), 679 (m) 
cm-1; HRMS (ESI): m/z calcd for C13H19O2S ([M+H]+) 239.1100; found: 239.1101. 
 
 
Compound 421: To a flame dried 2-neck RB flask under N2 was added iPr2NH (5 mL, 
35.96 mmol, 1.8 equiv) followed by THF (28 mL). The reaction was 
cooled to -10 oC using an ice/brine bath, and nBuLi (2.5 M in hexanes, 
13 mL, 31.97 mmol, 1.6 equiv) was added dropwise. The reaction was 
stirred at -10 oC for 15 min, before a solution of methyl phenylacetate 
(2.8 mL, 19.98 mmol, 1.0 equiv) in THF (55 mL) was added dropwise. The reaction 
was then stirred at -10 oC for 30 mins, before a solution of allyl bromide (3.5 mL, 
39.96 mmol, 2.0 equiv) in THF (28 mL) was added slowly. The reaction was allowed 
to warm up to rt over 1 h, then quenched with H2O. The layers were separated and the 
aqueous washed with EtOAc (x3), and the combined organic layers were dried 
(MgSO4), filtered and concentrated in vacuo. The crude residue was purified by FCC 
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(95:5 PE:EtOAc) to afford compound 421 as pale brown oil (2.37 g, 12.46 mmol, 
62%). This batch was combined with another batch of 2.21 g prepared in the same 
manner for use in the next step. 1H NMR (400 MHz, CDCl3): δ 7.34-7.29 (m, 4H), 
7.28-7.23 (m, 1H), 5.78-5.67 (m, 1H), 5.07 (dq, J = 17.0, 1.5 Hz, 1H), 5.00 (dq, J = 
10.1, 1.2 Hz, 1H), 3.67-3.64 (m, 4H), 2.88-2.78 (m, 1H), 2.56-2.47 (m, 1H), in 
agreement with previously reported data.8 
 
Compound 220. Compound 421 (2.37 g, 12.46 mmol) was used according to 
representative procedure C to afford a sticky brown residue (2.70 
g). This was immediately used  according to representative 
procedure A, except that crude compound was purified by FCC 
(97:3 EtOAc:MeOH), to afford compound 220 as an off-white solid 
(2.24 g, 8.95 mmol, 58%). m.p. = 88-90oC; 1H NMR (500 MHz, CDCl3): δ 7.31-7.27 
(m, 4H,) 7.23-7.19 (m, 1H), 5.77-5.68 (m, 1H), 5.03 (dq, J= 1.4, 17.1, 1.4 Hz, 1H), 
4.94-4.92 (m, 1H), 4.32 (s, 1H), 3.43 (t, J= 7.5 Hz, 1H), 3.35 (s, 3H), 3.29 (s, 3H), 
2.86-2.80 (m, 1H), 2.51-2.45 (m, 1H); 13C NMR (100 MHz, CDCl3): δ 190.0, 141.2, 
136.7, 128.3 (2C), 228.0 (2C), 126.5, 115.8, 69.3, 56.2, 42.2, 42.1; IR (neat): ~ = 3069 
(m); 3007 (m); 2920 (m); 1642 (w); 1601 (w); 1566 (s); 1497 (w); 1455 (w); 1426 
(w); 1375 (s); 1303 (m); 1248 (w); 1167 (s); 1125 (m); 1105 (m); 1025 (s); 1001 (m); 
985 (m); 945 (m); 912 (s); 884 (w); 853 (s); 774 (s); 750 (m); 724 (m); 700 (s); 675 
(m) cm-1; HRMS (CI(NH3): m/z calcd for C14H18O2S+H+: 251.1106 [M+H]+; found: 
251.1096. 
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Compound 423: To a flame dried 2-neck RB flask under N2 was added iPr2NH (3.4 
mL, 23.97 mmol, 1.8 equiv) followed by THF (18 mL). The reaction was 
cooled to -10 oC using an ice/brine bath, and nBuLi (2.5 M in hexanes, 
8.5 mL, 21.31 mmol, 1.6 equiv) was added dropwise. The reaction was 
stirred at -10 oC for 15 min, before a solution of methyl phenylacetate (1.9 mL, 13.32 
mmol, 1.0 equiv) in THF (37 mL) was added dropwise. The reaction was then stirred 
at -10 oC for 30 mins, before benzyl bromide (3.2 mL, 26.64 mmol, 2.0 equiv) was 
added slowly. The reaction was allowed to warm up to rt over 1 h, then quenched with 
H2O. The layers were separated and the aqueous washed with EtOAc (x3), and the 
combined organic layers were dried (MgSO4), filtered and concentrated in vacuo. The 
crude residue was purified by FCC (petroleum ether/EtOAc = 95:5) to afford 
compound 423 as colourless oil (2.40 g, 7.05 mmol, 75%). 1H NMR (400 MHz, 
CDCl3): δ 7.33-7.29 (m, 4H), 7.28-7.21 (m, 3H), 7.19-7.15 (m, 1H), 7.14-7.09 (m, 
2H), 3.85 (dd, J = 6.8, 8.9 Hz, 1H), 3.60 (s, 3H), 3.42 (dd, J = 8.8, 13.7 Hz, 1H), 3.02 
(dd, J = 6.7, 13.6 Hz, 1H); in agreement with previously reported data9. 
 
Compound 221. Compound 423 (2.40 g, 7.05 mmol) was used according to 
representative procedure C to afford a sticky brown residue (2.86 g, 
12.63 mmol). This was then used immediately according to 
representative procedure A, except that crude compound was 
purified by FCC (DCM/MeOH = 98:2), to afford compound 221 as 
a cream powder (0.96 g, 3.19 mmol, 25%). m. p. 74-76 oC; 1H NMR (400 MHz, 
CDCl3): δ 7.33-7.26 (m, 4H), 7.22-7.18 (m, 3H), 7.15-7.12 (m, 3H), 4.24 (s, 1H), 3.64 
(t, J= 7.7 Hz, 1H), 3.44 (dd, J= 8.4, 13.3 Hz, 1H), 2.99-2.94 (m, 1H); 13C NMR (100 
MHz, CDCl3): δ 189.5 (e), 141.3 (e), 140.4 (e), 129.1 (o, 2C), 128.3 (o, 2C), 128.02 
(o, 2C), 127.97 (o, 2C), 126.5 (o), 125.8 (o), 69.7 (o), 58.2 (o), 42.1 (o, 2C), 39.4 (e);  
IR (neat): ~ = 3065 (w), 3026 (w), 3007 (w), 2992 (w), 2941 (w), 2915 (w), 2855 (w), 
1963 (w), 1732 (w), 1600 (w), 1568 (m), 1539 (s), 1493 (m), 1452 (m), 1377 (s), 1305 
(m), 1242 (m), 1185 (s), 1171 (s), 1108 (m), 1071 (m), 1031 (s), 1003 (w), 991 (w), 
963 (w), 945 (m), 895 (m), 861 (m), 831 (w), 801 (m), 770 (w), 760 (w), 745 (m), 733 
(s); HRMS (ESI): m/z calcd for C18H20O2S+Na+ [M+Na]+ 323.1082; found 323.1079. 
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Compound 222. Synthesised according to representative procedure A, except that 
crude compound was purified by FCC (DCM to 9:1 DCM:MeOH) 
followed by recrystallisation from EtOAc, from commercially 
available 2-cyclohexyl-2-phenylacetic acid (1 g, 4.58 mmol) to 
afford compound 222 as an off-white powder (486 mg, 1.66 mmol, 
36%). M.p. = 162-164 oC; 1H NMR (500 MHz, CDCl3): δ 7.33-7.29 
(m, 2H), 7.28-7.24 (m, 2H), 7.19 (tt, J = 6.5, 1.4 Hz, 1H), 4.41 (s, 1H), 3.37 (s, 3H), 
3.26 (s, 3H), 2.99 (d, J = 10.7 Hz, 1H), 2.06 (qq, J = 11.4, 3.5 Hz, 1H), 1.97-1.88 (m 
1H), 1.75-1.67 (m, 1H), 1.65-1.55 (m, 2H), 1.38-1.24 (m, 2H), 1.20-1.07 (m, 2H), 
1.05-0.95 (m, 1H), 0.71 (qd, J = 12.6, 3.7 Hz, 1H); 13C NMR (100 MHz, CDCl3): δ 
190.5 (e), 140.8 (e), 128.4 (o, 2C), 128.1 (o, 2C), 126.2 (o), 69.7 (o), 63.7 (o), 42.2 
(o), 42.0 (o), 40.2 (o), 32.1 (e), 31.0 (e), 26.5 (e), 26.2 (e, 2C); IR (neat): ~ = 3093 
(w), 3058 (w), 2998 (w), 2939 (w), 2914 (w), 2841 (w), 1595 (w), 1557 (s), 1492 (w), 
1446 (w), 1430 (w), 1376 (s), 1342 (w), 1323 (w), 1301 (w), 1254 (w), 1208 (w), 1174 
(s), 1134 (w), 1104 (m), 1065 (w), 1033 (s), 991 (w), 946 (w), 930 (w), 911 (w), 903 
(w), 895 (w), 886 (w), 860 (m), 848 (m), 830 (w), 800 (w), 786 (w), 780 (w), 758 (w), 
726 (w), 719 (w), 695 (s), 682 (w); HRMS (ESI): m/z calcd for C17H24O2S+H [M+H]+ 
293.1570; found 293.1570. 
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Compound 226: To a flame dried, 2-neck RB flask was added Pd(OAc)2 (43 mg, 0.19 
mmol, 3 mol%), ligand C (160 mg, 0.40 mmol, 6.3 mol%) and solid 
LiHMDS (2.66 g, 15.92 mmol, 2.5 equiv). The flask was evacuated 
and backfilled with N2 three times before dry toluene (25 mL, 0.25 
M) was added and the reaction was stirred at rt for 10 mins, then 
cooled to -10 oC using an ice/brine bath. Methyl (4-
methoxyphenyl)acetate (2.3 mL, 14.65 mmol, 2.3 equiv) was added dropwise, and the 
reaction was stirred at -10 oC for a further 10 mins. Bromobenzene (0.7 mL, 6.37 
mmol, 1.0 equiv) was added dropwise, and the reaction was heated at 80 oC for 30 
mins. The reaction was then filtered through a short plug of silica gel, eluting with 
toluene, and the filtrate was concentrated in vacuo. The crude residue was purified by 
FCC (9:1 PE:EtOAc) to afford compound 226 as a pale yellow liquid (791 mg, 3.09 
mmol, 48%), which was combined with an earlier batch of 101 mg for use in the next 
step.  1H NMR (500 MHz, CDCl3): δ 7.34-7.27 (m, 4H), 7.27-7.25 (m, 1H), 7.23 (d, J 
= 8.6 Hz, 2H), 6.86 (d, J = 8.8 Hz, 2H), 4.98 (s, 1H), 3.78 (s, 3H), 3.74 (s, 3H); in 
agreement with previously reported data10. 
 
Compound 223. Compound 226 (892 mg, 3.47 mmol, 1.0 equiv) was used according 
to representative procedure C to afford a sticky brown solid (414 
mg, 1.71 mmol). 1H NMR (500 MHz, CDCl3): δ 7.33-7.22 (m, 7H), 
6.87 (d, J = 8.8 Hz, 2H), 5.00 (s, 1H), 3.77 (s, 3H), in agreement 
with previously reported data11. This was then used immediately 
according to representative procedure A, except that crude compound was purified by 
FCC (95:5 DCM:MeOH) followed by recrystallisation in EtOAc, to afford compound 
223 as a  white powder (133 mg, 0.42 mmol, 25%). 1H NMR (400 MHz, CDCl3): δ  
7.28 (m, 4H), 7.20 (m, 3H), 6.83 (d, J= 8.6 Hz, 2H), 4.79 (s, 1H), 4.37 (s, 1H), 3.78 
(s, 3H), 3.38 (s, 6H); 13C NMR (100 MHz, CDCl3): δ 189.3 (e), 158.2 (e), 141.4 (e), 
133.2 (e), 129.9 (o, 2C), 128.9 (o, 2C), 128.3 (o, 2C), 126.4 (o), 113.7 (o, 2C), 71.0 
(o), 61.3 (o), 55.2 (o), 42.1 (o, 2C); IR (neat): ~ = 3065 (w), 3011 (w), 2920 (w), 2836 
(w), 2051 (w), 1610 (w), 1567 (s), 1509 (s), 1492 (m), 1465 (w), 1455 (w), 1443 (w), 
1425 (w), 1373 (s), 1300 (m), 1248 (s), 1167 (s), 1110 (m), 1026 (s), 982 (w), 939 (w), 
923 (w), 883 (w), 868 (m), 844 (m), 834 (m), 805 (w), 784 (m), 770 (w), 753 (w), 739 
(m), 728 (m), 701 (m), 672 (m) cm-1; HRMS (ESI): m/z calcd for C18H20O3S+Na+ 
[M+Na]+ 339.1031; found 339.1025. 
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3.3 Synthesis of Compounds 224-225, 265-268, 274-275, 282-
284, 302-307, 318-322, 348, 356, 381, 394 and 412 
 
 
Representative Procedure D: Under air, 4-methoxyphenylacetic acid (2 g, 12.03 
mmol, 1.0 equiv) and 4-nitrophenol (2.19 g, 15.64 mmol, 1.3 equiv) were dissolved in 
THF, and DCC (3.23 g, 15.64 mmol, 1.3 equiv) was added. The reaction was stirred 
at rt for 18 h, then filtered through Celite. The Celite pad was washed with DCM, and 
the filtrated was concentrated in vacuo. The residue was purified by FCC (4:1 
PE:EtOAc) to afford compound 425 as an amorphous yellow solid (2.50 g, 8.71 mmol, 
72%). 
 
Compound 425. 1H NMR (500 MHz, DMSO-d6): δ 8.30 (d, J = 9.1 Hz, 2H), 7.43 (d, 
J = 9.1 Hz, 2H), 7.31 (d, J = 8.9 Hz, 2H), 6.93 (d, J = 8.9 
Hz, 2H), 3.95 (s, 2H), 3.75 (s, 3H); 13C NMR (100 MHz, 
DMSO-d6): δ 172.9 (e), 158.4 (e), 155.4 (e), 135.8 (e), 
130.6 (o, 2C), 130.3 (o, 2C), 127.0 (e), 126.2 (o, 2C), 114.0 (o, 2C), 55.0 (o), 40.0 (e);  
IR (neat): ~ = 3121 (w), 3086 (w), 3016 (w), 2934 (w), 2913 (w), 2839 (w), 2117 (w), 
2040 (w), 1927 (w), 1757 (s), 1611 (s), 1587 (m), 1531 (w), 1514 (s), 1488 (s), 1464 
(m), 1455 (m), 1442 (w), 1402 (w), 1345 (s), 1335 (s), 1302 (m), 1243 (s), 1213 (s), 
1201 (s), 1177 (s), 1165 (m), 1101 (s), 1025 (s), 1011 (s), 970 (w), 951 (w), 916 (m), 
871 (s), 855 (s), 826 (s), 820 (s), 805 (m), 767 (m), 750 (s), 727 (w), 701 (m), 675 (m), 
685 (w), 642 (w) cm-1; HRMS (ESI): m/z calcd for C15H13NO5+Na+ [M+Na]+: 
310.0691; found 310.0690. 
 
Representative Procedure E: To a flame dried, 2-neck RB flask under N2 was added 
compound 210 (5.51 g, 25.05 mmol, 3.0 equiv) and KOtBu (2.81 g, 25.05 mmol, 3.0 
equiv), and the flask was evacuated and backfilled with N2 three times. THF (30 mL) 
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was added and the suspension protected from light and heated at reflux for 2 h. The 
reaction was then cooled to 0 oC, and a solution of compound 425 (2.4 g, 8.35 mmol, 
1.0 equiv) in THF (17 mL) was added dropwise. The reaction was stirred at rt for 15 
min, then filtered through Celite. The Celite pad was washed with DCM, and the 
filtrate was concentrated in vacuo and purified by FCC (9:1 DCM:MeOH) to afford 
compound 227 as a yellow powder (1.62 g, 6.76 mmol, 81%). 
 
Compound 227. m.p. =  1H NMR (500 MHz, CDCl3): δ 7.15 (d, J = 8.7 Hz, 2H), 6.83 
(d, J = 8.7 Hz, 2H), 4.23 (s, 1H), 3.78 (s, 3H), 3.40 (s, 2H), 
3.34 (s, 6H); 13C NMR (100 MHz, CDCl3): δ 189.0 (e), 158.2 
(e), 130.3 (o, 2C), 129.2 (e), 113.8 (o, 2C), 69.5 (o), 55.2 (o), 
47.1 (e), 42.1 (o, 2C); IR (neat): ~ = 3069 (w), 3016 (w), 2964 (w), 2927 (w), 2840 
(w), 1610 (w), 1583 (w), 1562 (s), 1509 (s), 1469 (w), 1459 (w), 1443 (w), 1431 (w), 
1375 (s), 1329 (w), 1274 (w), 1246 (s), 1186 (w), 1168 (s), 1155 (s), 1117 (m), 1087 
(m), 1022 (s), 995 (m), 957 (w), 935 (m), 857 (w), 846 (m), 832 (m), 813 (m), 789 (s), 
758 (w), 719 (m), 698 (w), 687 (m) cm-1; HRMS (ESI) m/z calcd for C12H16O3S+Na+ 
263.0718 [M+Na]+; found: 263.0727; elemental analysis calcd for C12H16O3S: C 
59.98, H 6.71, S 13.34; found: C 59.99, H 6.73, S 13.41. 
Compound 426. Synthesised according to representative procedure D from 4-
trifluoromethylphenylacetic acid (2 g, 9.80 mmol) to 
afford compound 426 as a pale green amorphous solid 
(1.45 g, 4.46 mmol, 46%). 1H NMR (500 MHz, CDCl3): 
δ 8.26 (d, J = 9.3 Hz, 2H), 7.65 (d, J = 8.2 Hz, 2H), 7.50 (d, J = 8.2 Hz, 2H), 7.26 (d, 
J = 9.4 Hz, 2H), 3.97 (s, 2H); 13C NMR (100 MHz, CDCl3): δ 168.3 (e), 155.1 (e), 
145.5 (e), 136.5 (e), 130.1 (e, q, J = 32.5 Hz), 129.8 (o, 2C), 125.8 (o, q, J = 4.1 Hz, 
2C), 125.2 (o, 2C), 124.0 (e, q, J = 272.0 Hz), 122.3 (o, 2C), 40.9 (e); IR (neat): ~ = 
3120 (w), 3088 (w), 1759 (w), 1666 (w), 1593 (m), 1519 (s), 1490 (m), 1453 (w), 1421 
(w), 1412 (w), 1349 (m), 1337 (s), 1322 (s), 1219 (s), 1207 (m), 1161 (m), 1111 (s), 
1063 (s), 1020 (s), 968 (w), 928 (w), 876 (s), 865 (m), 854 (s), 825 (s), 770 (m), 753 
(w), 738 (s), 704 (s), 679 (m), 665 (w) cm-1; HRMS (ESI): m/z calcd for 
C15H10F3NO4+Na+ [M+Na]+: 348.0460; found 348.0459. 
 
 Page | 132  
 
Compound 228: Synthesised according to representative procedure E, except that 
crude material was purified by FCC (97:3 DCM:MeOH) 
followed by trituration in Et2O, from compound 426 (1.32 g, 
4.06 mmol) to afford compound 228 as a white powder (727 
mg, 2.61 mmol, 64%).  m.p. = 80-82 oC; 1H NMR (400 MHz, CDCl3): δ 7.55 (d, J = 
8.0 Hz, 2H), 7.37 (d, J = 8.0 Hz, 2H), 4.28 (s, 1H), 3.52 (s, 2H), 3.36 (s, 6H); 13C NMR 
(125 MHz, CDCl3): δ 186.9 (e), 141.1 (e), 129.6 (o, 2C), 128.6 (q, J = 32.6 Hz), 125.2 
(o, q, J = 3.6 Hz, 2C), 124.3 (e, q, J = 272.1 Hz), 70.0 (o), 47.5 (e), 42.1 (o, 2C); IR 
(neat): ~ = 3088 (w), 3014 (w), 2926 (w), 1614 (w), 1562 (s), 1482 (w), 1417 (m), 
1403 (m), 1375 (s), 1315 (s), 1288 (m), 1252 (w), 1205 (w), 1187 (m), 1157 (s), 1113 
(s), 1092 (s), 1061 (s), 1026 (s), 1017 (s), 988 (m), 959 (m), 951 (m), 935 (m), 912 
(w), 870 (s), 845 (m), 821 (s), 779 (m), 758 (m), 741 (w), 721 (w), 710 (m), 692 (s) 
cm-1; HRMS (ESI): m/z calcd for C12H13F3O2S+H+: 279.0661 [M+H]+; found: 
279.0657; elemental analysis calcd (%) for C12H13F3O2S: C 51.79, H 4.71; found: C 
51.63, H 4.69. 
 
Compound 427. Synthesised according to representative procedure D, from 2-(3,4-
dimethoxyphenyl)propanoic acid (1.24 g, 5.90 mmol, 
1.0 equiv), to afford compound 427 as an amorphous 
yellow solid (3.49 g, 9.69 mmol, 62%). 1H NMR (500 
MHz, CDCl3): δ 8.23 (d, J = 9.3 Hz, 2H), 7.18 (d, J = 9.3 Hz, 2H), 6.94 (dd, J = 8.1, 
2.0 Hz, 1H), 6.90 (d, J = 2.2 Hz, 1H), 6.88 (d, J = 8.3 Hz, 2H), 3.93 (q, J = 7.3 Hz, 
1H), 3.90 (s, 3H), 3.89 (s, 3H), 1.62 (d, J = 7.2 Hz, 3H); 13C NMR (125 MHz, CDCl3): 
δ 172.3 (e), 155.5 (e), 149.2 (e), 148.5 (e), 141.6 (e), 131.7 (e), 125.1 (o, 2C), 122.2 
(o, 2C), 119.6 (o), 111.4 (o), 110.5 (o), 55.91 (o), 55.87 (o), 45.1 (o), 18.3 (o); IR 
(neat): ~ = 3081 (w), 2936 (w), 2836 (w), 2019 (w), 1755 (s), 1614 (w), 1591 (w), 
1516 (s), 1489 (s), 1454 (m), 1419 (w), 1345 (s), 1253 (m), 1235 (m), 1205 (s), 1143 
(s), 1070 (s), 1026 (s), 918 (w), 891 (w), 863 (m), 810 (w), 782 (w), 765 (w), 751 (w), 
718 (w), 682 (w) cm-1; HRMS (ESI): m/z calcd for C17H17NO6+Na+: 354.0948 
[M+Na]+; found: 354.0956. 
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Compound 268. Synthesised according to representative procedure E, except that 
crude compound was purified by FCC (98:2 DCM:MeOH), 
from compound 427 (1.24 g, 3.74 mmol) to afford compound 
268 as a pale green amorphous gum (1.08 g, 3.79 mmol, quant). 
1H NMR (400 MHz, CDCl3): δ 6.86-6.77 (m, 3H), 4.28 (s, 1H), 
3.87 (s, 3H), 3.85 (s, 3H), 3.47 (q, J = 7.5 Hz, 1H), 3.36 (s, 3H); 3.32 (s, 3H), 1.43 (d, 
J = 7.2 Hz, 3H);13C NMR (100 MHz, CDCl3): δ 192.1 (e), 148.9 (e), 147.5 (e), 135.9 
(e), 119.5 (o), 111.0 (o), 110.9 (o), 68.7 (o), 55.8 (o), 55.8 (o), 49.9 (o), 42.1 (o), 42.0 
(o), 18.4 (o); IR (neat): ~  = 3431 (w), 3007 (w), 2964 (w), 2926 (w), 2835 (w), 2251 
(w), 1567 (s), 1513 (s), 1453 (m), 1416 (m), 1375 (s), 1300 (w), 1260 (s), 1232 (s), 
1174 (s), 1141 (s), 1077 (w), 1057 (w), 1025 (w), 944 (w), 916 (w), 856 (m), 812 (w), 
778 (w), 762 (w), 730 (w), 676 (w) cm-1; HRMS (ESI): m/z calcd for C14H21O4S+H+ 
[M+H]+ 285.1155; found 285.1154. 
 
Compound 428. Synthesised according to representative procedure D from racemic 
naproxen (1 g, 4.34 mmol) to afford compound 428 
as white solid (1.21 g, 3.39 mmol, 40%). m.p.: 133–
135 °C; 1H NMR (500 MHz, CDCl3): δ 8.21 (d, J = 
9.2 Hz, 2H), 7.79-7.72 (m, 3H), 7.47 (dd, J = 8.5, 2.0 Hz, 1H), 7.20-7.14 (m, 4H), 4.12 
(q, J = 7.0 Hz, 1H), 3.93 (s, 3H), 1.71 (d, J = 7.2 Hz, 3H); 13C NMR (125 MHz, 
CDCl3): δ 172.2 (e), 157.8 (e), 155.5 (e), 145.2 (e), 134.3 (e), 133.9 (e), 129.2 (o), 
128.9 (e), 127.5 (o), 126.1 (o), 125.8 (o), 125.0 (o), 122.2 (o), 119.2 (o), 105.6 (o), 
55.2 (o), 45.5 (o), 18.2 (o); IR (neat): ~ = 3116 (w), 3080 (w), 2988 (w), 2937 (w), 
2459 (w), 2117 (w), 1924 (w), 1754 (s),  1632 (w), 1616 (w), 1603 (m), 1592 (m), 
1533 (m), 1523 (s), 1505 (m), 1489 (m), 1463 (w), 1452 (w), 1417 (w), 1390 (w), 1377 
(w), 1345 (s), 1325 (m), 1290 (w), 1264 (m), 1227 (m), 1205 (s), 1161 (s), 1127 (s), 
1083 (w), 1067 (s), 1030 (m), 1012 (m), 1012 (w), 994 (w), 958 (w), 927 (w), 899 (m), 
853 (s), 814 (m), 789 (m), 754 (w), 740 (m), 700 (m), 675 (w), 657 (w) cm-1; HRMS 
(CI(CH4)): m/z calcd for C20H17NO5+H+: 352.1185 [M+H]+; found: 352.1183.  
 
 Page | 134  
 
Compound 269. Synthesised according to representative procedure E, except that 
crude compound was purified by FCC (DCM/MeOH 
98 :2), from compound 428 (1.20 g, 3.41 mmol) to afford 
compound 269 as an off-white solid (855 mg, 2.81 mmol, 
82%). m.p.: 118–119 °C; 1H NMR (500 MHz, CDCl3): δ 7.70-7.65 (m, 3H), 7.41 (dd, 
J = 8.5, 2.0 Hz, 1H), 7.13-7.10 (m, 2H), 4.30 (s, 1H), 3.91 (s, 3H), 3.66 (q, J = 7.1 Hz, 
1H), 3.36 (s, 3H), 3.30 (s, 3H), 1.52 (d, J = 7.1 Hz, 3H); 13C NMR (125 MHz, CDCl3): 
δ 192.0 (e), 157.3 (e), 138.5 (e), 133.3 (e), 129.2 (o), 129.0 (e), 126.79 (o), 126.76 (o), 
125.7 (o), 118.6 (o), 105.5 (o), 69.1 (o), 55.2 (o), 50.3 (o), 42.1 (o), 42.0 (o), 18.2 (o); 
IR (neat): ~ = 3008 (w), 2977 (w), 2919 (w), 1630 (w), 1604 (m), 1564 (s), 1504 (m), 
1481 (w), 1439 (w), 1417 (w), 1371 (s), 1308 (w), 1292 (w), 1264 (m), 1227 (m), 1193 
(w), 1164 (s), 1070 (m), 1024 (s), 944 (w), 927 (w), 892 (w), 854 (s), 818 (m), 785 
(w), 754 (w), 742 (w), 692 (w), 674 (w) cm-1; HRMS (ESI): m/z calcd for 
C17H20O3S+H+: 305.1211 [M+H]+; found: 305.1207; elemental analysis calcd (%) for 
C17H20O3S: C 67.08, H 6.62, S 10.53; found: C 66.83, H 6.57, S 10.54. 
 
Compound 429. Synthesised according to representative procedure D from N-Me-
carprofen12 (598 mg, 2.08 mmol) to afford compound 429 
as yellow solid (645 mg, 1.58 mmol, 76%). The compound 
was contaminated by some DCC, and was characterized 
only by 1H NMR before being used without further 
purification in the next step. 1H NMR (500 MHz, CDCl3): δ 
8.21 (d, J = 9.2 Hz, 2H), 8.04 (d, J = 4.5 Hz, 1H), 8.03 (d, J 
= 1.4 Hz, 1H), 7.43 (dd, J = 8.6, 2.1 Hz, 1H), 7.40 (d, J = 1.0 Hz, 1H), 7.32 (d, J = 8.7 
Hz, 1H), 7.26 (dd, J = 8.3, 1.5 Hz, 1H), 7.18 (d, J = 9.2 Hz, 2H), 4.19 (q, J = 7.2 Hz, 
1H), 3.86 (s, 3H), 1.74 (d, J = 7.2 Hz, 3H). 
 
Compound 270. Synthesised according to representative procedure E, except that 
crude compound was purified by FCC (DCM/MeOH = 
90 :10), from compound 429 (645 mg, 1.58 mmol) to afford 
compound 270 as white powder (1.21 g, 3.39 mmol, 40%). 
m.p.: 133–135 °C; 1H NMR (500 MHz, CDCl3): δ 7.99 (d, J 
= 1.9 Hz, 1H), 7.94 (d, J = 8.1 Hz, 1H), 7.39 (dd, J = 2.0, 8.4 Hz, 1H), 7.34 (s, 1H), 
 Page | 135  
 
7.28 (d, J = 8.7 Hz, 1H), 7.18 (d, J = 8.4 Hz, 1H), 4.34 (s, 1H), 3.82 (s, 3H), 3.74 (q, 
J = 7.0 Hz, 1H), 3.36 (s, 3H), 3.31 (s, 3H), 1.57 (d, J = 7.2 Hz, 3H); 13C NMR (125 
MHz, CDCl3): δ 191.9 (e), 142.2 (e), 141.8 (e), 139.5 (e), 125.3 (o), 124.3 (e), 123.8 
(e), 120.4 (e), 120.3 (o), 119.7 (o), 119.4 (o), 109.3 (o), 107.6 (o), 68.9 (o), 51.1 (o), 
42.2 (o), 42.1 (o), 29.2 (o), 18.7 (o); IR (neat): ~ = 3022 (w), 2922 (w), 2552 (w), 1630 
(w), 1600 (w), 1556 (s), 1493 (w), 1466 (s), 1415 (m), 1369 (s), 1356 (s), 1334 (m), 
1307 (w), 1172 (s), 1140 (m), 1072 (w), 1063 (w), 1026 (s), 995 (m), 957 (w), 923 
(w), 849 (m), 835 (w), 810 (s), 796 (s), 759 (w), 759 (w), 725 (w), 686 (w) cm-1; 
HRMS (ESI): m/z calcd for C19H2035ClNO2S+Na+: 384.0801 [M+Na]+; found: 
384.0790; elemental analysis calcd (%) for C19H20ClNO2S: C 63.06, H 5.57, N 4.03, 
S 9.22; found: C 62.76, H 5.59, N 3.73, S 9.21.  
Compound 430. Synthesised according to representative procedure D from racemic 
zaltoprofen (2 g, 6.70 mmol) to afford compound 430 
as a beige amorphous solid (2.44 g, 5.82 mmol, 87%). 
1H NMR (500 MHz, CDCl3): δ 8.26-8.18 (m, 3H), 7.67 
(d, J = 7.9 Hz, 1H), 7.61 (dd, J = 8.0, 1.0 Hz, 1H), 7.47 
(d, J = 2.0 Hz, 1H), 7.44 (td, J = 7.4, 1.8 Hz, 1H), 7.36-
7.30 (m, 1H), 7.24 (d, J = 7.9, 1.9 Hz, 1H), 7.18 (d, J = 9.3 Hz, 2H), 4.40 (s, 2H), 3.99 
(q, J = 7.1 Hz, 1H), 1.62 (d, J = 7.2 Hz, 3H); 13C NMR (125 MHz, CDCl3): δ 191.6 
(e), 171.5 (e), 155.3 (e), 141.4 (e), 140.0 (e), 138.4 (e), 136.1 (e), 134.0 (e), 132.6 (o), 
131.8 (o), 131.5 (o), 130.8 (o), 128.6 (o), 126.9 (o) 126.2 (o), 125.2 (o, 2C), 122.2 (o, 
2C), 51.1 (e), 45.3 (o), 18.3 (o); IR (neat): ~ = 3115 (w), 3080 (w), 2980 (w), 2936 
(w), 2115 (w), 1758 (s), 1670 (s), 1615 (w), 1589 (m), 1519 (s), 1488 (m), 1458 (m), 
1428 (w), 1377 (w), 1344 (s), 1284 (s), 1238 (w), 1202 (s), 1158 (s), 1114 (s), 1068 
(s), 1041 (m), 1022 (m), 1011 (m), 993 (w), 924 (w), 892 (w), 863 (s), 845 (m), 832 
(w), 811 (w), 755 (s), 729 (m), 695 (w), 677 (w), 661 (w) cm-1; HRMS (ESI): m/z 
calcd for C23H17NO5S+Na+: 442.0725 [M+Na]+; found: 442.0732 
Compound 271. Synthesised according to representative procedure E, excpet that 
crude compound was purified by FCC (EtOAc/MeOH = 
90 :10), from compound 430 (1.11 g, 2.65 mmol) to afford 
compound 271 as an amorphous pink gum (444 mg, 1.19 
mmol, 45%). 1H NMR (400 MHz, CDCl3): δ 8.19 (dd, J = 
8.0, 1.4 Hz, 1H), 7.59 (dd, J = 8.0, 1.0 Hz, 1H), 7.56 (d, J = 8.0 Hz, 1H), 7.42 (ddd, J 
 Page | 136  
 
= 7.9, 7.2, 1.6 Hz, 1H), 7.37 (d, J = 2.0 Hz, 1H), 7.30 (ddd, J = 8.1, 7.2, 1.3 Hz, 1H), 
7.16 (dd, J = 8.0, 2.0 Hz, 1H), 4.35 (s, 2H), 4.28 (s, 1H), 3.52 (q, J = 7.3 Hz, 1H), 3.36 
(s, 3H), 3.30 (s, 3H), 1.42 (d, J = 7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ 191.6 
(e), 190.7 (e), 145.6 (e), 140.5 (e), 137.5 (e), 136.2 (e), 132.4 (o), 132.2 (e), 131.4 (o), 
131.2 (o), 130.8 (o), 128.7 (o), 126.7 (o), 126.5 (o), 69.1 (o), 51.1 (e), 49.9 (o), 42.2 
(o), 42.1 (o), 18.4 (o); IR (neat): ~ = 3011 (w), 2924 (w), 2552 (w), 1737 (m), 1667 
(s), 1563 (s), 1459 (s), 1428 (m), 1411 (m), 1374 (s), 1282 (s), 1238 (m), 1175 (s), 
1127 (m), 1074 (w), 1024 (s), 942 (w), 886 (w), 853 (m), 806 (w), 797 (w), 753 (s), 
729 (m), 690 (w), 661 (w) cm-1; HRMS (ESI): m/z calcd for C20H20O3S2+Na+: 
395.0752 [M+Na]+; found: 395.0750. 
 
 
Compound 279: 4-bromo-1H-indole (3 g, 15.4 mmol) was dissolved in THF (22 
mL, 0.7 M) and cooled to 0 oC with an ice bath. NaH (60% in mineral oil, 
0.60 g, 25.1 mmol, 1.02 equiv) was added portion-wise and the reaction 
was allowed to warm up to room temperature over 1 h. TsCl (3.0 g, 15.69 
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mmol, 1.02 equiv) was added (CAUTION: exotherm) and the reaction stirred at rt 
for 16 h. The reaction was poured into 5% aqueous NaHCO3 solution (183 mL) and 
extracted with Et2O (3x 100 mL). The combined organic layers were washed once 
with brine, dried (MgSO4), filtered and concentrated in vacuo. The resulting dark 
brown solid was recrystallised from ethanol to afford compound 279 as a beige solid. 
(4.33 g, 12.4 mmol, 80%).  1H NMR (500 MHz, CDCl3): δ 7.94 (dt, J = 0.8, 8.2 Hz, 
1H), 7.76 (d, J = 8.4 Hz, 2H), 7.62 (d, J = 3.7 Hz, 1H), 7.38 (dd, J = 0.8, 7.8 Hz, 1H), 
7.24 (d, J = 7.9 Hz, 2H), 7.17 (t, J = 8.1 Hz, 1H), 6.72 (dd, J = 3.7, 0.8 Hz, 1H), 2.35 
(s, 3H),  13C NMR (100 MHz, CDCl3): δ 145.3 (e), 135.0 (e), 131.4 (e), 130.0 (o, 
2C), 126.8 (o, 2C), 126.2 (o), 125.5 (o), 115.0 (e), 112.5 (o), 108.8 (o), 21.6 (o), in 
agreement with previously reported data13;  HRMS (ESI): m/z calcd for 
C15H1279BrNO2S+H+ [M+H]+ 349.9845; found 349.9846. 
 
Compound 280. SIPr (0.04 g, 0.09 mmol, 3 mol%) and Pd2(dba)3 (0.09 g, 0.09 mmol, 
3 mol%) were weighed into a flame dried 2-neck flask, which was then 
evacuated and backfilled with N2 three times. LiHMDS (1 M in toluene, 
7 mL, 7.22 mmol, 2.3 equiv) was added, followed by compound 279 (1.10 
g, 3.14 mmol, 1.0 equiv), tert-butyl acetate (0.5 mL, 4.08 mmol, 1.3 
equiv) and toluene (7 mL, 0.44 M). The reaction was left to stir overnight 
at room temperature, then partitioned between an aqueous saturated solution of NH4Cl 
and Et2O. The layers were separated, and the aqueous layer was washed 3 times with 
Et2O. The combined organic layers were washed with brine, dried over MgSO4, 
filtered, and concentrated under vacuum. The residue was purified by flash 
chromatography (petroleum ether/ethyl acetate, 93:7) to afford compound 280 as a 
pale brown viscous oil (0.861 g, 2.23 mmol, 71% yield). 1H NMR (500 MHz, CDCl3): 
δ 7.89 (d, J = 8.4 Hz, 1H), 7.76 (d, J = 8.6 Hz, 2H), 7.57 (d, J = 4.1 Hz, 1H), 7.27-7.24 
(m, 1H), 7.21 (d, J = 8.0 Hz, 2H), 7.11 (dd, J = 7.4, 0.8 Hz, 1H), 6.72 (dd, J = 3.7, 0.8 
Hz, 1H), 3.70 (s, 2H), 2.34 (s, 3H), 1.37 (s, 9H); 13C NMR (125 MHz, CDCl3): δ 170.3 
(e), 144.9 (e), 135.3 (e), 134.8 (e), 130.4 (e), 129.8 (o, 2C), 127.6 (e), 126.8 (o, 2C), 
126.1 (o), 124.6 (o), 124.1 (o), 112.4 (o), 107.4 (o), 81.0 (e), 40.2 (e), 27.9 (o, 3C), 
21.5 (o); IR (neat): ~ = 3123 (w), 3035 (w), 2976 (w), 1690 (s), 1597 (w), 1520 (w), 
1452 (m), 1460 (m), 1424 (s), 1370 (s), 1312 (m), 1279 (s), 1247 (s), 1212 (w), 1177 
(s), 1163 (s), 1147 (s), 1124 (s), 1105 (s), 1088 (m), 1079 (m), 1029 (m), 998 (w), 972 
(w), 938 (m), 901 (w), 884 (w), 857 (w), 833 (m), 812 (w), 787 (w), 754 (s), 741 (s), 
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724 (m), 703 (w), 687 (w), 653 (w), 668 (s) cm-1; HRMS (ESI): m/z calcd for 
C21H23NO4S+Na+: 408.1240 [M+Na]+; found: 408.1242.  
Compound 281. iPr2NH (1.5 mL, 11.0 mmol, 1.8 equiv) was dissolved in THF (9 
mL) and cooled to -10 °C using an ice/brine bath, and nBuLi (2.5 M in 
hexanes, 4 mL, 1.6 equiv, 9.8 mmol) was added dropwise. The reaction 
was stirred at -10 °C for 15 minutes, then 280 (2.4 g, 6.1 mmol, 1.0 equiv) 
was added dropwise. The reaction was stirred at -10 °C for 30 minutes, 
then MeI (0.8 mL, 12.3 mmol, 2.0 equiv) was added. The reaction was 
stirred at room temperature for 1 h, then quenched with aqueous saturated solution of 
NH4Cl. The layers were separated, and the aqueous layer was washed 3 times with 
Et2O. The combined organic layers were washed with brine, dried over MgSO4, 
filtered, and concentrated under vacuum. The residue was purified by flash 
chromatography (petroleum ether/EtOAc, 94:6) to afford 281 as a pale-yellow oil (471 
mg, 1.2 mmol, 19%). 1H NMR (500 MHz, CDCl3): δ 7.88 (dt, J = 8.3, 0.8 Hz, 1H); 
7.76 (d, J = 8.4 Hz, 2H); 7.57 (d, J = 3.8 Hz, 1H); 7.28-2.4 (m, 1H); 7.22 (d, J = 8.0 
Hz, 2H); 7.15 (d, J = 7.5 Hz, 1H); 6.78 (dd, J = 3.8, 0.7 Hz, 1H); 13C NMR (125 MHz, 
CDCl3): δ 173.3 (e), 144.8 (e), 135.3 (e), 134.8 (e), 134.0 (e), 129.8 (o, 2C), 129.6 (e), 
126.8 (o, 2C), 124.7 (o), 121.2 (o), 112.1 (o), 107.4 (o), 80.7 (e), 43.8 (o), 27.8 (o, 
3C), 21.5 (o), 17.4 (o); IR (neat): ~ = 2977 (w), 2934 (w), 1723 (s), 1597 (m), 1528 
(w), 1482 (w), 1455 (w), 1423 (w), 1392 (w), 1366 (s), 1326 (m), 1307 (w), 1282 (m), 
1254 (m), 1214 (m), 1179 (s), 1164 (s), 1151 (s), 1133 (s), 1089 (s), 1022 (m), 1000 
(m), 930 (w), 890 (w), 847 (m), 812 (m), 759 (s), 703 (m), 679 (s) cm-1; HRMS (ESI): 
m/z calcd for C22H25NO4S+Na+: 422.1397 [M+Na]+; found: 422.1396.  
Compound 282. Compound 281 (1.39 g, 3.48 mmol, 1.0 equiv) and NaI (1.04 g, 6.97 
mmol, 2 equiv) were dissolved in MeCN (3.5 mL) under N2, and TMSCl 
(0.9 mL, 6.97 mmol, 2 equiv) was added. The reaction was heated at 45 °C 
for 2 h, then cooled to rt and quenched with water (9 mL) and extracted 3 
times with EtOAc. The combined organic layers were washed with water 
and then with saturated aqueous sodium thiosulphate solution to remove 
inorganic salts and iodine, respectively, and the organic layer was dried over MgSO4, 
filtered, and concentrated under vacuum. The residue was purified by flash 
chromatography (DCM/MeOH = 98:2) to afford 282 (589 mg, 1.71 mmol, 50% yield) 
as cream-coloured solid, whose identity was confirmed by 1H NMR and HRMS only. 
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1H NMR (500 MHz, CDCl3): δ 7.90 (dt, J = 8.4, 0.8 Hz, 1H), 7.77 (d, J = 8.4 Hz, 2H), 
7.59 (d, J = 3.7 Hz, 1H), 7.28 (d, J = 7.7 Hz, 1H), 7.23 (d, J = 8.1 Hz, 2H), 7.18 (d, J 
= 7.5 Hz, 1H), 6.76 (dd, J = 3.8, 0.7 Hz, 1H), 4.04 (q, J = 7.5 Hz, 1H), 2.35 (s, 3H), 
1.55 (d, J = 7.2 Hz, 3H); HRMS (ESI): m/z calcd for C18H17NO4S+Na+: 366.0770 
[M+Na]+; found: 366.0771. 
Compound 431. Synthesised according to representative procedure D from 
compound 282 (361 mg, 1.05 mmol) to afford compound 431 as 
pale green amorphous solid (393 mg, 0.85 mmol, 80%). 1H NMR 
(500 MHz, CDCl3) δ 8.18 (d, J = 9.3 Hz, 2H), 7.97 (d, J = 8.5 
Hz, 1H), 7.80 (d, J = 8.5 Hz, 2H), 7.65 (d, J = 3.7 Hz, 1H), 7.34 
(t, J = 7.7 Hz, 1H), 7.26-7.23 (m, 2H), 7.06 (d, J = 9.0 Hz, 2H), 
6.83 (d. J = 3.7 Hz, 1H), 4.29 (q, J =  7.1 Hz, 1H), 2.36 (s, 3H), 1.67 (d, J = 7.1 Hz, 
3H); 13C NMR (100 MHz, CDCl3): δ 171.8 (e), 155.4 (e), 141.2 (e), 135.3 (e), 135.0 
(e), 132.0 (e), 130.0 (o, 2C), 129.3 (e), 127.0 (o, 2C), 126.7 (o), 125.1 (o, 2C), 125.0 
(o), 122.3 (o, 2C), 121.6 (o), 112.9 (o), 106.4 (o), 43.2 (o), 21.6 (o), 17.5 (o); IR (neat): 
~ = 3117 (w), 3084 (w), 2987 (w), 2856 (w), 2114 (w), 1757 (s), 1615 (w), 1592 (s), 
1522 (s), 1489 (w), 1450 (w), 1424 (w), 1401 (w), 1373 (m), 1360 (m), 1344 (s), 1324 
(w), 1307 (w), 1284 (w), 1203 (m), 1179 (s), 1164 (s), 1130 (s), 1087 (s), 1074 (s), 
1053 (s), 1021 (m), 1013 (m), 996 (m), 952 (w), 923 (w), 892 (m), 864 (m), 838 (w), 
812 (w), 759 (s), 712 (w), 702 (w), 674 (s) cm-1; HRMS (CI(NH3)): m/z calcd for 
C24H20N2O6S+H+: 465.1120 [M+H]+; found: 465.1119.  
Compound 277. Synthesised according to representative procedure E, except that 
crude compound was purified by FCC (DCM/MeOH = 98 :2) followed 
by trituration of the solid obtained from the product containing fractions, 
from compound 431 (1.20 g, 3.41 mmol) to afford compound 277 as 
white powder (224 mg, 0.54 mmol, 63%). m.p.: 113–116 °C; 1H NMR 
(500 MHz, CDCl3): δ 7.84 (d, J = 8.4 Hz, 1H), 7.78 (d, J = 8.5 Hz, 2H), 7.55 (d, J = 
3.8 Hz, 1H), 7.25–7.21 (m, 2H), 7.17 (d, J = 7.5 Hz, 1H), 6.79 (dd, J = 3.7, 0.7 Hz, 
1H), 4.17 (s, 1H), 3.83 (q, J = 7.2 Hz, 1H), 3.31 (s, 3H), 3.26 (s, 3H), 2.35 (s, 3H), 
1.49 (d, J = 7.2 Hz, 3H) (one multiplet (1H) is masked by residual CHCl3); 13C NMR 
(125 MHz, CDCl3): δ 191.2  (e), 144.9  (e), 136.2  (e), 135.3  (e), 134.7  (e), 129.8  (o, 
2C), 129.7  (e), 126.9  (o, 2C), 125.7  (o), 124.7  (o), 121.4  (o), 111.6  (o), 107.3  (o), 
70.0  (o), 47.9  (o), 42.1  (o), 42.0  (o), 21.5  (o), 17.6  (o); IR (neat): ~ = 3087 (w), 
N
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2996 (w), 2918 (w), 1590 (m), 1568 (s), 1494 (w), 1481 (w), 1454 (w), 1420 (m), 1371 
(s), 1357 (s), 1296 (m), 1283 (m), 1268 (m), 1178 (s), 1163 (s), 1128 (s), 1086 (s), 
1030 (s), 2703 (m), 680 (s), 667 (s) cm-1; HRMS (ESI): m/z calcd for 
C21H24NO4S2+H+: 418.1141 [M+H]+; found: 418.1148; elemental analysis calcd (%) 
for C17H20O3S: C 60.41, H 5.55, N 3.35, S 15.36; found: C 60.32, H 5.64, N 3.25, S 
15.36. 
Compound 432. Compound 282 (645 mg, 1.88 mmol, 1 equiv) was dissolved in 
MeOH (59 mL, 0.032 M) and a 5M aq solution of KOH (6 mL, 
0.32 M) was added. The reaction was heated at reflux for 20 h, 
and then cooled to rt, and the MeOH removed in vacuo. The 
residue was diluted with H2O (5 mL) the acidified to pH 1 with 
conc. HCl. During the addition, a solid precipitated, which was 
filtered off, the filter cake washed with 2N HCl, and the solid was dried in a vacuum 
desiccator overnight to afford an off-white solid (313 mg, 1.65 mmol) that was used 
without further purification by diluting it in THF (14 mL) at 0 ℃ under N2. MeI (1 
mL, 16.5 mmol, 10 equiv) was added, followed by NaH (60% in oil, 158 mg, 6.60 
mmol, 4 equiv) is small portions. After stirring at r.t. for 3 h, reaction was quenched 
with H2O (20 mL) and washed with EtOAc (3 × 15 mL). The aqueous layer was 
acidified to pH 2-3 with 2N HCl, and then extracted with CH2Cl2 (3 × 20 mL). The 
combined organic layers were dried over MgSO4, filtered and concentrated under 
vacuum to afford compound a pink solid (322 mg, 1.58 mmol) that was used without 
further purification according to representative procedure D to afford 432 as pale green 
amorphous solid (365 mg, 1.12 mmol, 71%). 1H NMR (500 MHz, CDCl3): δ 8.18 (d, 
J = 9.2 Hz, 2H), 7.31 (d, J = 8.1 Hz, 1H), 7.28-7.25 (m, 1H), 7.16-7.10 (m, 4H), 6.63 
(d, J = 3.0 Hz, 1H), 4.38 (q, J = 7.2 Hz, 1H), 3.83 (s, 3H), 1.73 (d, J = 7.2 Hz, 3H); 
13C NMR (125 MHz, CDCl3): δ 172.5 (e), 155.8 (e), 137.0 (e), 131.4 (e), 129.1 (o), 
126.9 (e), 125.0 (o, 2C), 122.4 (o, 2C), 121.9 (o), 117.8 (o), 108.8 (o), 98.9 (o), 43.7 
(o), 33.0 (o), 17.5 (o); IR (neat): ~ = 3081 (w), 2930 (w), 2854 (w), 2114 (w), 1756 
(s), 1614 (w), 1592 (m), 1521 (s), 1489 (m), 1445 (w), 1419 (w), 1344 (s), 1304 (m), 
1275 (w), 1240 (w), 1206 (s), 1156 (s), 1132 (s), 1073 (s), 1048 (m), 1012 (m), 996 
(w), 934 (w), 892 (m), 863 (m), 841 (w), 748 (s), 710 (m), 679 (w) cm-1; HRMS (ESI): 
m/z calcd for C18H16N2O4+H+: 325.1183 [M+H]+; found: 325.1182. 
N
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Compound 278. Synthesised according to representative procedure E, except that 
crude compound was purified by FCC (DCM/MeOH = 98 :2) followed 
by trituration of the solid obtained from the product containing fractions, 
from compound 432 (365 mg, 1.12 mmol) to afford compound 278 as 
cream-coloured powder (199 mg, 0.72 mmol, 64%). m.p.: 119–121 °C; 
1H NMR (500 MHz, CDCl3): δ 7.22-7.16 (m, 2H), 7.06 (dd, J = 6.0, 2.0 Hz, 1H), 7.03 
(d, J = 3.1 Hz, 1H), 6.58 (d, J = 3.2 Hz, 1H), 4.24 (s, 1H), 3.96 (q, J = 7.3 Hz, 1H), 
3.78 (s, 3H), 3.33 (s, 3H), 3.27 (s, 3H), 1.56 (d, J = 7.2 Hz, 3H); 13C NMR (125 MHz, 
CDCl3): δ 136.7 (e), 135.6 (e), 128.3 (o), 127.5 (e), 121.7 (o), 117.4 (o), 107.5 (o), 
99.5 (o), 68.5 (o), 48.1 (o), 42.2 (o), 42.0 (o), 32.9 (o), 17.4 (o); IR (neat): ~ = 3090 
(w), 3072 (w), 3006 (w), 2994 (w), 2693 (w), 2914 (w), 2861 (w), 1713 (w), 1679 (w), 
1562 (s), 1515 (w), 1492 (s), 1444 (m), 1424 (m), 1416 (m), 1376 (s), 1360 (m), 1339 
(m), 1309 (m), 1291 (m), 1278 (m), 1258 (w), 1240 (w), 1180 (s), 1168 (s), 1128 (m), 
1082 (s), 1062 (w), 1032 (s), 996 (m), 948 (m), 906 (w), 882 (w), 856 (s), 804 (w), 
781 (m), 759 (s), 709 (s), 671 (m) cm-1; HRMS (ESI): m/z calcd for C15H19NO2S+H+: 
278.1209 [M+H]+; found: 278.1217; elemental analysis calcd (%) for C15H19NO2S: C 
64.95, H 6.90, N 5.05, S 11.56; found: C 64.99, H 6.92, N 4.94, S 11.40. 
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Compound 433. In a flame dried 2-neck 250 mL RB flask under N2, compound 288 
(11.9 g, 56.53 mmol, 1 equiv), paraformaldehyde (2.55 g, 
84.80 mmol, 1.5 equiv), and K2CO3 (7.81 g, 56.53 mmol, 
1 equiv) were dissolved in dry DMF (40 mL, 1.4 M) and 
heated at 100 oC for 1 h. After cooling to room temperature, 
H2O (200 mL) was added and the mixture was extracted with EtOAc (3 x 100mL). 
The combined organic layers were washed with H2O (5 x 100 mL), dried (MgSO4), 
filtered and concentrated in vacuo. The residue was purified by FCC (PE:EtOAc 4:1) 
to afford compound 289 as a bright yellow oil. (3.00 g, 13.53 mmol, 24%). 1H NMR 
(500 MHz, CDCl3): δ 7.02 (m, 3H), 6.85 (d, J = 8.1 Hz, 1H), 6.28 (d, J = 1.3 Hz, 1H), 
5.85 (d, J = 1.3 Hz, 1H), 3.89 (s, 6H), 3.83 (s, 3H). Then, following a reported 
procedure14, pyrrole (1.90 mL, 27.06 mmol, 2 equiv) was added to a solution of KOtBu 
(3.03 g, 27.06 mmol, 2 equiv) in 8% aqueous DMSO (61 mL) under N2. A solution of 
compound 289 (3.0 g, 13.53 mmol, 1 equiv) in DMSO (27 mL) was added dropwise 
at rt, and the reaction was left to stir at rt for 3 h. The reaction was poured into an ice-
water bath (135 mL), then washed with DCM (3 x 50 mL). The aqueous layer was 
acidified to pH 1 with conc HCl, then extracted with DCM (3 x 100 mL). The 
combined organic layers from the second extraction were washed with H2O (5 x 50 
mL), brine (1 x 50 mL), dried (MgSO4), filtered and concentrated in vacuo. The crude 
residue was purified by FCC (98:2 DCM:MeOH) to afford compound 290 (3.71 g, 
13.48 mmol, quant) as a pale brown amorphous solid whose identity was confirmed 
by 1H NMR only before being used in the next step. 1H NMR (500 MHz, DMSO-d6): 
δ 6.89 (d, J = 8.4 Hz, 1H), 6.82 (td, J = 2.2, 9.1 Hz, 2H), 6.67 (t, J = 2.1 Hz, 2H), 5.90 
(t, J = 2.2 Hz, 2H), 4.43 (dd, J = 8.6, 13.9 Hz, 1H), 4.09 (dd, J = 6.9, 13.8 Hz, 1H), 
3.94 (dd, J = 6.6, 8.5 Hz, 1H), 3.72 (s, 3H); 3.71 (s, 3H).  Synthesised according to 
representative procedure D from compound 290 (2.29 g, 8.32 mmol) to afford 
compound 433 as pale brown solid (1.06 g, 2.67 mmol, 32%). m.p.: 68–70 °C; 1H 
NMR (500 MHz, CDCl3): δ 8.22 (d, J = 9.2 Hz, 2H), 7.07 (d, J = 9.2 Hz, 2H), 6.94 
(dd, J = 8.3, 2.0 Hz, 1H), 6.89 (d, J = 8.2 Hz, 1H), 6.81 (d, J = 2.1 Hz, 1H), 6.65 (t, J 
= 2.0 Hz, 2H), 6.16 (t, J = 2.1 Hz, 2H), 4.62 (dd, J = 13.7, 9.0 Hz, 1H), 4.24 (dd, J = 
13.8, 5.8 Hz, 1H), 4.19 (dd, J = 9.0, 5.8 Hz, 1H), 3.90 (s, 3H), 3.88 (s, 3H); 13C NMR 
(125 MHz, CDCl3): δ 170.2 (e), 155.1 (e), 149.5 (e), 149.3 (e), 145.5 (e), 127.0 (e), 
125.2 (o, 2C); 122.3 (o, 2C); 121.0 (o, 2C), 120.1 (o), 111.6 (o), 110.9 (o), 108.8 (2C, 
o), 56.0 (o), 55.9 (o), 53.6 (o), 52.4 (e)); IR (neat): ~ = 3120 (w), 3079 (w), 2989 (w), 
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2953 (w), 2836 (w), 1751 (s), 1619 (m), 1592 (m), 1525 (s), 1513 (s), 1492 (m), 1466 
(m), 1453 (m), 1440 (w), 1422 (w), 1347 (s), 1285 (m), 1272 (w), 1249 (m), 1233 (m), 
1203 (m), 1182 (w), 1162 (w), 1125 (s), 1088 (s), 1072 (m), 1060 (w), 1037 (w), 1022 
(s), 968 (w), 943 (w), 896 (m), 864 (m), 849 (w), 841 (w), 819 (w), 769 (w), 754 (w), 
738 (w), 724 (s), 701 (m) cm-1; HRMS (ESI): m/z calcd for C21H20N2O6+H+: 397.1394 
[M+H]+; found: 397.1391; elemental analysis calcd (%) for C21H20N2O6: C 63.63, H 
5.09, N 7.07; found: C 63.51, H 5.26, N 7.24.  
Compound 285. Synthesised according to representative procedure E, except that 
crude compound was purified by FCC (DCM/MeOH = 98 :2), 
from compound 433 (3.99 g, 10.06 mmol) to afford compound 
285 as cream-coloured solid (1.70 g, 4.85 mmol, 48%). m.p.: 
78–80 °C; 1H NMR (500 MHz, CDCl3): δ 6.86–6.77 (m, 3H), 6.57 (t, J = 2.0 Hz, 2H), 
6.04 (t, J = 2.0 Hz, 2H), 4.58 (dd, J = 13.6, 8.6 Hz, 1H), 4.28 (s, 1H), 4.08 (dd, J = 
13.6, 6.0 Hz, 1H), 3.86 (s, 3H), 3.85 (s, 3H), 3.75–3.63 (m, 1H), 3.33 (s, 3H), 3.28 (s, 
3H); 13C NMR (100 MHz, CDCl3): δ 187.8 (e), 148.9 (e), 148.2 (e), 131.4 (e), 121.1 
(o. 2C), 120.1 (o), 111.1 (o), 111.0 (o), 107.7 (o. 2C), 70.8 (o), 57.6 (o), 55.85 (o), 
55.80 (o), 52.3 (e), 41.94 (o), 41.89 (o); IR (neat): ~ = 3113 (w), 3075 (w), 3015 (w), 
2929 (w), 1698 (w), 1646 (s), 1561 (s), 1525 (m), 1494 (w), 1466 (m), 1374 (s), 1325 
(s), 1307 (m), 1253 (m), 1243 (m), 1175 (s), 1147 (m), 1085 (s), 1029 (s), 994 (m), 
967 (m), 941 (m), 918 (m), 876 (w), 856 (s), 776 (w), 740 (s), 702 (m), 679 (w) cm-1; 
HRMS (ESI): m/z calcd for C18H23NO4S+Na+: 372.1245 [M+Na]+; found: 372.1250. 
 
 
Representative Procedure F: In a 2-neck RB flask under N2, 2-aminoethanol (10.0 
mL, 163.7 mmol, 1.0 equiv) and NaOAc (13.6 g, 165.4 mmol, 1.01 equiv) were 
dissolved in AcOH (25 mL, 6.5 M) and H2O (76 mL, 2.2 M), and the reaction was 
heated to 90 oC for 5 mins. 2,5-dimethoxytetrahydrofuran (21 mL, 163.7 mmol, 1.0 
equiv) was added, and the reaction was heated at 90 oC for 18 h. After cooling to room 
temperature, the reaction was diluted with EtOAc and washed once with brine and 
once with water. The combined organic layers were dried (MgSO4), filtered and 
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concentrated in vacuo to afford a brown liquid that was purified by FCC (petroleum 
ether:EtOAc = 3:2) to afford compound 291 as a clear viscous liquid (8.74 g, 78.64 
mmol, 48%). This was combined with a second batch of 1.26 g prepared using the 
same method for use in the next step.  
 
Compound 291. 1H NMR (500 MHz, CDCl3): 6.71 (t, J = 2.1 Hz, 2H); 6.18 (t, J = 2.2 
Hz, 2H); 4.03 (t, J = 5.3 Hz, 2H); 3.87 (t, J = 5.4 Hz, 2H), in agreement 
with previously reported data15. 
 
 
Compound 292. Triphenylphosphine (35 g, 135.0 mmol, 1.5 equiv) was dissolved in 
dry DCM (692 mL, 0.13 M) under N2 and iodine (34 g, 135.0 mmol, 1.5 
equiv) was added at rt in small portions. The reaction was left to stir at 
rt for 10 mins, before imidazole (15.3 g, 224.9 mmol, 2.5 equiv) was 
added in small portions, and the reaction was stirred at rt for a further 10 mins. 
Compound 291 (10 g, 90.0 mmol, 1 equiv) was added to the reaction dropwise, and 
the reaction was stirred at rt for 1 h, before being quenched with sat. aq. sodium 
thiosulfate solution (692 mL), and stirred for a further 5 mins. The layers were then 
separated, the aqueous was extracted with DCM (2 x 200 mL), and the combined 
organic layers were dried (MgSO4), filtered and concentrated in vacuo. The crude 
residue was purified by FCC (95:5 PE:EtOAc) to afford compound 292 as a light 
brown liquid (12.7 g, 57.31 mmol, 64%). 1H NMR (400 MHz, CDCl3): δ ppm 6.68 (t, 
J = 2.2 Hz, 2H); 6.19 (t, J = 2.0 Hz, 2H); 4.25 (t, J = 7.4 Hz, 2H); 3.39 (t, J = 7.6 Hz, 
2H), in agreement with previously reported data16. 
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Compound 434. A flame-dried 2-neck 250 mL flask under N2 containing iPr2NH (6 
mL, 42.81 mmol, 1.8 equiv) in THF (25 mL) was 
cooled to -10 °C using an ice/brine bath before adding 
nBuLi (2.5 M in hexanes, 16 mL, 39.65 mmol, 1.6 
equiv) dropwise. The reaction was then left to stir at -
10 °C for 30 minutes before a solution of methyl 2-(3,4-
dimethoxyphenyl)acetate (5 g, 24.78 mmol, 1 equiv) in 
THF (49 mL) was added dropwise. The reaction was left to stir at -10 °C for 30 mins, 
then compound 292 (10.95 g, 49.56 mmol, 2 equiv) was added. The reaction was then 
left to stir at room temperature for 1 h before being quenched with H2O and extracted 
3 times with EtOAc. The combined organic layers were washed once with brine, dried  
over MgSO4, filtered and concentrated under vacuum to afford a pale-yellow oil (2.69 
g, 8.87 mmol, 37%) that was dissolved in THF/H2O (1:1, 35 mL, 0.25 M) before 
NaOH (1.77 g, 44.35 mmol, 5 equiv) was added. The reaction was stirred at reflux for 
15 h, then carefully acidified to pH 2 using 2N HCl. The reaction was then quickly 
extracted 3 times with CH2Cl2. The combined organic layers were dried over MgSO4, 
filtered and concentrated under vacuum to afford a brown solid (2.55 g, 8.1 mmol, 
quant.) that was used according to representative procedure D to afford 434 as pale-
brown amorphous solid (1.81 g, 4.41 mmol, 48%). 1H NMR (500 MHz, CDCl3): δ 
8.25 (d, J = 9.3 Hz, 2H), 7.15 (d, J = 9.4 Hz, 2H), 6.97-6.88 (m, 3H), 6.67 (t, J = 2.1 
Hz, 2H), 6.22 (t, J = 2.1 Hz, 2H), 4.05-3.98 (m, 1H), 3.93 (s, 3H), 3.92 (s, 3H), 3.91-
3.83 (m, 1H), 3.63 (t, J = 7.8 Hz, 1H), 2.73-2.62 (m, 1H), 2.41-2.30 (m, 1H); 13C NMR 
(125 MHz, CDCl3): δ 171.2 (e), 155.3 (e), 149.4 (e), 148.9 (e), 145.4 (e), 129.0 (e), 
125.1 (o, 2C), 122.2 (o, 2C), 120.5 (o, 2C), 120.4 (o), 111.6 (o), 111.0 (o), 108.5 (o, 
2C), 56.02 (o), 55.92 (o), 47.9 (o), 46.7 (e), 34.2 (e); IR (neat): ~ = 3080 (w), 2933 
(w), 2855 (w), 2115 (w), 1755 (m), 1703 (w), 1615 (w), 1591 (m), 1515 (s), 1500 
(m),1489 (m), 1463 (m), 1452 (m), 1420 (w), 1344 (s), 1283 (m), 1261 (s), 1236 (s), 
1205 (s), 1157 (m), 1141 (s), 1111 (s), 1089 (m), 1025 (m), 940 (w), 862 (m), 809 (w), 
764 (w), 726 (s), 683 (w) cm-1; HRMS (ESI): m/z calcd for C22H22N2O6+H+: 411.1551 
[M+H]+; found: 411.1551. 
 
MeO
OMe
N
O
O
NO2
434
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Compound 286. Synthesised according to represenatative procedure E, from 
compound 434 (1.81 g, 4.41 mmol), except that crude 
compound was purified by FCC (DCM/MeOH = 98:2), to 
afford compound 286 as cream-coloured solid (716 mg, 1.97 
mmol, 45%). m.p.: 92–93 °C; 1H NMR (500 MHz, CDCl3): 
δ 6.82–6.78 (m, 3H), 6.62 (t, J = 2.1 Hz, 2H), 6.13 (t, J = 2.1 Hz, 2H), 4.30 (s, 1H), 
3.89–3.84 (m, 7H), 3.81–3.74 (m, 1H), 3.36 (s, 3H), 3.29 (s, 3H), 3.19 (t, J = 8.0 Hz, 
1H), 2.60–2.50 (m, 1H), 2.18–2.09 (m, 1H); 13C NMR (125 MHz, CDCl3): δ 189.9 
(e), 148.9 (e), 147.8 (e), 133.3 (e), 120.6 (o. 2C), 120.1 (o), 111.1 (o), 111.0 (o), 107.8 
(o. 2C), 69.8 (o), 55.84 (o), 55.79 (o), 52.5 (o), 47.4 (e), 42.1 (o), 41.9 (o), 34.4 (e); IR 
(neat): ~ = 3016 (w), 2927 (w), 2843 (w), 1606 (w), 1590 (w), 1559 (s), 1515 (s), 1451 
(m), 1417 (m), 1360 (s), 1322 (w), 1308 (w), 1289 (w), 1257 (s), 1225 (s), 1172 (s), 
1140 (s), 1087 (m), 1065 (w), 1029 (s), 1019 (s), 998 (m), 982 (w), 971 (w), 946 (w), 
857 (m), 844 (s), 813 (m), 767 (m), 749 (w), 721 (s), 684 (w) cm-1; HRMS (ESI): m/z 
calcd for C19H25NO4S+H+: 364.1583 [M+H]+; found: 364.1579; elemental analysis 
calcd (%) for C19H25NO4S: C 62.79, H 6.93, N 3.85, S 8.82; found: C 62.61, H 6.96, 
N 3.83, S 8.64. 
 
 
 
Compound 295. Synthesised according to representative procedure F, from 3-
bromopropan-1-amine hydrobromide 293 (10 g, 45.68 mmol) to 
afford compound 295 as a brown oil (3.40 g, 18.25 mmol, 40%). 1H 
NMR (500 MHz, CDCl3): δ 6.68 (t, J = 2.1 Hz, 2H), 6.16 (t, J = 2.1 Hz, 2H), 4.08 (t, 
J = 6.4 Hz, 2H), 3.31 (t, J = 6.2 Hz, 2H), 2.26 (quint, J = 6.2 Hz, 2H); in agreement 
with previously reported data17. 
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Compound 435. In a flame dried 2-neck RB flask under N2, iPr2NH (2.3 mL, 16.44 
mmol, 1.8 equiv) was dissolved in THF (13 mL) and the solution 
was cooled to -10 oC using an ice/brine bath. nBuLi (2.5 M in 
hexanes, 6 mL, 14.62 mmol, 1.6 equiv) was added dropwise, and 
the reaction was stirred at -10 oC for 15 mins. A solution of methyl phenylacetate (1.3 
mL, 9.14 mmol, 1.0 equiv) in THF (25 mL) was added dropwise, and the reaction was 
stirred at -10 oC for 30 mins. Compound 295 (3.4 g, 18.27 mmol, 2.0 equiv) was added 
and the reaction was stirred at room temperature for 1 hour. The reaction was quenched 
with water, the layers were separated and the aqueous was extracted three times with 
EtOAc. The combined organic layers were washed once with brine, dried (MgSO4), 
filtered and concentrated in vacuo. The crude residue was purified by FCC 
(hexane/Et2O = 9:1) to afford compound 435 as a pale brown oil (1.14 g, 4.43 mmol, 
48%).  1H NMR (500 MHz, CDCl3): δ 7.39-7.20 (m, 5H); 6.60 (t, J = 2.2 Hz, 2H); 
6.12 (t, J = 2.0 Hz, 2H); 3.91-3.80 (m, 2H); 3.65 (s, 3H); 3.50 (t, J = 6.6 Hz, 1H); 2.13-
2.00 (m, 1H); 1.84-1.62 (m, 3H); 13C NMR (125 MHz, CDCl3): δ 175.8 (e), 141.7 (e), 
128.5 (o, 2C), 127.0 (o), 126.3 (o, 2C), 120.4 (o, 2C), 108.1 (o, 2C), 53.3 (e), 52.2 (o), 
49.6 (o), 31.8 (e), 26.3 (e); IR (neat): ~ = 3029 (w), 2951 (w), 2872 (w), 1729 (s), 1601 
(w), 1584 (w), 1547 (w), 1498 (m), 1453 (m), 1434 (m), 1353 (m), 1280 (m), 1208 
(m), 1151 (s), 1088 (s), 1072 (m), 1030 (w), 1005 (w), 969 (w), 919 (w), 821 (w), 721 
(s), 697 (s) cm-1; HRMS (ESI): m/z calcd for C16H19NO2+H+: 258.1489 [M+H]+; 
found: 258.1487. 
Compound 436. Compound 435 (1.14 g, 4.43 mmol) was used according to 
representative procedure C to afford a sticky brown solid (0.98 g, 
4.03 mmol, 91%) which was used immediately according to 
representative procedure D to afford compound 436 as a beige 
amorphous solid (1.19 g, 3.26 mmol, 81%).  1H NMR (500 MHz, 
CDCl3): δ 8.22 (d, J = 9.1 Hz, 2H), 7.43-7.28 (m, 5H), 7.14 (d, J = 
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9.1 Hz, 2H), 6.63 (t, J = 2.1 Hz, 2H), 6.15 (t, J = 2.1 Hz, 2H), 3.91 (t, J = 6.4 Hz, 2H), 
3.72 (t, J = 7.2 Hz, 1H), 1.96-1.69 (m, 4H); 13C NMR (100 MHz, CDCl3): δ 171.3 (e), 
155.4 (e), 137.4 (e), 131.4 (e), 129.1 (o, 2C), 128.0 (o), 127.9 (o, 2C), 125.2 (o, 2C), 
122.3 (o, 2C), 120.5 (o, 2C), 108.3 (o, 2C), 51.3 (o), 49.2 (e), 30.3 (e), 29.4 (e); IR 
(neat): ~ = 3115 (w), 3071 (w), 2990 (w), 2928 (w), 2854 (w), 2115 (m), 1924 (w), 
1760 (m), 1708 (w), 1616 (w), 1590 (m), 1519 (s), 1489 (m), 1466 (w), 1454 (m), 
1423 (w), 1380 (w), 1343 (s), 1321 (s), 1288 (w), 1261 (w), 1244 (w), 1204 (s), 1164 
(w), 1115 (s), 1091 (s), 1063 (s), 1048 (s), 1010 (m), 982 (w), 956 (w), 931 (w), 900 
(s), 865 (s), 857 (s), 813 (w), 770 (w), 746 (s), 719 (w), 708 (m), 675 (w) cm-1; HRMS 
(ESI): m/z calcd for C21H20N2O4+H+: 365.1496 [M+H]+; found: 365.1494. 
Compound 287. Synthesised according to representative procedure E, except that 
crude compound was purified by FCC (DCM/MeOH = 98 :2) 
followed by trituration of the solid obtained from the product 
containing fractions, from compound 436 (1.19 g, 0.98 mmol) to 
afford compound 287 as an off white powder (398 mg, 1.25 mmol, 
38%). m.p. = 68-70 oC ; 1H NMR (400 MHz, CDCl3): δ 7.31-7.24 (m, 4H), 7.23-7.18 
(m, 1H), 6.61 (t, J = 1.9 Hz, 2H), 6.11 (t, J = 2.0 Hz, 2H), 4.30 (s, 1H), 3.92-3.77 (m, 
2H), 3.35 (s, 3H), 3.32-3.26 (m, 4H), 2.14-2.03 (m, 1H), 1.82-1.62 (m, 3H); 13C NMR 
(100 MHz, CDCl3): δ 190.2 (e), 141.4 (e), 128.4 (o, 2C), 127.4 (o, 2C), 126.6, 120.4 
(o, 2C), 107.8 (o, 2C), 69.7 (o), 56.1 (o), 49.5 (e), 42.1 (o), 41.9 (o), 30.1 (e), 29.9 (e); 
IR (neat): ~ = 3023 (w), 2926 (w), 2238 (w), 1724 (w), 1562 (s), 1499 (w), 1451 (w), 
1375 (s), 1302 (w), 1281 (m), 1176 (s), 1119 (w), 1088 (m), 1069 (w), 1024 (m), 988 
(w), 968 (w), 908 (s), 856 (w), 721 (vs), 698 (vs) cm-1; HRMS (ESI): m/z calcd for 
C18H23NO2S+H+: 318.1522 [M+H]+; found: 318.1524. 
Compound 437. Synthesised according to representative procedure D from 2-(1H-
pyrrol-1-yl)acetic acid  (1.89 g, 15.10 mmol) to afford 
compound 437 as pale-brown amorphous solid (1.89 g, 7.68 
mmol, 51%). The compound was contaminated by some DCC, 
and was characterized only by 1H NMR before being used 
without further purification in the next step. 1H NMR (500 MHz, CDCl3): δ 7.28 (d, J 
= 9.2 Hz, 2H), 7.32 (d, J = 9.2 Hz, 2H), 6.75 (t, J = 2.0 Hz, 2H), 6.26 (t, J = 2.1 Hz, 
2H), 4.94 (s, 2H). 
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Compound 306. Synthesised according to representative procedure E, except that 
crude compound was purified by FCC (DCM/MeOH = 95:5), from 
compound 437 (1.00 g, 4.06 mmol) to afford compound 306 as white 
solid (555 mg, 2.78 mmol, 68%). m.p.: 95–97 °C; 1H NMR (500 MHz, 
CDCl3): δ 6.65 (t, J = 2.0 Hz, 2H), 6.17 (t, J = 2.0 Hz, 2H), 4.44 (s, 
2H), 4.07 (s, 1H), 3.37 (s, 6H); 13C NMR (125 MHz, CDCl3): δ 186.2 (e), 121.8 (o, 
2C), 108.7 (o, 2C), 68.8 (o), 56.9 (e), 42.1 (o, 2C); IR (neat): ~ = 3106 (w), 3068 (w), 
3023 (w), 3006 (m), 2921 (w), 2240 (w), 1723 (w), 1548 (s), 1493 (w), 1424 (w), 1403 
(w), 1375 (s), 1324 (m), 1308 (m), 1288 (m), 1174 (s), 1164 (s), 1089 (m), 1064 (m), 
1028 (s), 991 (m), 974 (m), 964 (m), 916 (m), 859 (m), 816 (w), 762 (m), 726 (s), 701 
(s) cm-1; HRMS (ESI): m/z calcd for C9H13NO2S+H+: 200.0740 [M+H]+; found: 
200.0742. 
 
Compound 438: Synthesised according to representative procedure F, from racemic 
alanine (2 g, 22.45 mmol) to afford compound 438 as a sticky brown 
gum that was used without further purification (3.13 g, 22.49 mmol, 
quant). 1H NMR (500 MHz, CDCl3): δ ): δ ppm 6.75 (t, J = 2.2 Hz, 2H), 
6.21 (t, J = 2.2 Hz, 2H), 4.81 (q, J = 7.0 Hz, 1H), 1.77 (d, J = 7.4 Hz, 3H), in agreement 
with previously reported data18. 
 
Compound 439. Synthesised according to representative procedure D from 
compound 438 (1.52 g, 7.99 mmol) to afford compound 439 as 
viscous yellow oil (1.42 g, 4.56 mmol, 57%). 1H NMR (500 
MHz, CDCl3): δ 8.26 (d, J = 9.1 Hz, 2H), 7.24 (d, J = 9.1 Hz, 
2H), 6.84 (t, J = 2.1 Hz, 2H), 6.25 (t, J = 2.1 Hz, 2H), 5.04 (q, 
J = 7.3 Hz, 1H), 1.89 (d, J = 7.3 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ 168.9 (e), 
155.0 (e), 153.5 (e), 125.3 (o, 2C), 122.2 (o, 2C), 119.7 (o, 2C), 109.3 (o, 2C), 57.0 
(o), 18.0 (o); IR (neat): 3116 (w), 2989 (w), 2922 (w), 2865 (w), 1764 (s), 1702 (m), 
1662 (s), 1615 (w), 1591 (m), 1521 (s), 1489 (s), 1453 (w), 1410 (w), 1346 (s), 1302 
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(m), 1282 (w), 1248 (w), 1228 (w), 1200 (s), 1159 (s), 1107 (w), 1091 (s), 1064 (m), 
1050 (m), 1011 (m), 961 (w), 946 (w), 911 (w), 895 (w), 864 (m), 849 (w), 835 (w), 
812 (w), 789 (w), 748 (w), 720 (s), 702 (s), 677 (w); HRMS (ESI): m/z calcd for 
C13H12N2O4+Na+: 283.0695 [M+Na]+; found: 283.0692.  
Compound 307. Synthesised according to representative procedure E, except that 
crude compound was purified by FCC (DCM/MeOH = 98 :2) followed 
by trituration of the solid obtained from the product containing 
fractions, from compound 439 (2.49 g, 9.56 mmol)  to afford compound 
307 as off-white solid (1.66 g, 7.79 mmol, 81%). m.p.: 86–87 °C; 1H 
NMR (500 MHz, CDCl3): δ 6.74 (t, J = 2.1 Hz, 2H), 6.17 (t, J = 2.1 Hz, 2H), 4.52 (q, 
J = 7.4 Hz, 1H), 4.02 (s, 1H), 3.36 (s, 3H), 3.35 (s, 3H), 1.68 (d, J = 7.3 Hz, 3H); 13C 
NMR (125 MHz, CDCl3): δ 189.2 (e), 119.8 (o, 2C), 108.1 (o, 2C), 68.2 (o), 61.7 (o), 
41.9 (o), 41.8 (o), 18.0 (o); IR (neat): ~ = 3099 (w), 2996 (w), 2916 (w), 1537 (s), 1493 
(w), 1458 (w), 1435 (w), 1403 (w), 1382 (s), 1363 (m), 1327 (w), 1300 (s), 1282 (m), 1270 
(w), 1173 (s), 1090 (m), 1064 (w), 1027 (s), 994 (w), 958 (w), 945 (w), 881 (w), 855 (s), 751 
(w), 727 (s), 703 (m), 679 (w) cm-1; HRMS (CI(CH4)): m/z calcd for C10H15NO2S+H+: 
214.0902 [M+H]+; found: 214.0890; elemental analysis calcd (%) for C10H14NO2S: C 
56.31, H 7.09, N 6.57, S 15.03; found: C 56.18, H 7.11, N 6.40, S 14.53. 
 
Compound 441. In a flame dried 2-neck RB flask under N2, iPr2NH (3.3 mL, 23.50 
mmol, 1.8 equiv) was dissolved in dry THF (18 mL), and the 
solution was cooled to -10 oC with an ice/brine bath. nBuLi 
(2.5 M in hexanes, 8.4 mL, 20.90 mmol, 1.6 equiv) was added 
dropwise, and the reaction was stirred at -10 oC for 15 mins. 
A solution of 440 (2 g, 13.06 mmol, 1.0 equiv) in THF (36 mL) was added dropwise, 
and the reaction was stirred at -10 oC for 30 mins. Allyl bromide (2.3 mL, 26.12 mmol, 
2.0 equiv) was added, and the reaction was warmed to rt, and stirred for 1 h. The 
reaction was quenched with water, extracted three times with ethyl acetate, and the 
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combined organic layers were washed with brine, dried (MgSO4), filtered and 
concentrated in vacuo to give a brown oil (2.09 g, 10.81 mmol, 83%). This oil was 
dissolved in THF/H2O (1:1, 43 mL, 0.25 M), and powdered NaOH (2.16 g, 54.05 
mmol, 5.0 equiv) was added. The reaction was stirred at reflux for 16 h, then cooled 
to rt and the layers were separated. The aqueous was carefully acidified with 2N HCl, 
and extracted three times with DCM. The combined organic layers were dried 
(MgSO4), filtered and concentrated in vacuo to afford a sticky brown solid (1.62 g, 
9.81 mmol, 91%). The solid was then used according to representative procedure D to 
afford compound 441 as an amorphous cream-coloured solid (1.10 g, 3.84 mmol, 
39%). 1H NMR (500 MHz, CDCl3): δ 8.26 (d, J = 9.3 Hz, 2H), 7.23 (d, J = 9.2 Hz, 
2H), 6.84 (t, J = 2.1 Hz, 2H), 6.24 (t, J = 2.1 Hz, 2H), 5.80-5.69 (m, 1H), 5.24 (dq, J = 
17.1, 1.5 Hz, 1H), 5.18 (dq, J = 10.3, 1.1 Hz, 1H), 4.90 (dd, J = 8.4, 7.0 Hz, 1H), 3.06-
2.99 (m, 1H), 2.95-2.91 (m, 1H). This compound contained DCC, and was therefore 
characterised by 1H NMR only before being used in the next step. 
 
Compound 308. Synthesised according to representative procedure E, except that 
crude compound was purified by FCC (DCM/MeOH = 98:2), from 
compound 441 (1.10 g, 3.84 mmol) to afford compound 308 as a 
beige coloured solid (293 mg, 1.22 mmol, 32%). m.p. = 85-87 oC; 1H 
NMR (500 MHz, CDCl3): δ 6.73 (t, J = 2.2 Hz, 2H), 6.16 (t, J = 2.2 
Hz, 2H), 5.69 (quin d, J = 6.9, 3.6, 6.9 Hz, 1H), 5.10 (dq, J = 17.0, 1.5 Hz, 1H), 5.01 
(dq, J = 10.3, 1.4 Hz, 1H), 4.40 (dd, J = 5.1, 10.2 Hz, 1H), 4.14 (s, 1H), 3.36 (s, 3H), 
3.35 (s, 3H), 3.00-2.92 (m, 1H), 2.74-2.64 (m, 1H); 13C NMR (100 MHz, CDCl3): δ 
187.3 (e), 134.2 (o), 120.1 (o, 2C), 117.5 (e), 108.2 (o, 2C), 69.2 (o), 66.3 (o), 42.0 
(o), 41.8 (o), 36.3 (o); IR (neat): ~ 3135 (w), 3075 (w), 3001 (w), 2917 (w), 1704 (w), 
1641 (w), 1571 (s), 1488 (m), 1412 (m), 1387 (s), 1327 (m), 1313 (s), 1269 (m), 1239 
(w), 1172 (w), 1135 (m), 1112 (m), 1086 (s), 1073 (m), 1053 (w), 1026 (s), 1003 (m), 
959 (m), 946 (w), 925 (s), 906 (w), 851 (s), 786 (w), 757 (w), 730 (s), 680 (m), 658 
(w) cm-1; HRMS (ESI): m/z calcd for C12H17NO2S+H [M+H]+ 240.1053; found 
240.1051. 
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Compound 442: Synthesised according to representative procedure F from racemic 
phenylglycine (2 g, 12.12 mmol) to afford compound 442 as a sticky 
brown gum that was used without further purification (2.60 g, 12.92 
mmol, 98%). 1H NMR (500 MHz, CDCl3): δ ppm 7.46 – 7.30 (m, 5H), 
6.74 (t, J = 3.0 Hz, 2H), 6.21 (t, J = 3.0 Hz, 2H), 5.90 (s, 1H), in agreement 
with previously reported data18. 
 
Compound 444. Synthesised according to representative procedure D from 
compound 442 (2.6 g, 12.92 mmol) to afford compound 444 as 
pale-green amorphous solid (2.76 g, 8.56 mmol, 66%). 1H NMR 
(500 MHz, CDCl3): δ 8.30–8.23 (m, 2H), 7.50–7.39 (m, 5H), 
7.31–7.26 (m, 2H), 6.82 (t, J = 2.2 Hz, 2H), 6.25 (t, J = 2.2 Hz, 2H), 6.12 (s, 1H); 13C 
NMR (125 MHz, CDCl3): δ 167.3 (e), 154.8 (e), 145.7 (e), 129.4 (o), 129.3 (o, 2C), 
127.9 (o, 2C), 125.3 (o, 2C), 122.2 (o, 2C), 120.9 (o, 2C), 109.4 (o, 2C), 65.4 (o); IR 
(neat): ~ = 2934 (w), 2836 (w), 2162 (w), 1757 (m), 1614 (w), 1591 (m), 1450 (s), 
1489 (s), 1463 (m), 1419 (w), 1345 (s), 1205 (s), 1157 (s), 1142 (s), 1115 (s), 1089 
(s), 1026 (s), 959 (w), 907 (w), 862 (m), 807 (w), 763 (w), 728 (s), 682 (w) cm-1; 
HRMS (ESI): m/z calcd for C18H14N2O4+Na+: 345.0851 [M+Na]+; found: 345.0850. 
Compound 309. Synthesised according to representative procedure E, except that 
crude compound was purified by FCC on a BIOTAGE flash 
chromatography system (gradient 0-10% MeOH in DCM), from 
compound 444 (2.76 g, 8.56 mmol) to afford compound 309 as white 
solid (1.02 g, 3.70 mmol, 43 %). m.p.: 125–126 °C; 1H NMR (500 MHz, CDCl3): δ 
7.39-7.28 (m, 5H), 6.69 (t, J = 2.1 Hz, 2H), 6.16 (t, J = 2.1 Hz, 2H), 5.62 (s, 1H), 4.31 
(s, 1H), 3.43 (s, 3H), 3.40 (s, 3H); 13C NMR (125 MHz, CDCl3): δ 186.0 (e), 137.5 
(e), 128.6 (o. 2C), 128.5 (o. 2C), 128.1 (o), 121.0 (o. 2C), 108.3 (o. 2C), 70.7 (o), 69.9 
(o), 42.2 (o), 42.0 (o); IR (neat): ~ = 3279 (w), 3114 (w), 3075 (w), 3016 (m), 2929 
 Page | 153  
 
(m), 1698 (w), 1646 (s), 1532 (s), 1525 (m), 1466 (m), 1373 (s), 1325 (s), 1307 (m), 
1253 (m), 1243 (m), 1175 (s), 1146 (m), 1086 (s), 1029 (s), 995 (m), 967 (m), 941 (m), 
917 (m), 876 (w), 856 (s), 776 (m), 742 (s), 703 (m), 672 (w) cm-1; HRMS (ESI): m/z 
calcd for C15H17NO2S+Na+: 298.0878 [M+Na]+; found: 298.0868. 
Compound 443: Synthesised according to representative procedure F from racemic 
phenylalanine (2 g, 12.12 mmol) to afford compound 443 as a sticky 
brown gum that was used without further purification (2.61 g, 12.12 
mmol, quant). 1H NMR (500 MHz, CDCl3): δ ppm 7.29 (t, J = 7.5 Hz, 
2H), 7.21 (t, J = 7.3 Hz, 1H), 7.12 (d, J = 7.3 Hz, 2H), 6.73 (t, J=1.8 Hz, 2H), 6.23 (t, 
J = 1.8 Hz, 2H), 4.53 (dd, J  =10.4, 4.8 Hz, 1H), 2.65-2.60 (m, 1H); 2.52-2.34 (m, 3H), 
in agreement with previously reported data18. 
 
Compound 445. Synthesised according to representative procedure D from 
compound 443 (2.62 g, 12.17 mmol) to afford compound 445 
as pale-green amorphous solid (1.55 g, 4.61 mmol, 38%); 1H 
NMR (500 MHz, CDCl3): δ 8.23 (d, J = 2.6 Hz, 2H), 7.34-
7.27 (m, 3H), 7.14 (dd, J = 7.6, 1.6 Hz, 2H), 7.10-7.05 (m, 
2H), 6.14 (t, J = 2.1 Hz, 2H), 6.23 (t, J = 2.1 Hz, 2H), 5.05 (t, J = 7.9 Hz, 1H), 3.55 
(dd, J = 13.7, 7.7 Hz, 1H, 3.42 (dd, J = 13.7, 8.0 Hz, 1H); 13C NMR (125 MHz, 
CDCl3): δ 167.6 (e), 154.4 (e), 145.4 (e), 135.2 (e), 128.8 (o, 2C), 128.6 (o, 2C), 127.2 
(o), 125.0 (o, 2C), 121.9, (o, 2C), 119.8 (o, 2C), 109.1 (o, 2C), 63.2 (o), 39.2 (e); IR 
(neat): ~ = 3277 (w), 3115, (w), 3085 (w), 3030 (w), 2934 (w), 2857 (w), 1760 (s), 
1702 (w), 1667 (m), 1617 (m), 1592 (m), 1520 (s), 1486 (s), 1455 (m), 1446 (m), 1420 
(w), 1389 (w), 1344 (s), 1312 (m), 1277 (s), 1243 (m), 1202 (s), 1174 (m), 1157 (m), 
1125 (s), 1107 (m), 1093 (s), 1071 (s), 1032 (m), 1024 (m), 1012 (m), 990 (w), 969 
(m), 916 (w), 895 (m), 865 (m), 843 (m), 807 (w), 789 (w), 755 (m), 746 (m), 746 (s), 
719 (s), 698 (s), 680 (s) cm-1; HRMS (ESI): m/z calcd for C19H16N2O4+H+: 337.1183 
[M+H]+; found: 337.1186. 
Compound 310. Synthesised according to representative procedure E, except that 
crude compound was purified by FCC using a BIOTAGE flash 
chromatography system (gradient 0-10% MeOH in EtOAc),from 
compound 445 (1.45 g, 4.31 mmol) to afford compound 310 as 
brown powder (0.78 g, 2.71 mmol, 63%). m.p.: 90–92 °C; 1H NMR (500 MHz, 
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CDCl3): δ 7.23-7.13 (m, 3H), 7.07-7.02 (m, 2H), 6.70 (t, J = 2.1 Hz, 2H), 6.12 (t, J = 
2.1 Hz, 2H), 4.53 (dd, J = 9.7, 5.4 Hz, 1H), 4.17 (s, 1H), 3.54 (dd, J = 14.1, 5.4 Hz, 
1H), 3.35 (s, 3H), 3.31 (s, 3H), 3.16 (dd, J = 14.1, 9.7 Hz, 1H); 13C NMR (125 MHz, 
CDCl3): δ 186.7 (e), 138.2 (e), 128.9 (o. 2C), 128.3 (o. 2C), 126.5 (o), 120.3 (o. 2C), 
108.2 (o. 2C), 69.6 (o), 68.1 (o), 42.1 (o), 41.8 (o), 38.5 (e); IR (neat): ~ = 3113 (w), 
3075 (w), 3015 (w), 2929 (w), 1698 (w), 1646 (s), 1561 (s), 1525 (m), 1494 (w), 1466 
(m), 1374 (s), 1325 (s), 1307 (m), 1253 (m), 1243 (m), 1175 (s), 1147 (m), 1085 (s), 
1029 (s), 994 (m), 967 (m), 941 (m), 918 (m), 876 (w), 856 (s), 776 (w), 740 (s), 702 
(m), 679 (w) cm-1; HRMS (ESI): m/z calcd for C16H19NO2S+Na+: 312.1029 [M+Na]+; 
found: 312.1027; elemental analysis calcd (%) for C16H19NO2S: C 66.41, H 6.62, N 
4.84, S 11.08; found: C 66.35, H 6.56, N 4.72 S 11.09. 
Compound 446.  Homophenylalanine (2 g, 11.16 mmol) and NaOAc (915 mg, 11.16 
mmol, 1.0 equiv) were dissolved in AcOH (1.7 mL), water 
(5 mL), and 1,2-DCE (7 mL). After heating at 90 °C for 5 
minutes, 2,5-dimethoxytetrahydrofuran (1.5 mL, 11.16 
mmol, 1 equiv) was added, and the reaction was heated at 
90 °C for 16 h before being cooled to room temperature and diluted with ethyl acetate. 
After washing with brine, and then water, the combined organic layers were dried over 
MgSO4, filtered and concentrated under vacuum to afford   4-phenyl-2-(1H-pyrrol-1-
yl)butanoic acid (2.25 g, 9.81 mmol, 88%) that was used without further purification 
according to representative procedure D to afford compound 446 as pale-green 
amorphous solid (1.94 g, 5.54 mmol, 56%); 1H NMR (500 MHz, CDCl3): δ 8.25 – 
8.20 (m, 2H), 7.36 – 7.22 (m, 4H), 7.19 (m, 4H), 6.82 (t, J = 2.1, 2H), 6.28 (t, J = 2.1, 
2H), 4.81 – 4.73 (m, 1H), 2.78 – 2.66 (m, 1H), 2.66 – 2.45 (m, 3H), 2.45 – 2.27 (m, 
1H); 13C NMR (125 MHz, CDCl3): δ 168.1 (e), 154.6 (e), 139.3 (e), 128.4 (o, 2C), 
128.3 (o, 2C), 128.2 (e), 126.3 (o), 124.9 (o, 2C), 121.9 (o, 2C), 119.8 (o, 2C), 109.1 
(o, 2C), 60.4 (o), 33.5 (e), 31.3 (e); IR (neat): ~ = 3079 (w), 2934 (w), 2836 (w), 2115 
(w), 1754 (s), 1614 (m), 1591 (m), 1516 (s), 1489 (s), 1463 (m), 1419 (w), 1345 (s), 
1262 (s), 1237 (s), 1205 (s), 1157 (s), 1142 (s), 1115 (s), 1089 (s), 1026 (m), 959 (w), 
907 (w), 862 (m), 808 (w), 763 (w), 728 (s), 682 (w) cm-1; HRMS (CI(CH4)): m/z 
calcd for C20H18N2O4+H+: 351.1339 [M+H]+; found: 351.1337. 
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Compound 311. Synthesised according to representative procedure E, except that 
crude compound was purified by FCC using a BIOTAGE flash 
purification system (gradient 0-10% MeOH in DCM), from 
compound 446 (1.45 g, 4.31 mmol) to afford compound 311 as 
white solid (0.95 g, 3.13 mmol, 56%.). m.p.: 65–68 °C; 1H NMR (500 MHz, CDCl3): 
δ 7.31–7.26 (m, 2H), 7.21–7.11 (m, 3H), 6.73 (s, 2H), 6.21 (s, 2H), 4.28 (dd, J = 10.9, 
4.2 Hz, 1H), 4.09 (s, 1H), 3.33 (s, 6H), 2.67-2.44 (m, 3H), 2.29-2.20 (m, 1H); 13C 
NMR (125 MHz, CDCl3): δ 188.2 (e), 140.9 (e), 128.6 (o, 2C), 128.4 (o, 2C), 126.0 
(o), 120.1 (o, 2C), 108.3 (o, 2C), 68.7 (o), 65.6 (o), 42.1 (o), 41.9 (o), 33.5 (e), 32.2 
(e); IR (neat): ~ = 3076 (w), 3001 (w), 2953 (w), 2919 (w), 2861 (w), 1571 (s), 1510 
(w), 1487 (w), 1454 (w), 1435 (w), 1415 (s), 1390 (s), 1350 (w), 1313 (w), 1301 (w), 
1277 (w), 1263 (w), 1235 (w), 1183 (s), 1169 (s), 1125 (s), 1089 (s), 1071 (w), 1062 
(w), 1050 (w), 1028 (s), 1000 (w), 948 (w), 927 (w), 927 (w), 909 (w), 857 (m), 798 
(w), 760 (m), 748 (m), 760 (s), 698 (s), 678 (m) cm-1; HRMS (ESI): m/z calcd for 
C17H21NO2S+H+: 304.1366 [M+H]+; found: 304.1362. 
 
Representative Procedure G: Followng a reported procedure19, in a flame dried 2-
neck 250 mL RB flask, 2-coumaranone (2.5 g, 18.64 mmol, 1 equiv) and compound 
327 (8.10 g, 22.37 mmol, 1.2 equiv) were dissolved in dry toluene (40 mL, 0.46 M) 
and protected from light with aluminium foil. The reaction was heated at reflux for 48 
h, then cooled to rt and concentrated in vacuo. The crude residue was purified by FCC 
(2.5% EtOAc in n-hexane) to afford compound 328 as a pale yellow oil (1.50 g, 6.87 
mmol, 46%).  
 
Compound 328. 1H NMR (400 MHz, CDCl3): δ 7.52 (d, J = 7.2 Hz, 1H), 7.44 (d, J = 
7.6 Hz, 1H), 7.22 (quint. d, J = 2.0, 7.6 Hz, 2H), 6.58 (s, 1H), 4.20 
(q, J = 7.3 Hz, 2H), 3.94 (q, J = 7.5 Hz, 1H), 1.62 (d, J = 7.3 Hz, 3H), 
1.26 (t, J = 7.0 Hz, 3H), in agreement with previously reported 
data20. 
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Compound 447: Compound 328 (1.53 g, 7.01 mmol, 1 equiv) was dissolved in 
EtOH/H2O (1:1, 44 mL, 0.16 M) and NaOH (0.56 g, 14.02 mmol, 
2 equiv) was added. The reaction was stirred at rt for 2.5 h, then 
carefully acidified to pH 3 using 2N HCl. The reaction was then 
quickly extracted with DCM (x3), the combined organic layers were dried (MgSO4), 
filtered and concentrated in vacuo (the organic layers were left on the rotavap for ca. 
30 mins, taking care not to increase the water bath temperature above 30 oC. The 
residual solvent was then removed on a hi-vacuum line) to afford compound 447 as a 
light brown solid (1.32 g, 6.94 mmol, quant.). m.p. = 58-60 oC; 1H NMR (500 MHz, 
CDCl3): δ 7.52 (d, J = 7.5 Hz, 1H), 7.45 (d, J = 8.2 Hz, 1H), 7.28-7.23 (m, 1H), 7.20 
(t, J = 7.6 Hz, 1H), 6.62 (s, 1H), 4.00 (q, J = 7.2 Hz, 1H), 1.66 (d, J = 7.6 Hz, 3H); 13C 
NMR (100 MHz, CDCl3): δ 178.0 (e), 155.4 (e), 154.8 (e), 128.0 (e), 124.1 (o), 122.7 
(o), 120.8 (o), 111.1 (o), 103.5 (o), 39.7 (o), 15.5 (o); IR (neat): ~ = 2989 (w); 2946 
(w); 2889 (w); 2616 (w); 2533 (w); 2050 (w); 1941 (w); 1903 (w); 1790 (w); 1693 (s); 
1606 (m); 1588 (w); 1497 (w); 1453 (s); 1412 (m); 1375 (m); 1348 (w); 1327 (w); 
1303 (w); 1286 (m); 1256 (s); 1230 (m); 1215 (s); 1171 (s); 1154 (m); 1110 (w); 1070 
(m); 1006 (w); 932 (s); 882 (m); 859 (w); 816 (m); 741 (s); 731 (s); 670 (s) cm-1, 
HRMS (ESI): m/z calcd for C11H10O3-H-: 189.0557 [M-H]-; found: 189.0556. 
 
Compound 448. Synthesised according to representative procedure D from 
compound 447 (1.52 g, 7.99 mmol) to afford compound 448 as 
viscous yellow oil (1.42 g, 4.56 mmol, 57%). 1H NMR (500 
MHz, CDCl3): δ 8.26 (d, J = 8.8 Hz, 2H), 7.57 (d, J = 8.0 Hz, 
1H), 7.49 (d, J = 8.0 Hz, 1H), 7.32-7.22 (m, 4H), 6.70 (s, 1H), 
4.24 (q, J = 7.3 Hz, 1H), 1.78 (d, J = 7.3 Hz, 3H); 13C NMR (100 
MHz, CDCl3): δ 170.0 (e), 155.3 (e), 154.86 (e)2 154.81 (e), 145.4 (e), 128.1 (e), 125.2 
(o, 2C), 124.3 (o), 122.9 (o), 122.3 (o, 2C), 120.9 (o), 111.1 (o), 103.8 (o), 40.1 (o), 
15.6 (o); IR (neat): ~ = 3116 (w), 3096 (w), 2990 (w), 2936 (w), 2856 (w), 2116 (w), 
1810 (w), 1763 (w), 1615 (m), 1592 (m), 1521 (s), 1489 (m), 1454 (s), 1379 (w), 1345 
(s), 1254 (w), 1201 (s), 1154 (s), 1120 (s), 1063 (s), 1011 (m), 993 (w), 939 (w), 897 
(m), 888 (w), 864 (s), 847 (w), 807 (w), 779 (w), 748 (s), 710 (w), 679 (w) cm-1; 
HRMS (ESI): m/z  calcd for C17H13NO5+H+: 312.0827 [M+H]+; found: 312.0830. 
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Compound 321. Synthesised according to representative procedure E, except that 
crude compound was purified by FCC (DCM/MeOH = 98:2) 
followed by trituration in Et2O of the solid obtained from the 
product containing fractions, from compound 448 (1.42 g, 4.56 
mmol) to afford compound 321 as white solid (638 mg, 2.41 mmol, 
53%). m.p.: 70–74 °C; 1H NMR (500 MHz, CDCl3): δ 7.50 (d, J = 
7.8 Hz, 1H), 7.43 (d, J = 7.8 Hz, 1H), 7.24-7.16 (m, 2H), 6.54 (s, 1H), 4.40 (s, 1H), 
3.72 (q, J = 7.2 Hz, 1H), 3.38 (s, 3H), 3.36 (s, 3H), 1.56 (d, J = 7.2 Hz, 3H); 13C NMR 
(125 MHz, CDCl3): δ 188.5 (e), 159.4 (e), 154.6 (e), 128.7 (e), 123.4 (o), 122.4 (o), 
120.5 (o), 111 (o), 102.5 (o), 68.7 (o), 44.8 (o), 42.11 (o), 42.08 (o), 16.1 (o); IR (neat): 
~ = 3093 (w), 3015 (w), 3000 (w), 2980 (w), 2914 (w), 1561 (s), 1472 (w), 1455 (s), 
1384 (s), 1366 (s), 1327 (w), 1310 (w), 1299 (w), 1255 (m), 1179 (s), 1141 (m), 1106 
(w), 1053 (w), 1027 (s), 994 (s), 957 (w), 937 (m), 883 (w), 852 (s), 816 (w), 803 (s), 
740 (s), 708 (w), 693 (w), 657 (m) cm-1; HRMS (ESI): m/z calcd for C14H16O3S+Na+ 
[M+Na]+: 287.0718; found: 287.0720. 
 
Compound 449. Synthesised from ethyl 1-(benzofuran-3-yl)propanote19 (1.09 g, 5.73 
mmol), to afford compound 449 as pale-brown amorphous 
solid (1.38 g, 4.43 mmol, 78%). 1H NMR (500 MHz, 
CDCl3): δ 8.22 (d, J = 9.0 Hz, 2H), 7.69 (d, J = 7.7 Hz, 
1H), 7.67 (s, 1H), 7.53 (d, J = 8.0 Hz, 1H), 7.38-7.32 (m, 1H), 7.32-7.27 (m, 1H), 7.19 
(d, J = 9.1 Hz, 2H), 4.21 (q, J = 7.4 Hz, 1H), 1.77 (d, J = 7.1 Hz, 3H); 13C NMR (125 
MHz, CDCl3): δ 171.5 (e), 155.5 (e), 150.4 (e), 149.8 (e), 136.5 (e), 126.5 (e), 125.2 
(o, 2C), 124.5 (o), 122.9 (o), 122.3 (o, 2C), 119.8, 111.9 (o), 36.3 (o), 17.0 (o); IR 
(neat): ~ = 3115 (w), 3071 (w), 2990 (w), 2928 (w), 2854 (w), 2115 (m), 1924 (w), 
1760 (m), 1708 (w), 1616 (w), 1590 (m), 1519 (s), 1489 (m), 1466 (w), 1454 (m), 
1423 (w), 1380 (w), 1343 (s), 1321 (s), 1288 (w), 1261 (w), 1244 (w), 1204 (s), 1164 
(w), 1115 (s), 1091 (s), 1063 (s), 1048 (s), 1010 (m), 982 (w), 956 (w), 931 (w), 900 
(s), 865 (s), 857 (s), 813 (w), 770 (w), 746 (s), 719 (w), 708 (m), 675 (w) cm-1; HRMS 
(ESI): m/z calcd for C17H13NO5S+Na+: 334.0691 [M+Na]+; found: 334.0695. 
 
 Page | 158  
 
Compound 322. Synthesised according to representative procedure E, except that 
crude compound was purifed by FCC (DCM/MeOH = 98 :2) 
followed by trituration in Et2O of the solid obtained from the 
product containing fractions, from compound 449  (1.38 g, 4.43 
mmol) to afford compound 322 as an off-white powder (400 mg, 
1.51 mmol, 34%); m.p.: 52-55 °C; 1H NMR (500 MHz, CDCl3): δ 7.62 (d, J = 7.8 Hz, 
1H), 7.52 (s, 1H), 7.46 (dt, J = 8.2, 0.8 Hz, 1H), 7.29-7.25 (m, 1H), 7.23-7.18 (m, 1H), 
4.39 (s, 1H), 3.69 (q, J = 7.2 Hz, 1H), 3.36 (s, 3H), 3.33 (s, 3H), 1.55 (d, J = 7.2 Hz, 
3H); 13C NMR (125 MHz, CDCl3): δ 190.8 (e), 155.4 (e), 141.4 (o), 127.4 (e), 124.1 
(o), 122.3 (o), 122.2 (e), 120.2 (o), 111.4 (o), 68.5 (o), 42.11 (o), 42.05 (o), 41.0 (o), 
17.5 (o); IR (neat): ~ = 3109 (w); 2994 (w); 2975 (w); 2915 (w); 1615 (w); 1577 (s); 
1555 (s); 1471 (w); 1453 (s); 1415 (m); 1404 (m); 1382 (s); 1362 (s); 1329 (m); 1307 
(w); 1280 (w); 1250 (w); 1172 (s); 1145 (m); 1120 (w); 1094 (m); 1083 (m); 1061 
(m); 1039 (s); 1023 (s); 992 (m); 980 (m); 945 (w); 890 (w); 757 (s); 716 (w); 698 
(w); 684 (w) cm-1; HRMS (ESI): m/z calcd for C14H16O3S+Na+: 287.0712 [M+Na]+; 
found: 287.0718. 
 
 
Compound 451: Synthesised according to representative procedure B, from 
compound 450 (4.1 g, 20.32 mmol) to afford compound 451 as a 
pale brown oil (3.08 g, 14.18 mmol, 70%). 1H NMR (500 MHz, 
CDCl3): δ 7.67 (dt, J  = 0.9, 8.1 Hz, 1H), 7.30 (dt, J = 0.9, 8.2 Hz, 
1H), 7.26-7.22 (m, 1H), 7.15-7.11 (m, 1H), 7.00 (s, 1H), 4.04 (q, J = 7.1 Hz, 1H), 3.76 
(s, 3H), 3.68 (s, 3H), 1.61 (d, J = 7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ 175.7 
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(e), 137.0 (e), 126.8 (e), 126.3 (o), 121.8 (o), 119.3 (o), 119.2 (o), 114.0 (e), 109.3 (o), 
52.0 (o), 36.8 (o), 32.7 (o), 18.1 (o), in agreement with previously reported data21. 
 
Compound 452. Compound 451 (3.08 g, 14.18 mmol, 1.0 equiv) was dissolved in 
THF/H2O (1:1, 55 mL, 0.25 M) and NaOH (2.84 g, 70.9 
mmol, 5.0 equiv) was added. The reaction was heated at 
reflux for 15 h, then carefully acidified to pH 2 using 2N 
HCl. The reaction was then quickly extracted three times 
with DCM and the combined organic layers were dried (MgSO4), filtered and 
concentrated in vacuo  to afford a pale-brown solid (2.87 g, 14.12 mmol, quant.) that 
was used without further purification according to representative procedure D to 
afford compound 452 as pale-green amorphous solid (3.96 g, 12.21 mmol, 86%). 1H 
NMR (500 MHz, CDCl3): δ 8.20 (d, J = 9.3 Hz, 2H), 7.74 (dt, J = 8.0, 0.9 Hz, 1H), 
7.34 (dt, J = 8.3, 1.0 Hz, 1H), 7.31-7.27 (m, 2H), 7.17 (d, J = 9.3 Hz, 2H), 7.09 (s, 
1H), 4.29 (q, J = 7.4 Hz, 1H), 3.80 (s, 3H), 1.74 (d, J = 7.2 Hz, 3H); 13C NMR (125 
MHz, CDCl3): δ 171.5 (e), 155.9 (e), 145.2 (e), 137.0 (e), 131.5 (e), 129.1 (o), 125.1 
(o, 2C), 122.3 (o, 2C), 121.8 (o), 119.0 (o), 112.1 (e), 108.8 (o), 101.2 (o), 45.2 (o), 
34.2 (o), 17.5 (o); IR (neat): ~ = 3081 (w), 2934 (w), 2837 (w), 2115 (w), 1760 (m), 
1653 (w), 1615 (w), 1591 (m), 1513 (s), 1488 (s), 1463 (m), 1418 (w), 1345 (s), 1259 
(s), 1234 (s), 1203 (s), 1158 (s), 1140 (s), 1097 (s), 1024 (s), 962 (w), 930 (w), 913 
(w), 913 (w), 884 (w), 862 (s), 806 (w), 782 (w), 758 (m), 722 (s), 682 (w) cm-1; 
HRMS (ESI): m/z calcd for C18H16N2O4+H+: 325.1183 [M+H]+; found: 325.1181. 
Compound 323. Synthesised according to representative procedure E, except that 
crude compound was purified by FCC (Et2O followed by a gradient 
of 1-2% MeOH in DCM) followed by trituration in Et2O of the solid 
obtained from the product containing fractions, from compound 
452  (2.35 g, 7.24 mmol) to afford compound 323 as cream-
coloured powder (677 mg, 2.44 mmol, 34%); m.p.: 71-73 °C; 1H NMR (500 MHz, 
CDCl3): δ 7.64 (dt, J = 7.8, 0.8 Hz, 1H), 7.28 (dt, J = 8.4, 1.1 Hz, 1H), 7.23-7.17 (m, 
1H), 7.10-7.05 (m, 1H), 6.97 (s, 1H), 4.39 (s, 1H), 3.80 (q, J = 7.2 Hz, 1H), 3.76 (s, 
3H), 1.54 (d, J = 7.2 Hz, 3H); 13C NMR (125 MHz, CDCl3): δ 192.8 (e), 137.0 (e), 
127.3 (e), 126.1 (o), 121.4 (o), 119.4 (o), 118.6 (o), 116.6 (e), 109.1 (o), 68.1 (o), 42.11 
(o), 42.05 (o), 41.95 (o), 32.6 (o), 18.3 (o); IR (neat): ~ = 3123 (w); 3086 (w); 3047 
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(w); 3026 (w); 3006 (w); 2984 (w); 2970 (w); 2933 (w); 2909 (w); 2824 (w); 1559 (s); 
1544 (m); 1480 (w); 1468 (m); 1446 (w); 1426 (w); 1380 (s); 1367 (m); 1360 (m); 
1322 (m); 1303 (m); 1270 (w); 1230 (w); 1209 (w); 1169 (s); 1137 (m); 1114 (m); 
1082 (w); 1043 (s); 1008 (m); 994 (w); 977 (w); 944 (w); 924 (w); 887 (w); 854 (m); 
832 (w); 801 (w); 758 (w); 741 (s); 702 (m); 671 (m); 641 (w); 627 (w); 572 (w); 558 
(w); 539 (w); 519 (w) cm-1; HRMS (ESI): m/z calcd for C15H19NO2S+H+: 278.1209 
[M+H]+; found: 278.1216. 
 
 
Compound 332: Following a reported procedure22, in a flame dried, 3-neck 500 mL 
RB flask under N2, powdered NaOH (4.22 g, 105.7 mmol, 10 equiv) 
was suspended in dry DCM (330 mL, 0.03 M), and the suspension 
was cooled to -20 oC using a temperature controlled cryogenic bath. 
Compound 331 (2 g, 10.57 mmol, 1 equiv), TBAB (0.17 g, 0.53 mmol, 5 mol%) and 
TsCl (20 g, 105.7 mmol, 10 equiv) were added in that order, and the reaction was 
stirred at -20 oC for 20 h, before being quenched with 2N HCl (151 mL) at -20 oC. The 
reaction was allowed to warm up to rt and the layers were separated. The organic layer 
was washed twice with brine, dried (MgSO4), filtered and concentrated in vacuo. The 
crude residue was purified by FCC (95:5 then 4:1 PE:EA, with the product eluting 
during 4:1 PE:EA) to afford compound 332 as a light brown oil (3.25 g, 9.46 mmol, 
90%). 1H NMR (500 MHz, CDCl3): δ 7.97 (dt, J = 0.9, 8.4 Hz, 1H), 7.77 (d, J = 8.4 
Hz, 2H), 7.57 (t, J = 1.2 Hz, 1H), 7.49 (dt, J = 1.0, 7.9 Hz, 1H), 7.35-7.29 (m, 1H), 
7.25-7.20 (m, 3H), 3.71 (s, 3H), 3.69 (d, J = 1.0 Hz, 2H), 2.34 (s, 3H); 13C NMR (100 
MHz, CDCl3): δ 170.9 (e), 135.2 (e), 134.9 (e), 130.3 (e), 129.8 (o, 2C), 126.8 (o, 2C), 
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124.8 (o), 124.7 (o), 123.2 (o), 119.4 (o), 114.9 (e), 113.6 (o), 52.1 (o), 30.7 (e), 21.5 
(o); in agreement with previously reported data23.  
 
Compound 453. Compound 332 (1.5 g, 4.37 mmol) was used according to 
representative procedure B to afford  a pale yellow liquid (474 mg, 1.33 
mmol, 30%) and its identity was verified by 1H NMR (500 MHz, CDCl3): 
δ 7.96 (dt, J = 0.9, 8.3 Hz, 1H), 7.76 (d, J = 8.4 Hz, 2H), 7.55 (dt, J = 8.0, 
1.0 Hz, 1H), 7.51 (s, 1H), 7.33-7.28 (m, 1H), 7.24-7.20 (m, 3H), 3.92 (q, 
J = 7.3 Hz, 1H), 3.66 (s, 3H), 2.34 (s, 3H), 1.59 (d, J = 7.3 Hz, 3H). Some of this 
material (345 mg, 0.96 mmol, 1 equiv) was dissolved in 1,4-dioxane/H2O (2:1, 45 mL, 
0.02 M), and a 5% aqueous solution of KOH (3 mL) was added. The reaction was 
stirred at rt for 4 h, then acidified to pH 2-3 with 2N HCl, and extracted with 3 times 
with CH2Cl2. The combined organic layers were dried over MgSO4, filtered and 
concentrated under vacuum. The crude residue was purified by flash chromatography 
on SiO2 (CH2Cl2/MeOH, 98:2) to afford compound 453 as an off white solid (330 mg, 
0.96 mmol, quant.). m.p. = 108-110 oC; 1H NMR (500 MHz, CDCl3): δ 10.75 (br s, 
1H), 7.95 (d, J = 8.2 Hz, 1H), 7.75 (d, J = 8.1 Hz, 2H), 7.56 (d, J = 8.0 Hz, 1H), 7.53 
(s, 1H), 7.31 (t, J = 7.7 Hz, 1H), 7.24 (d, J = 7.7 Hz, 1H), 7.21 (d, J = 8.3 Hz, 2H), 
3.93 (q, J = 7.2 Hz, 1H), 2.33 (s, 3H), 1.61 (d, J = 7.1 Hz, 3H); 13C NMR (100 MHz, 
CDCl3): δ 179.7 (e), 144.9 (e), 135.2 (e), 135.1 (e), 129.9 (o, 2C), 129.6 (e), 126.8 (o, 
2C), 124.8 (o), 123.6 (o), 123.2 (o), 120.9 (e), 119.8 (o), 113.7 (o), 36.7 (o), 21.5 (o), 
17.0 (o); IR (neat): ~ = 2979 (w), 2941 (w), 2639 (w), 1920 (w), 1744 (w), 1700 (s), 
1594 (w), 1562 (w), 1492 (w), 1446 (m), 1420 (w), 1397 (w), 1373 (s), 1304 (m), 1282 
(m), 1247 (w), 1233 (w), 1210 (w), 1187 (m), 1172 (s), 1134 (s), 1122 (s), 1108 (m), 
1086 (s), 1050 (w), 1016 (m), 997 (m), 959 (m), 865 (w), 811 (m), 794 (w), 760 (m), 
749 (s), 729 (m), 701 (m), 665 (s) cm-1; HRMS (ESI neg): m/z calcd for C18H17NO4S-
H–: 342.0806 [M-H]–; found: 342.0800. 
 
Compound 454. Synthesised according to representative procedure D from 
compound 453 (300 mg, 0.87 mmol) to afford compound 
454 as a pale green amorphous solid (317 mg, 0.68 mmol, 
78%). 1H NMR (500 MHz, CDCl3): δ 8.21 (d, J = 9.1 Hz, 
2H), 8.01 (dt, J = 8.3, 0.3 Hz, 1H), 7.78 (d, J = 8.5 Hz, 2H), 
7.62 (dt, J = 7.9, 0.9 Hz, 1H), 7.61 (s, 1H), 7.39-7.33 (m, 1H), 7.30-7.27 (m, 1H), 7.22 
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(d, J = 8.4 Hz, 2H), 7.11 (d, J = 9.2 Hz, 2H), 4.19 (q, J = 7.2 Hz, 1H), 2.34 (s, 3H), 
1.74 (d, J = 7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ 171.3 (e), 155.3 (e), 145.3 
(e), 145.1 (e), 135.2 (e), 135.1 (e), 129.9 (o, 2C), 129.3 (e), 126.8 (o, 2C), 125.1 (o, 
2C), 123.8 (o), 123.4 (o), 122.2 (o, 2C), 120.5 (e), 119.5 (o), 113.9 (o), 37.1 (o), 21.5 
(o), 17.0 (o); IR (neat): ~ = 3115 (w), 2984 (w), 2938 (w), 2116 (w), 1916 (w), 1760 
(s), 1615 (w), 1592 (m), 1522 (s), 1489 (m), 1447 (m), 1369 (m), 1346 (s), 1325 (w), 
1307 (w), 1283 (w), 1204 (s), 1188 (s), 1173 (s), 1120 (s), 1087 (s), 1074 (s), 1012 
(w), 1000 (w), 957 (w), 897 (w), 864 (w), 846 (w), 812 (w), 763 (w), 745 (m), 732 (s), 
702 (w) cm-1; HRMS (ESI): m/z calcd for C24H20N2O6S+Na+: 487.0934 [M+Na]+; 
found: 487.0936. 
 
Compound 324. Synthesised according to representative procedure E, except that 
crude compound was purified by FCC (DCM/MeOH = 98 :2) 
followed by trituration in Et2O of the solid obtained from the 
product containing fractions, from compound 454 (317 mg, 0.68 
mmol) to afford compound 324 as pale green powder (177 mg, 
0.42 mmol, 62%). m.p.: 49–51 °C; 1H NMR (500 MHz, CDCl3): δ 7.95 (dt, J = 8.3, 
0.8 Hz, 1H), 7.75 (d, J = 8.5 Hz, 2H), 7.55 (dt, J = 8.0, 1.0 Hz, 1H), 7.45 (d, J = 0.8 
Hz, 1H), 7.30-7.26 (m, 1H), 7.23-7.16 (m, 3H), 4.23 (s, 1H), 3.66 (q, J = 7.2 Hz, 1H), 
3.30 (s, 3H), 3.29 (s, 3H), 2.32 (s, 3H), 1.52 (d, J = 7.2 Hz, 3H); 13C NMR (125 MHz, 
CDCl3): δ 190.8 (e), 144.8 (e), 135.34 (e), 135.28 (e), 130.4 (e), 129.8 (o, 2C), 126.7 
(o, 2C), 124.8 (e), 124.6 (o), 123 (o), 122.9 (o), 120.1 (o), 113.7 (o), 68.4 (o), 42.11 
(o), 42.04 (o), 42.01 (o), 21.5 (o), 17.6 (o); IR (neat): ~ = 3015 (w), 2925 (w), 1570 
(s), 1494 (w), 1446 (s), 1358 (s), 1304 (m), 1277 (m), 1168 (s), 1120 (s), 1101 (s), 
1087 (s), 1020 (s), 998 (m), 961 (m), 899 (w), 854 (m), 812 (m), 764 (w) cm-1; HRMS 
(ESI): m/z calcd for C21H23NO4S2+H+: 418.1141 [M+H]+; found: 418.1145. 
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Compound 456. Synthesised according to representative procedure D, from 
compound 455 (1.99 g, 9.78 mmol) to afford compound 456 as 
a pale green amorphous solid (1.56 g, 4.81 mmol, 49%). 1H 
NMR (500 MHz, CDCl3): δ 8.24 (d, J = 9.2 Hz, 2H), 7.62 (dt, J 
= 7.9, 0.9 Hz, 1H), 7.32 (dt, J = 8.3, 0.9 Hz, 1H), 7.28-7.23 (m, 
1H), 7.17 (d, J = 9.2 Hz, 2H), 7.16-7.11 (m, 1H), 6.93 (s, 1H), 3.76 (s, 3H), 3.23 (t, J 
= 7.6 Hz, 2H), 3.00 (t, J = 7.5 Hz, 2H), in agreement with previously reported data24.  
Compound 325. Synthesised according to representative procedure E, except that 
crude compound was purified by FCC (DCM/MeOH = 98:2) 
followed by trituration in Et2O of the solid obtained from the 
product containing fractions, from compound 456 (1.56 g, 4.81 
mmol) to afford compound 325 as an off-white powder (577 mg, 
2.07 mmol, 43%). m.p.: 68–70 °C; 1H NMR (500 MHz, CDCl3): δ 7.61 (d, J = 7.8 Hz, 
1H), 7.28–7.25 (m, 1H), 7.22-7.18 (m, 1H), 7.10-7.06 (m, 1H), 6.86 (s, 1H), 4.37 (s, 
1H), 3.73 (s, 3H), 3.35 (s, 6H), 3.08–3.02 (m, 2H), 2.58-2.54 (m, 2H); 13C NMR (125 
MHz, CDCl3): δ 190.5 (e), 136.9 (e), 127.8 (e), 126.1 (o), 121.4 (o), 119.0 (o), 118.5 
(o), 114.6 (e), 109.0 (o), 69.1 (o), 42.2 (o, 2C), 41.7 (e), 32.5 (o), 21.5 (e); IR (neat): 
~ = 3057 (w), 3025 (w), 3002 (w), 2911 (w), 2852 (w), 1614 (w), 1555 (s), 1485 (m), 
1472 (m), 1448 (m), 1417 (m), 1373 (s), 1321 (m), 1308 (m), 1280 (w), 1245 (m), 
1201 (w), 1165 (s), 1127 (m), 1104 (w), 1060 (w), 1032 (s), 1011 (m), 990 (m), 954 
(w), 926 (w), 849 (s), 802 (w), 790 (w), 778 (w), 758 (w), 734 (s), 724 (s), 684 (w) 
cm-1; HRMS (ESI): m/z calcd for C15H19NO2S+H+: 278.1209 [M+H]+; found: 
278.1216; elemental analysis calcd (%) for C15H19NO2S: C 64.95, H 6.90, N 5.05, S 
11.56; found: C 64.92, H 6.82, N 5.00, S 11.57. 
 
 
 Page | 164  
 
Compound 350. NaH (60% in oil, 430 mg, 10.74 mmol, 1.2 equiv) was added in small 
portion to a solution of tert-butyl 4-(1H-pyrrole-2-
carbonyl)piperazine-1-carboxylate (2.5 g, 8.95 mmol) in 
dry DMF (36 mL) at 0 °C under N2. After stirring at room 
temperature for 1 h, ethyl 2-bromoacetate (1.1 mL, 9.84 
mmol, 1.1 equiv) was added. After stirring at room 
temperature for 16 h, the reaction was quenched and 
extracted 3 times with EtOAc. The combined organic layers were washed first with 
water, then brine, and then dried over MgSO4, filtered and concentrated under vacuo 
to afford a pale-brown oil (2.62 g, 7.17 mmol, 80%) that was dissolved in 1,4-dioxane 
(118 mL) before a 5% aqueous solution of NaOH (118 mL) was added. After  at room 
temperature for 1 h, the reaction was then acidified to pH 2-3 with 2N HCl, then 
extracted with CH2Cl2 (4  100 mL). The combined organic layers were passed 
through a phase separator cartridge, and the filtrate was concentrated under vacuum to 
afford a brown gum (2.39 g, 7.09 mmol, quant.) that was then used without further 
purification according to representative procedure B to afford 350 as pale-brown 
amorphous solid (1.54 g, 3.36 mmol, 47%). 1H NMR (500 MHz, CDCl3): δ 8.29-8.24 
(m, 2H), 7.93-7.32 (m, 2H), 6.84 (dd, J = 2.5, 1.6 Hz, 1H), 6.47 (dd, J = 3.8, 1.5 Hz, 
1H), 6.25-6.19 (m, 1H), 5.16 (s, 2H), 3.80–3.60 (m, 4H), 3.49-3.43 (m, 4H), 1.47 (s, 
9H); 13C NMR (125 MHz, CDCl3): δ 166.6 (e), 162.7 (e), 154.9 (e), 154.3 (e), 145.2 
(e), 126.6 (o), 125.0 (o, 2C), 124.0 (e), 122.0 (o, 2C), 114.0 (o), 107.8 (o), 80.0 (e), 
50.1 (e), 28.1 (o, 3C) (Two resonances of methylene carbon nuclei of piperazine are 
not visible due to slow rotation of Boc group); HRMS (ESI): m/z calcd for 
C22H26N4O7+Na+: 481.1694 [M+Na]+; found: 481.1710. 
Compound 351. Synthesised according to representative procedure E, except that 
crude compound was purified by FCC using a BIOTAGE 
flash chromatography system (gradient 0-30% MeOH in 
EtOAc), from compound 350 (770 mg, 1.68 mmol) to 
afford compound 351 as white solid (538 mg, 1.31 mmol, 78%). m.p.: 125–127 °C; 
1H NMR (500 MHz, CDCl3): δ 6.75 (dd, J = 2.5, 1.7 Hz, 1H), 6.33 (dd, J = 3.8, 1.6 
Hz, 1H), 6.14 (dd, J = 3.7, 2.7 Hz, 1H), 4.73 (s, 2H), 4.13 (s, 1H), 3.74–3.67 (m, 4H), 
3.42–3.50 (m, 4H), 3.36 (s, 6H), 1.47 (s, 9H); 13C NMR (125 MHz, CDCl3): δ 185.0 
(e), 163.2 (e), 154.6 (e), 126.5 (o), 125.0 (e), 112.9 (o), 107.4 (o), 80.2 (e), 67.9 (o), 
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55.0 (e), 42.2 (o. 2C), 28.3 (o, 3C) (Two signals of methylene carbon nuclei of 
piperazine are not visible due to slow rotation of the Boc group); IR (neat): ~ = 3082 
(w), 2975 (w), 2917 (w), 2867 (w), 1674 (s), 1624 (s), 1561 (s), 1470 (m), 1455 (m), 
1418 (s), 1378 (s), 1325 (m), 1305 (m), 1280 (m), 1242 (s), 1183 (s), 1164 (s), 1138 
(m), 1123 (s), 1072 (m), 1055 (w), 1022 (m), 997 (m), 970 (w), 954 (w), 917 (w), 856 
(m), 842 (w), 826 (w), 806 (w), 784 (w), 770 (w), 736 (m), 706 (w), 691 (w), 672 (w), 
657 (w) cm-1; HRMS (ESI): m/z calcd for C19H29N3O5S+Na+: 434.1720 [M+Na]+; 
found: 434.1731. 
 
N
H
NHBoc
OH
O
NaOH (2 equiv)
MeI (3 equiv)
DMSO (0.5 M)
40 oC, 16 h
N
NHBoc
O
O
457
85%
N
NHBoc
OH
O
NaOH (1.5 equiv)
DMSO (0.3 M)
rt, 16 h
356
quant  
Compound 457. Following a reported procedure25, in a flame dried 2-neck 25 mL RB 
flask under N2, L-tryptophan (1 g, 3.28 mmol, 1.0 equiv) and NaOH 
(0.26 g, 6.57 mmol, 2.0 equiv) were dissolved in dry DMSO (7 mL, 
0.5 M) and stirred at 40 oC for 2 h. MeI (0.6 mL, 9.86 mmol, 3.0 
equiv) was added and the reaction was stirred at 40 oC for 16 h. 
Water was added to the reaction, and the mixture was extracted with EtOAc (x3). The 
combined organic layers were washed with water (x5), dried (MgSO4), filtered and 
concentrated in vacuo. The crude residue was purified by FCC (7:3 PE:EtOAc) to 
afford compound 457 as a colourless liquid (933 mg, 2.81 mmol, 85%). 1H NMR (500 
MHz, CDCl3): δ 7.53 (d, J = 8.0 Hz, 1H), 7.28 (d, J = 8.1 Hz, 1H), 7.24-7.20 (m, 1H), 
7.10 (t, J = 7.4 Hz, 1H), 6.85 (s, 1H), 5.05 (br d, J = 7.2 Hz, 1H), 4.63 (q, J = 6.9 Hz, 
1H), 3.75 (s, 3H), 3.68 (s, 3H), 3.27 (s, 2H), in agreement with previously reported 
data25. 
 
 
 
 
 
N
NHBoc
O
O
457
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Compound 356. Following a reported procedure25, compound 457 (0.93 g, 2.81 
mmol, 1.0 equiv) was dissolved in DMSO (9 mL, 0.3 M) and a 1M 
aqueous solution of NaOH (0.7 M) was added. The reaction was 
stirred at rt for 16 h, then diluted with H2O and washed with EtOAc 
(x3). The aqueous layer was acidified with 2N HCl, then extracted 
with DCM (x3). The combined DCM layers were washed with H2O (x5), dried 
(MgSO4), filtered and concentrated in vacuo to afford compound 356 as a light brown 
powder which was used without further purification (0.89 g, 2.79 mmol, quant.). 1H 
NMR (500 MHz, CDCl3): δ 7.60 (d, J = 8.2 Hz, 1H), 7.26 (d, J = 8.3 Hz, 1H), 7.21-
7.17 (m, 1H), 7.10-7.06 (m, 1H), 6.91 (s, 1H), 5.09 (br s, 1H), 4.60 (q, J = 6.1 Hz, 1H), 
3.73 (s, 3H), 3.39-3.23 (m, 2H), in agreement with previously reported data25. 
 
 
 
Compound 357. To a flame dried, 2-neck RB flask under N2 was added compound 
356 (2.28 g, 7.16 mmol, 2.0 equiv) and EDCI•HCl (1.03 g, 
5.37 mmol, 1.5 equiv), followed by dry DCM (14 mL, 0.25 M). 
The reaction was stirred at rt for 5 mins, before 4-nitrophenol 
211 (0.50 g, 3.58 mmol, 1.0 equiv) was added, and the reaction 
was allowed to stir at rt for 20 h. The reaction was diluted with DCM and washed with 
sat. aq. NaHCO3 solution (x3). The organic layer was dried, filtered and concentrated 
in vacuo, and the crude residue was purified by FCC (petroleum ether/EtOAc = 4:1) 
to afford compound 357 as a pale yellow amorphous solid (0.701 g, 1.60 mmol, 44%). 
1H NMR (500 MHz, CDCl3): δ 8.20 (d, J = 8.9 Hz, 2H), 7.58 (d, J = 8.0 Hz, 1H), 7.34 
(d, J = 8.1 Hz, 1H), 7.29-7.24 (m, 1H), 7.12 (t, J = 7.5 Hz, 1H), 7.01 (d, J = 9.1 Hz, 
2H), 6.96 (s, 1H), 5.13 (br d, J = 7.2 Hz, 1h), 4.83 (q, J = 7.5 Hz, 1H), 3.79 (s, 3H), 
3.45 (dd, J = 5.8, 14.5 Hz, 1H), 3.38 (dd, J = 6.1, 14.8 Hz, 1H); 13C NMR (100 MHz, 
CDCl3): δ 170.4 (e), 155.3 (e), 155.1 (e), 145.4 (e), 137.0 (e), 127.9 (e), 127.6 (o), 
125.1 (o, 2C), 122.3 (o), 122.1 (o, 2C), 119.4 (o), 118.8 (o), 109.4 (o), 80.4 (e), 54.6 
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(o), 32.3 (o), 28.3 (o, 3C), 27.7 (e); HRMS (ESI): m/z calcd for C23H25N3O6+Na+ 
[M+Na]+ 462.1636; found 462.1647. 
 
Compound 358. Synthesised according to representative procedure E, except that 
crude compound was purified by FCC (98:2 DCM:MeOH) 
followed by trituration in Et2O, from compound 357 (701 mg, 1.59 
mmol) to afford compound 358 as a light brown powder (310 mg, 
0.79 mmol, 50%), m.p. = 40-43 oC; [α]D = -11.16 (MeOH, l = 0.25 
dm, c = 8.6); Chiral HPLC analysis (Chiralpak AD-H), 25% isopropanol/hexane  at 
0.75 mL/min. flow rate, 254 nm; tR (major) 8.52 min., tR (minor) 9.69 min., 92% 
enantiomeric excess.; 1H NMR (500 MHz, CDCl3): δ 7.62 (d, J = 7.8 Hz, 1H), 7.25 
(d, J = 7.2 Hz, 1H), 7.17 (t, J = 7.1 Hz, 1H), 7.05 (t, J = 7.6 Hz, 1H), 6.92 (s, 1H), 5.32 
(d, J = 8.4 Hz, 1H), 4.36 (q, J = 6.6 Hz, 1H), 4.27 (s, 1H), 3.74 (s, 3H), 3.25 (s, 3H), 
3.21-3.20 (m, 1H), 3.14 (dd, J = 6.9, 14.2 Hz, 1H), 3.06 (s, 3H), 1.43 (s, 9H);  13C 
NMR (100 MHz, CDCl3): δ 187.5 (e), 136.7 (e), 128.6 (e), 127.5 (o), 121.4 (o), 119.3 
(o), 118.6 (o), 110.2 (e), 109.0 (o), 83.3 (e), 69.2 (o), 57.6 (o), 41.8 (o), 41.6 (o), 32.6 
(o), 28.9 (e), 28.4 (o, 3C); IR (neat): 3397 (br, w), 3008 (w), 2976 (w), 2924 (w), 1696 
(s), 1565 (s), 1483 (s), 1474 (s), 1437 (m), 1389 (s), 1376 (s), 1364 (s), 1326 (m), 1247 
(m), 1162 (s), 1020 (s), 937 (w), 894 (w), 854 (m), 739 (s), 685 (w); HRMS (ESI): m/z 
calcd for C20H28N2O4S+H+ [M+H]+ 393.1843; found: 393.1842. 
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Representative Procedure H: Indole (2 g, 17.07 mmol, 1.0 equiv) was dissolved in 
dry DMF (68 mL, 0.25 M) under N2, and cooled to 0 oC. NaH (60% in oil, 0.8 g, 32.78 
mmol, 1.2 equiv) was added in small portions, and the reaction stirred at rt for 1 h. 
Methyl bromoacetate (1.8 mL, 18.78 mmol, 1.1 equiv) was added and the reaction was 
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allowed to stir at rt for 16 h. The reaction was quenched with water, and extracted with 
EtOAc (3x 100 mL). The combined organic layers were washed with water (x5), brine 
(once), dried (MgSO4), filtered and concentrated in vacuo. The residue was purified 
by FCC (9:1 hexane:Et2O) to afford compound 383 as a colourless oil (1.63 g, 8.62 
mmol, 50%).  
 
Compound 383. 1H NMR (500 MHz, CDCl3): δ ppm 7.64 (dt, J = 0.9, 7.9 Hz, 1H),; 
7.26-7.21 (m, 2H), 7.16-7.11 (m, 1H), 7.10 (d, J = 3.1 Hz, 1H), 6.57 
(dd, J = 0.6, 3.2 Hz, 1H), 4.87 (s, 2H), 3.74 (s, 3H); in agreement with 
previously reported data26. 
 
Compound 379. Synthesised according representative procedure C, from compound 
383 (1.63 g, 8.62 mmol) to afford compound 379 as a cream powder 
that was used without further purification (1.30 g, 7.42 mmol, 87%). 
1 H NMR (500 MHz, DMSO-d6): δ 12.94 (br s, 1H); 7.54 (d, J = 7.9 
Hz, 1H); 7.37 (d, J = 8.2 Hz, 1H); 7.32 (d, J = 3.2 Hz, 1H); 7.12 (t, J = 7.7 Hz, 1H); 
7.02 (t, J = 7.3 Hz, 1H); 6.44 (d, J = 3.1 Hz, 1H); 5.00 (d, J = 2.4 Hz, 2H), in agreement 
with previously reported data26. 
 
Compound 458. Synthesised according to representative procedure D, from 
compound 379 to afford compound 458 as a bright yellow 
amorphous solid (1.90 g, 6.41 mmol, 88%). 1H NMR (500 
MHz, CDCl3): δ  8.25 (d, J = 9.3 Hz. 2H), 7.68 (dt, J = 0.9, 
8.0 Hz, 1H), 7.34 (dd, J = 0.8, 8.3 Hz, 1H), 7.31-7.26 (m, 2H), 7.20-7.15 (m, 2H), 6.63 
(dd, J = 0.8, 3.2 Hz, 1H), 5.15 (s, 2H); 13C NMR (100 MHz, CDCl3): δ 166.2 (e), 154.7 
(e), 145.6 (e), 136.5 (e), 128.8 (e), 128.3 (o), 125.3 (o, 2C), 122.5 (o), 122.1 (o), 121.4 
(o), 120.3 (o, 2C), 108.7 (o), 103.3 (o), 47.9 (e); IR (neat): 3111 (w), 3078 (w), 2931 
(w), 2856 (w), 2115 (w), 1912 (w), 1786 (m), 1667 (m), 1615 (w), 1589 (m), 1519 (s), 
1487 (m), 1461 (s), 1417 (w), 1392 (w), 1341 (s), 1332 (s), 1290 (s), 1245 (m), 1204 
(s), 1161 (m), 1130 (s), 1105 (s), 1012 (m), 961 (w), 953 (w), 920 (m), 864 (m), 848 
(s), 816 (m), 798 (m), 764 (w), 755 (m), 737 (s), 710 (s), 677 (w), 661 (w); HRMS 
(ESI): m/z calcd for C16H11DN2O4+H+ [M+H]+ 298.0933; found 298.0929. 
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Compound 381. Synthesised according representative procedure E, except that 
crude compound was purified by FCC (98:2 DCM:MeOH) 
followed by trituration in Et2O, from compound 458 (1.90 g, 6.42 
mmol) to afford compound 381 as a cream powder (1.12 g, 4.51 
mmol, 70%). m.p. = 90-95 oC; 1H NMR (500 MHz, CDCl3): δ  7.64 (dt, J = 1.0, 7.9 
Hz, 1H), 7.31 (dd, J = 0.8, 8.4 Hz, 1H), 7.23-7.19 (m, 1H), 7.14-7.11 (m, 1H), 7.10 
(d, J = 3.2 Hz, 1H), 4.68 (s, 2H), 3.99 (s, 1H), 3.34 (s, 6H), 13C NMR (100 MHz, 
CDCl3): δ 185.3 (e), 136.4 (e), 128.6 (e), 128.5 (e), 121.8 (o), 120.9 (o), 119.6 (o), 
109.4 (o), 102.0 (o), 69.1 (o), 53.7 (o), 41.9 (o, 2C);  IR (neat/cm-1): 3122 (w), 3076 
(w), 3030 (w), 3011 (w), 2988 (w), 2909 (w), 1723 (w), 1608 (w), 1557 (s), 1513 
(w), 1483 (w), 1463 (m), 1428 (m), 1385 (s), 1363 (m), 1335 (s), 1319 (s), 1257 (m), 
1177 (s), 1152 (s), 1119 (w), 1088 (w), 1041 (s), 1012 (w), 997 (w), 974 (w, 956 
(w), 946 (w), 926 (m), 861 (s), 767 (s), 749 (s), 725 (s), 692 (m); HRMS (ESI): m/z 
calcd for C13H15NO2S+H+ [M+H]+ 250.0896; found: 250.0899. 
 
 
Compound 384. Following a reported procedure27, indole (3 g, 25.61 mmol, 1.0 
equiv) was dissolved in THF (43 mL, 0.6 M) and cooled to 0 oC. NaH 
(60% in oil, 2.4 g, 102.4 mmol, 2.5 equiv) was added in small portions, 
and the reaction was allowed to stir at 0 oC for 30 mins, before 
benzenesulfonyl chloride (3.9 mL, 30.73 mmol, 1.2 equiv) was added. The reaction 
was allowed to stir at room temperature for 16 h, then quenched with water and 
extracted with EtOAc (x3). The combined organic layers were washed with water (x5), 
then once with brine, dried (MgSO4), filtered and concentrated in vacuo. The crude 
residue was purified by FCC (petroleum ether/EtOAc = 95:5) to afford compound 384 
as colourless solid, 6.58 g, 25.57 mmol, quant. 1H NMR (500 MHz, CDCl3): δ ppm 
8.00 (d, J = 8.4 Hz, 1H), 7.90-7.86 (m, 2H), 7.57 (d, J = 3.7 Hz, 1H), 7.55-7.51 (m, 
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2H), 7.46-7.41 (m, 2H), 7.34-7.29 (m, 1H), 7.25-7.21 (m, 1H), 6.647 (dd, J = 0.8, 3.6 
Hz, 1H); in agreement with previously reported data27. 
 
Compound d-384. Following a reported procedure27, compound 384 (3 g, 11.66 
mmol, 1.0 equiv) was dissolved in dry THF (19 mL, 0.6 M) under N2, 
and the solution was cooled to -78 oC using a dry ice/acetone bath. 
nBuLi (2.5 M in hexanes, 12 mL, 29.15 mmol, 2.5 equiv) was added 
dropwise. Once the addition was complete, the reaction was allowed to stir at rt for 1 
h, during which time it turned dark brown. The reaction was then cooled back to -78 
oC, and D2O (3 mL, 1 mL/1 g of 384) was added dropwise. Once the addition was 
complete, the reaction was allowed to warm up to rt over 1 h, during which time the 
reaction turned pale yellow and a white precipitate could be seen. The reaction was 
quenched with solid K2CO3 and dry Et2O (117 mL, 0.1 M with respect to 384) was 
added. The suspension was stirred for 30 mins and the solid was filtered through cotton 
wool. The solid was washed with Et2O and the filtrate was concentrated in vacuo. The 
residue was purified by FCC  (petroleum ether/EtOAc = 95:5) to afford compound d-
384 as an off-white solid  (2.11 g, 8.17 mmol, 70%). 1H NMR (400 MHz, CDCl3): δ 
8.00 (d, J = 8.4 Hz, 1H), 7.88 (d, J = 8.4 Hz, 1H), 7.56-7.50 (m, 2H), 7.47-7.41 (m, 
2H), 7.35-7.29 (m, 1H), 7.25-7.20 (m, 1H), 6.66 (2, 1H); in agreement with previously 
reported data27. 
 
Compound d-382. Following a reported procedure, in a 2-neck RB flask under N2, 
compound d-384 (2.1 g, 8.17 mmol, 1.0 equiv) was dissolved in MeOH 
(11 mL, 0.77 M), and a  2 M aqueous NaOH solution (14 mL, 0.6 M) 
was added. The reaction was heated at reflux for 16 h, then the MeOH 
was removed in vacuo. The residue was extracted with DCM (3 x 20 mL), and the 
combined organic layers were dried (MgSO4), filtered and concentrated in vacuo to 
afford compound ### as a white solid which was used in the next step without further 
purification (804 mg, 6.80 mmol, 84%).  1H NMR (400 MHz, CDCl3): δ ppm 8.13 (br 
s, 1H), 7.66 (d, J = 7.9 Hz, 1H), 7.41 (d, J = 8.2 Hz, 1H), 7.21 (t, J = 7.0 Hz, 1H), 7.13 
(t, J = 7.6 Hz, 1H), 6.57 (s, 1H).); in agreement with previously reported data27. 
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Compound d-383. Synthesised according to representative procedure H, from 
compound d-382 (804 mg, 6.80 mmol) to afford compound d-383 as 
a colourless oil that darkened on prolonged exposure to air (641 mg, 
3.37 mmol, 50%). 1H NMR (500 MHz, CDCl3): δ 7.64 (dt, J = 1.0, 
7.9 Hz, 1H), 7.26-7.21 (m, 2H), 7.16-7.12 (m, 1H), 6.57 (s, 1H), 4.87 (s, 2H), 3.74 (s, 
3H); 13C NMR (100 MHz, CDCl3): δ 169.1 (e), 136.5 (e), 128.6* (e), 122.1 (o), 121.2 
(o), 119.9 (o), 108.9 (o), 102.4 (o), 52.5 (o), 47.7 (e) (the triplet for the 13C nucleus in 
the deuterated position overlaps with the peak marked by an asterisk and is not 
visible); IR (neat): 3051 (w), 2952 (w), 1739 (s), 1613 (w), 1496 (w), 1461 (s), 1437 
(m), 1421 (m), 1392 (w), 1356 (m), 1329 (m), 1306 (w), 1275 (m), 1211 (s), 1173 (s), 
1113 (w), 1063 (w), 1011 (w), 954 (w), 928 (w), 901 (w), 844 (w), 798 (w), 740 (s), 
697 (w), 659 (m); HRMS (CI (CH4)): m/z calcd for C11H10DNO2+H+ [M+H]+ 
191.0295; found 191.0931.  
 
Compound d-379. Synthesised according to representative procedure C, from 
compound d-383 (641 mg, 3.37 mmol) to afford compound d-379 as 
an off-white powder that was used without further purification (559 
mg, 3.17 mmol, 94%). M.p. = 130-132 oC; 1H NMR (500 MHz, 
DMSO-d6): δ 12.93 (br s, 1H), 7.54 (dt, J = 1.0, 7.9 Hz, 1H), 7.37 (dq, J = 1.0, 8.4 Hz, 
1H), 7.14-7.09 (m, 1H), 7.05-7.00 (m, 1H), 6.43 (d, J = 0.9 Hz, 1H), 5.00 (s, 2H); 13C 
NMR (100 MHz, DMSO-d6): δ 170.5 (e), 136.3 (e), 128.1* (e), 121.1 (o), 120.3 (o), 
119.1 (o), 109.7 (o), 100.8 (o), 47.0 (e) (the triplet for the 13C nucleus in the deuterated 
position overlaps with the peak marked by an asterisk and is not visible); IR (neat): 
3050 (w), 2966 (w), 2932 (w), 2647 (w), 2551 (w), 2331 (w), 1932 (w), 1894 (w), 
1709 (vs), 1615 (w), 1512 (w), 1494 (w), 1486 (w), 1464 (s), 1431 (m), 1402 (m), 
1393 (m), 1363 (w), 1332 (m), 1305 (w), 1275 (w), 1230 (s), 1194 (s), 1170 (s), 1113 
(w), 1067 (w), 1050 (w), 1010 (w), 900 (m), 851 (m), 844 (m), 800 (s), 773 (w), 758 
(w); HRMS (CI (CH4)): m/z calcd for C10H8DNO2+H+ [M+H]+ 177.0769; found 
177.0777. 
 
Compound d-380. Synthesised according to representative procedure D, from 
compound d-379 (534 mg, 3.03 mmol) to afford compound 
d-380 as a bright yellow amorphous solid (552 mg, 1.86 
mmol, 61%). 1H NMR (500 MHz, CDCl3): δ ppm 8.25 (d, 
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J = 9.3 Hz, 2H), 7.68 (dt, J = 1.0, 7.9 Hz, 1H), 7.34 (dd, J = 0.8, 8.3 Hz, 1H), 7.31-
7.26 (m, 3H), 7.21-7.16 (m, 1H), 6.62 (d, J = 0.8 Hz, 1H), 5.15 (s, 2H); 13C NMR (100 
MHz, CDCl3): δ 166.3 (e), 154.7 (e), 145.6 (e), 136.4 (e), 128.8* (e), 126.4 (o), 125.3 
(o, 2C), 122.5 (o), 122.1 (o, 2C), 121.4 (o), 120.3 (o), 115.8 (o), 108.7 (o), 103.1 (o), 
47.9 (e) (the triplet for the 13C nucleus in the deuterated position overlaps with the 
peak marked by an asterisk and is not visible); IR (neat): 3111 (w), 3078 (w), 2931 
(w), 2856 (w), 2115 (w), 1912 (w), 1786 (m), 1667 (m), 1615 (w), 1589 (m), 1519 (s), 
1487 (m), 1461 (s), 1417 (w), 1392 (w), 1341 (s), 1332 (s), 1290 (s), 1245 (m), 1204 
(s), 1161 (m), 1130 (s), 1105 (s), 1012 (m), 961 (w), 953 (w), 920 (m), 864 (m), 848 
(s), 816 (m), 798 (m), 764 (w), 755 (m), 737 (s), 710 (s), 677 (w), 661 (w); HRMS 
(ESI): m/z calcd for C16H12DN2O4 [M+H]+: 298.0933; found 298.0929. 
 
Compound d-381. Synthesised according to representative procedure E, except that 
crude compound was purified by FCC (98:2 DCM:MeOH) 
followed by trituration in Et2O, from compound d-380 (552 mg, 
1.86 mmol) to afford compound d-381 as cream flakes (288 mg, 
1.15 mmol, 62%). m.p. = 96-100 oC; 1H NMR (500 MHz, CDCl3): δ 7.63 (dt, J = 
0.9, 7.9 Hz, 1H), 7.31 (dd, J = 0.9, 8.3 Hz, 1H), 7.23-7.18 (m, 1H), 7.14-7.09 (m, 
1H), 4.68 (s, 2H), 3.99 (s, 1H), 3.33 (s, 6H); 13C NMR (100 MHz, CDCl3): δ  185.3 
(e), 136.3 (e), 128.5* (e), 121.8 (o), 120.9 (o), 119.6 (o), 109.4 (o), 101.8 (o), 69.2 
(o), 53.4 (e), 41.9 (o, 2C) (the triplet for the 13C nucleus in the deuterated position 
overlaps with the peak marked by an asterisk and is not visible); IR (neat): 3417 (w), 
3115 (w), 3076 (w), 3029 (w), 3011 (w), 2988 (w), 2909 (w), 2324 (w), 1937 (w), 
1902 (w), 1769 (w), 1731 (w), 1607 (w), 1557 (s), 1460 (s), 1427 (m), 1384 (s), 
1356 (m), 1330 (m), 1315 (m), 1250 (w), 1171 (s), 1149 (s), 1041 (s), 1011 (m), 997 
(m), 974 (m), 956 (w), 946 (w), 926 (m), 896 (m), 863 (m), 843 (s), 808 (s), 750 (s), 
742 (s), 692 (w), 661 (m); HRMS (ESI): m/z calcd for C13H14DNO2+H+ [M+H]+ 
251.0959; found 251.0963. 
 
 
 Page | 174  
 
 
Compound 395. Following a reported procedure28, to a flame dried 2-neck RB flask 
under N2 were added successively [RuCl2(p-cymene)]2 (0.39 g, 0.64 
mmol, 5 mol%), MesCO2H (0.63 g, 3.86 mmol, 30 mol%), 
triphenylphosphine (0.66 g, 2.58 mmol, 20 mol%), K2CO3 (3.56 g, 25.78 
mmol, 2.0 equiv), 68 (1.8 mL, 12.89 mmol, 1.0 equiv), dry 1,4-dioxane 
(51 mL, 0.25 M) and methyl 2-bromopropanoate (4.3 mL, 38.66 mmol, 
3.0 equiv). The reaction was stirred at 120 oC for 18 h, then cooled to room temperature 
and concentrated in vacuo. The crude residue was purified by FCC (petroleum 
ether/ethyl acetate = 4:1) to afford compound 395 as a pale yellow oil. (2.10 g, 8.70 
mmol, 68%). 1H NMR (500 MHz, CDCl3): δ 8.71 (dq, J = 4.9, 1.0 Hz, 1H), 7.93 (t, J 
= 1.8 Hz, 1H), 7.86 (dt, J = 7.7, 1.3 Hz, 1H), 7.79-7.69 (m, 2H), 7.44 (t, J = 7.6 Hz, 
1H), 7.37 (dt, J = 7.7, 1.4 Hz, 1H), 7.27-7.22 (m, 1H), 3.83 (q, J = 7.3 Hz, 1H), 3.67 
(s, 3H), 1.56 (d, J = 7.2 Hz, 3H). This compound was synthesised for preliminary 
results only, so was not fully characterised. 
 
Compound 392. Compound 395 (2.10 g, 8.70 mmol, 1.0 equiv) was dissolved in 
EtOH/H2O (2.5:1, 18 mL, 0.48 M), and solid KOH (0.6 g, 10.47 mmol, 
1.2 equiv) was added. The reaction was stirred at 50 oC for 2 h, then the 
EtOH was removed in vacuo. The aqueous layer was washed three times 
with Et2O, then neutralised with 2M HCl, and concentrated to dryness 
to afford compound 392 as a beige solid which was characterised by 1H 
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NMR only. 1H NMR (500 MHz, DMSO-d6): δ 8.64 (dt, J = 4.9, 1.4 Hz, 1H), 7.97 (t, 
J = 1.7 Hz, 1H), 7.89-7.82 (m, 2H), 7.77 (dt, J = 7.3, 1.7 Hz, 1H), 7.34-7.27 (m, 3H), 
3.30 (q, J = 7.2 Hz, 1H), 1.28 (d, J = 7.0 Hz, 3H). 
 
Compound 393. Compound 392 (1.03 g, 4.53 mmol, 1.0 equiv) and 4-nitrophenol 
208 (0.82 g, 5.89 mmol, 1.3 equiv) were dissolved in THF (0.18 
M) and triethylamine (0.7 mL, 4.98 mmol, 1.1 equiv) and DCC 
(1.21 g, 5.89 mmol, 1.3 equiv) were added. The reaction was 
stirred at room temperature for 18 h, then filtered through Celite. 
The Celite pad was washed with DCM, and the filtrate was 
concentrated in vacuo. The crude residue was purified by FCC 
(petroleum ether/ethyl acetate = 4:1) to afford compound 393 as an amorphous off-
white solid (1.38 g, 3.96 mmol, 87%). This compound contained some DCC, and was 
characterised by 1H NMR only before  being used in the next step. 1H NMR (500 
MHz, CDCl3): δ 8.70 (d, J = 4.9 Hz, 1H), 8.22 (d, J = 9.1 Hz, 2H), 8.02 (t, J = 1.7 Hz, 
1H), 7.88 (dt, J = 7.7, 1.2 Hz, 1H), 7.82 (td, J = 7.8, 1.7 Hz, 1H), 7.64 (d, J = 8.0 Hz, 
1H), 7.51 (t, J = 7.6 Hz, 1H), 7.45 (dt, J = 7.8, 1.5 Hz, 1H), 7.33-7.28 (m, 1H), 7.19 
(d, J = 9.1 Hz, 2H), 4.08 (q, J = 7.3 Hz, 1H), 1.67 (d, J = 7.1 Hz, 3H). 
 
Compound 394. Synthesised according to representative procedure E, except that 
crude compound was purified by FCC (98:2 DCM:MeOH), from 
compound 393 (1.08 g, 3.57 mmol) to afford compound 394 as an off-
white solid (256 mg, 0.86 mmol, 24%). 1H NMR (400 MHz, CDCl3): δ 
8.69 (d, J = 4.9 Hz, 1H), 7.92 (s, 1H), 7.83 (dt, J = 7.4, 1.7 Hz, 1H), 
7.77-7.72 (m, 2H), 7.43-7.36 (m, 2H), 7.24-7.20 (m, 1H), 4.32 (s, 1H), 
3.64 (q, J = 7.2 Hz, 1H), 3.37 (s, 3H), 3.32 (s, 3H), 1.51 (d, J = 7.2 Hz, 3H). This 
compound was synthesised for preliminary results only, and so was not fully 
characterised. 
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Compound 408. NaOtBu (9.14 g, 95.11 mmol, 2.0 equiv) was suspended in dry DMF 
(119 mL), and a solution of 407 (5 mL, 47.56 mmol, 1.0 equiv) and TOSMIC 
(11.3 g, 57.07 mmol, 1.2 equiv) in dry DMF (119 mL) was added dropwise. 
The reaction was stirred at room temperature for 3 h, then diluted with ethyl 
acetate and washed three times with brine, then three times with water. The 
organic layer was dried (MgSO4), filtered and concentrated in vacuo. The 
crude residue was purified by FCC (petroleum ether/EtOAc = 3:2) to afford compound 
408 as an amorphous white solid (6.51 g, 45.15 mmol, 95%). 1H NMR (500 MHz, 
CDCl3): δ 8.60 (br s, 1H), 8.53 (dq, J = 4.9, 1.0 Hz, 1H), 7.61 (td, J = 7.8, 1.9 Hz, 1H), 
7.49 (dt, J = 8.1, 1.1 Hz, 1H), 7.44 (q, J = 1.8 Hz, 1H), 7.03 (ddd, J = 7.4, 5.0, 1.1 Hz 
1H), 6.84 (q, J = 2.5 Hz, 1H), 6.72 (q, J = 2.7 Hz, 1H), in agreement with previously 
reported data29. 
 
Compound 409. Compound 408 (6.4 g, 44.39 mmol, 1.0 equiv) was added to a 
solution of KOH (5.0 g, 88.78 mmol, 2.0 equiv) in dry DMF (114 mL, 
0.39 M), and the reaction was stirred at rt for 30 mins. Methyl 
bromoacetate (8.4 mL, 88.78 mmol, 2.0 equiv) was added and the reaction 
was stirred at room temperature for 2 h, The reaction was diluted with 
ethyl acetate and washed five times with water, then the organic layer was 
dried (MgSO4), filtered and concentrated in vacuo. The reside was purified by FCC 
(DCM/MeOH = 96:4) to afford compound 409 as a colourless oil (1.24 g, 5.71 mmol, 
13%). 1H NMR (500 MHz, CDCl3): δ 8.51 (dq, J = 4.9, 0.8 Hz, 1H), 7.60 (td, J = 7.7, 
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1.9 Hz, 1H), 7.45 (dt, J = 8.0, 1.1 Hz, 1H), 7.31 (t, J = 2.1 Hz, 1H), 7.05-7.00 (m, 1H), 
6.70 (t, J = 2.6 Hz, 1H), 6.69-6.67 (m, 1H), 4.67 (s, 2H), 3.77 (s, 3H). This compound 
was synthesised for preliminary results only, so was not fully characterised. 
 
Compound 411. Compound 409 (1.02 g, 4.74 mmol, 1.0 equiv) was dissolved in 
EtOH (7 mL, 0.7 M) and a 2M aqueous solution of KOH (2.5 
mL) was added. The reaction was stirred at 50 oC for 2 h, then 
the EtOH was removed in vacuo. The remaining aqueous 
solution was washed three times with Et2O, then neutralised 
with 2M HCl and concentrated to dryness. The solid residue 
was dried in a vacuum desiccator  overnight to afford an off-white powder (1.11 g, 
5.49 mmol). This was immediately suspended in THF (30 mL, 0.18 M) and Et3N (0.8 
mL, 6.04 mmol, 1.1 equiv) was added, followed by 211 (0.99 g, 7.14 mmol, 1.3 equiv) 
and DCC (1.47 g, 7.14 mmol, 1.3 equiv). The reaction was stirred at room temperature 
overnight, before being filtered through Celite, and the pad was washed with 
DCM/MeOH (1:1). The filtrate was concentrated in vacuo and purified by FCC 
(DCM/MeOH = 98:2) to afford compound 411 as a pale yellow amorphous solid. This 
compound was contaminated with 211, and so was characterised by 1H NMR only 
before being used in the next step. 1H NMR (500 MHz, CDCl3): δ 8.43 (dq, J = 5.2, 
0.9 Hz, 1H), 8.19 (d, J = 9.2 Hz, 2H), 7.72-7.68 (m, 1H), 7.53 (dt, J = 8.0, 1.0 Hz, 1H), 
7.27 (t, J = 2.0 Hz, 1H), 7.14-7.09 (m 3H), 6.69-6.66 (m, 2H), 4.78 (s, 2H). 
 
Compound 412. Synthesised according to representative procedure E, except that 
crude compound was purified by FCC (DCM/MeOH = 95:5) followed 
by recrystallisation from EtOAc of the solid collected from the product 
containing fractions, from compound 411 (2.69 g, 8.32 mmol) to afford 
compound 412 (152 mg, 0.56 mmol, 7%). 1H NMR (500 MHz, CDCl3): 
δ 8.54 (dq, J = 4.9, 0.9 Hz, 1H), 7.64 (td, J = 7.9, 1.9 Hz, 1H), 7.47 (dt, 
J = 8.1, 1.2 Hz, 1H), 7.28 (t, J = 2.0 Hz, 1H), 7.07 (ddd, J = 7.5, 4.9, 1.1 Hz, 1H), 6.75 
(dd, J = 2.8, 1.8 Hz, 1H), 6.68 (t, J = 2.6 Hz, 1H), 4.59 (s, 2H), 4.26 (s, 1H), 3.36 (s, 
6H). This compound was synthesised for preliminary results only, so was not fully 
characterised. 
 
N
N
O
O
411
NO2
 Page | 178  
 
3.4 HFIP Mediated Electrocyclisation of Sulfoxonium Ylides 
 
 
 
Representative procedure I: In a flame dried Schlenck tube equipped with a J-Young 
key and a Teflon stirrer bar under N2, compound 85 (189 mg, 0.66 mmol, 1.0 equiv) 
was dissolved in HFIP (3.3 mL, 0.2 M), and K2CO3 was added. The tube was sealed 
and placed in a pre-heated oil bath at 60 oC for 18 h. The reaction was cooled to rt and 
concentrated in vacuo. The residue was purified by FCC (hexane/EtOAc = 98:2) to 
afford compound 87 as sticky purple amorphous solid (125 mg, 0.60 mmol, 91%). 
 
Compound 87. 1H NMR (500 MHz, CDCl3): δ ppm 7.40 (d, J = 7.7 Hz, 1H); 7.37-
7.26 (m, 5H); 7.20 (d, J = 7.7 Hz, 1H); 7.12 (d, J = 7.0 Hz, 2H); 4.68 (s, 
1H); 3.68 (s, 2H); 13C NMR (100 MHz, CDCl3): δ 213.6 (e), 141.2 (e), 
138.0 (e), 137.1 (e), 128.6 (o, 2C), 128.3 (o), 2C), 127.9 (o), 127.7 (o), 
127.2 (o), 125.9 (o), 124.7 (o), 59.6 (o), 42.8 (o), in agreement with previously 
reported data30; HRMS (CI (CH4)): m/z calcd for C15H12O [M+H+] 209.0961; found 
209.0968. 
 
Compound 229. Synthesised according to representative procedure I at 60 oC, from 
compound 213 (148 mg, 0.66 mmol), to afford compound 229 as a 
yellow oil (44 mg, 0.30 mmol, 46%). 1H NMR (500 MHz, CDCl3): δ 
7.33-7.26 (m, 4H), 3.62 (d, J = 22.4 Hz, 1H), 3.51 (d, J = 22.6 Hz, 1H), 
3.49 (q, J = 7.6 Hz, 1H), 1.42 (d, J = 7.5 Hz, 3H), in agreement with previously 
reported data31. 
 
Compound 230. Synthesised according to representative procedure I at 60 oC, from 
compound 214 (185 mg, 0.66 mmol) to afford compound 230 as 
a sticky pale yellow solid (114 mg, 0.56 mmol, 79%). 1H NMR 
(500 MHz, CDCl3): δ 7.18 (d, J = 7.5 Hz, 1H), 7.09-7.06 (m, 2H), 3.58 (d, J = 22.5 
Hz, 1H), 3.51-3.43 (m, 2H), 2.47 (d, J = 7.2 Hz, 2H), 1.86 (sept, J = 6.8 Hz, 1H), 1.40 
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(d, J = 7.5 Hz, 3H), 0.91 (d, J = 6.6 Hz, 6H); 13C NMR (100 MHz, CDCl3): δ 218.3 
(e), 141.0 (e), 140.6 (e), 136.1 (e), 128.4 (o), 125.3 (o), 123.7 (o), 47.5 (o), 45.4 (e), 
43.0 (e), 30.3 (o), 22.3 (o, 2C), 15.5 (o); IR (neat): ~ = 3006 (w), 2970 (w), 2958 (w), 
2932 (w), 2909 (w), 2867 (w), 2849 (w), 2741 (w), 2633 (w), 1701 (vs), 1671 (vs), 
1611 (m), 1567 (m), 1497 (w), 1466 (w), 1428 (m), 1397 (m), 1384 (w), 1350 (s), 
1303 (w), 1285 (w), 1257 (s), 1244 (s), 1221 (s), 1192 (w), 1164 (w), 1149 (w), 1116 
(w), 1091 (w), 1059 (w), 1018 (w), 982 (w), 957 (w), 930 (m), 889 (m), 843 (m), 788 
(m), 731 (w), 711 (w), 685 (m) cm-1; HRMS (CI(CH4)): m/z calcd for C14H18O+H+ 
[M+H]+ 203.1436; found 203.1437 
 
Compound 231. Synthesised according to representative procedure I at 60 oC, from 
compound 215 (168 mg, 0.66 mmol) to afford compound 231 as a 
pale yellow oily solid (75 mg, 0.42 mmol, 65%) alongside compound 
232 as a colourless liquid (57 mg, 0.16 mmol, 25%). 1H NMR (400 
MHz, CDCl3): δ 7.20-7.18 (m, 1H), 6.86-6.83 (m, 2H), 3.82 (s, 3H), 3.58 (d, J = 22.3 
Hz, 1H), 3.49 (d, J = 23.0 Hz, 1H), 3.43 (q, J = 7.5 Hz, 1H), 1.38 (d, J = 7.4 Hz, 3H); 
13C NMR (100 MHz, CDCl3): δ 218.0 (e), 159.1 (e), 137.5 (e), 135.4 (e), 125.0 (o), 
113.7 (o), 110.0 (o), 55.4 (o), 47.1 (o), 43.2 (e), 15.8 (o); IR (neat): ~ = 2982 (w), 2968 
(w), 2930 (w), 2893 (w), 2871 (w), 2837 (w), 2039 (w), 1899 (w), 1736 (s), 1698 (w), 
1609 (m), 1583 (w), 1491 (s), 1467 (m), 1446 (m), 1430 (w), 1389 (w), 1373 (w), 1300 
(m), 1271 (s), 1226 (s), 1184 (m), 1167 (w), 1146 (s), 1087 (s), 1046 (s), 1021 (s), 989 
(w), 948 (w), 927 (w), 895 (w), 831 (s), 788 (w), 762 (m), 738 (w); 697 (w), 666 (w) 
cm-1; HRMS (CI(CH4)): m/z calcd for C11H12O2+H+ [M+H]+: 177.0916; found: 
177.0912. 
 
Compound 232. 1H NMR (400 MHz, CDCl3): δ ppm 7.28 (d, J = 8.9 Hz, 2H), 6.92 
(d, J = 8.9 Hz, 2H), 4.34 (hept, J = 5.8 Hz, 1H), 3.82 (s, 3H), 2.18 
(s, 3H), 1.72 (s, 3H); 13C NMR (100 MHz, CDCl3): δ 206.8, 
159.9, 130.2, 127.5 (2C), 114.2 (2C), 88.8, 70.5 (hept, J = 32.1 
Hz), 55.3, 25.2, 21.0 (the two quartets for the CF3 groups were not visible); 19F NMR 
(400 MHz, CDCl3): δ -72.6 (q, J = 9.6 Hz, 3F), -72.8 (q, J = 9.1 Hz, 3F); IR (neat): ~ 
= 2941 (w), 1722 (s), 1610 (m), 1583 (w), 1513 (s), 1465 (w), 1357 (s), 1286 (s), 1256 
(s), 1219 (s), 1193 (s), 1101 (s), 1033 (s), 901 (s), 832 (m), 784 (w), 742 (w), 687 (w) 
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cm-1; HRMS (ESI): m/z calcd for C14H14F6O3+Na+ [M+Na]+ 367.0739; found: 
367.0741. 
 
Compound 233. To a flame dried microwave vial under N2 was added compound 216 
(171 mg, 0.66 mmol, 1.0 equiv), followed by HFIP (3.3 mL, 0.2 M). 
K2CO3 (91 mg, 0.66 mmol, 1.0 equiv) was added, the vial was sealed, 
and the reaction was heated at 80 oC in the microwave for 2 h. The 
reaction was cooled to rt and concentrated in vacuo. The residue was purified by FCC 
(9:1 petroleum ether:EtOAc) to afford compound 233 as a pale pink amorphous solid 
(102 mg, 0.56 mmol, 86%). 1H NMR (500 MHz, CDCl3): 7.30 (br s, 1H), 7.29-7.27 
(m, 1H), 7.22-7.20 (m, 1H), 3.60 (d, J= 22.7 Hz, 1H), 3.50 (d, J= 22.8 Hz, 1H), 3.44 
(q, J= 7.4 Hz, 1H), 1.40 (d, J= 7.5 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ 216.5 (e), 
141.7 (e), 138.0 (e), 133.0 (e), 127.8 (o), 125.4 (o), 125.0 (o), 47.4 (o), 42.8 (e), 15.4 
(o); IR (neat): ~ = 2980 (w), 2934 (w), 2908 (w), 2645 (w), 1742 (s), 1703 (m), 1669 
(m), 1600 (w), 1561 (w), 1475 (s), 1450 (m), 1420 (m), 1397 (w), 1384 (w), 1366 (w), 
1280 (w), 1245 (w), 1186 (s), 1155 (w), 1111 (w), 1074 (w), 1060 (w), 1038 (w), 983 
(w), 960 (w), 936 (w), 903 (m), 882 (m), 850 (w), 833 (s), 786 (w), 759 (w), 718 (w), 
661 (w), 656 (w) cm-1; HRMS (CI(CH4)): m/z cald for C10H935ClO+H+ [M+H]+ 
181.0432; found 181.0433. 
 
Compound 234. Synthesised according to representative procedure I at 90 oC, from 
compound 217 (200 mg, 0.66 mmol) to afford compound 234 as a 
yellow powder (121 mg, 82%, 0.54 mmol). m.p. = 100-103 oC; 1H 
NMR (400 MHz, CDCl3): 7.46-7.42 (m, 2H), 7.15 (d, J = 8.0 Hz, 1H), 3.60 (d, J = 
22.6 Hz, 1H), 3.50 (d, J = 22.9 Hz, 1H), 3.42 (q, J = 7.4 Hz, 1H), 1.40 (d, J = 7.5 Hz, 
3H); 13C NMR (100 MHz, CDCl3): δ 216.4 (e), 142.3 (e), 138.4 (e), 130.7 (o), 128.0 
(o), 125.8 (o), 121.0 (e), 47.4 (o), 42.7 (e), 15.4 (o); IR (neat): ~ = 3011 (w), 2921 (w), 
2744 (w), 2639 (w), 2558 (w), 1747 (w), 1701 (s), 1668 (s), 1588 (m), 1555 (m), 1473 
(w), 1423 (m), 1412 (m), 1393 (w), 1358 (w), 1341 (m), 1287 (m), 1241 (s), 1099 (m), 
1059 (w), 1014 (w), 959 (m), 931 (m), 889 (m), 860 (m), 824 (s), 759 (m), 713 (w), 
682 (w) cm-1; HRMS (CI (CH4)): m/z calcd for C10H979BrO+H+ [M+H]+: 226.0930; 
found 226.0933. 
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Compound 235. Synthesised according to representative procedure I at 90 oC, from 
compound 218 (193 mg, 0.66 mmol) to afford compound 235 as a 
colourless liquid (89 mg, 0.42 mmol, 63%). 1H NMR (500 MHz, 
CDCl3): δ 7.61–7.55 (m, 2H), 7.40 (d, J = 7.9 Hz, 1H), 3.66 (d, J = 
22.6 Hz, 1H), 3.57 (d, J = 22.5 Hz, 1H), 3.53 (q, J = 7.3 Hz, 1H), 1.44 (d, J = 7.5 Hz, 
3H); 13C NMR (125 MHz, CDCl3): δ 216.0 (e), 147.3 (e), 137.1 (e), 129.9 (e, J = 32.0 
Hz), 124.60 (o, J = 3.7 Hz), 124.58 (o), 124.1 (e, J = 272 Hz ), 121.8 (o, J = 3.9 Hz), 
47.8 (o), 42.7 (e), 15.2 (o); 19F NMR (376 MHz, CDCl3): δ -62.4 (s, 3F); IR (neat): ~ 
= 2976 (w), 1753 (s), 1627 (w), 1437 (m), 1372 (w), 1334 (s), 1284 (s), 1243 (m), 
1184 (s), 1153 (s), 1121 (s), 1068 (s), 913 (w), 894 (m), 834 (m), 750 (w), 718 (w), 
690 (w) cm-1; HRMS (CI(CH4)): m/z calcd for C12H14O3+H+: 207.1016 [M+H]+; found 
207.1012 
 
Compound 237. Synthesised according to representative procedure I, from compound 
227 (159 mg, 0.66 mmol) to afford compound 237 as a colourless 
liquid (112 mg, 0.34 mmol, 51%). 1H NMR (400 MHz, CDCl3): δ 7.28 
(d, J = 8.7 Hz, 2H), 6.95 (d, J = 8.8 Hz, 2H), 5.09 (s, 1H), 4.14 (sept, 
J = 5.8 Hz, 1H), 3.83 (s, 3H), 2.22 (s, 3H); 13C NMR (125 MHz, 
CDCl3): δ 203.1 (e), 160.9 (e), 129.6 (o, 2C), 124.5 (e), 121.7 (e, q, J = 284.5 Hz), 
121.2 (e, q, J = 281.6 Hz), 114.7 (o, 2C), 88.4 (e), 72.9 (o, sept, J = 32.7 Hz), 55.3 (o), 
25.8 (o); IR (neat): ~ = 2938 (w), 1730 (s), 1610 (s), 1585 (w), 1513 (s), 1361 (s), 
1466 (w), 1361 (s), 1286 (s), 1260 (s), 1219 (s), 1192 (s), 1125 (s), 1102 (s), 1031 (m), 
905 (w), 879 (w), 833 (w), 741 (w), 687 (m) cm-1; HRMS (ESI): m/z calcd for 
C13H12F6O3+Na+: 353.0583 [M+Na]+; found 353.0584. 
 
 
Compound 239. Synthesised according to representative procedure I, from compound 
228 (184 mg, 0.66 mmol) to afford compound 239 as a 
colourless liquid (168.7 mg, 0.46 mmol, 70%). 1H NMR 
(500 MHz, CDCl3): δ 7.57 (d, J = 8.0 Hz, 2H), 7.32 (d, J = 
8.0 Hz, 2H), 5.75 (hept, J = 6.1 Hz, 1H), 3.08 (t, J = 7.6 Hz, 2H), 2.88 (t, J = 7.7 Hz, 
2H); 13C NMR (125 MHz, CDCl3): δ 169.2 (e), 143.1 (e), 129.2 (e, q, J = 32.5 Hz), 
128.6 (o, 2C), 126.6 (o, q, J = 3.7 Hz, 2C), 124.2 (e, q, J = 271.5 Hz), 120.4 (e, q, J = 
283.6 Hz, 2C), 66.6 (o, hept, J = 33.8 Hz), 34.4 (e), 30.1 (e); 19F NMR (376 MHz, 
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CDCl3): δ -62.56 (s, 3F), -73.13 (s, 6F); IR (neat): ~ = 2971 (w), 1781 (s), 1621 (w), 
1420 (w), 1386 (m), 1357 (m), 1325 (s), 1287 (m), 1268 (m), 1228 (s), 1200 (s), 1165 
(s), 1106 (vs), 1067 (vs), 1019 (m), 941 (w), 906 (m), 877 (w), 839 (m) cm-1; HRMS 
(ESI): m/z calcd for C13H9F9O2+Na+: 391.0357 [M+Na]+; found 391.0356. 
 
Compound 114. Synthesised according to representative procedure I at 60 oC, from 
compound 220 (165 mg, 0.66 mmol) to afford compound 114 as a 
yellow oil (102 mg, 0.59 mmol, 88%). 1H NMR (500 MHz, CDCl3): 
7.35-7.33 (m, 1H), 7.32-7.27 (m, 3H), 5.76-5.68 (m, 1H), 5.07 (dq, J = 1.7, 16.9, 1.5 
Hz, 1H), 5.02 (d, J = 10.1 Hz, 1H), 3.59-3.53 (m, 2H), 3.46 (d, J = 22.8 Hz, 1H), 2.74-
2.69 (m, 1H), 2.63-2.57 (m, 1H); 13C NMR (100 MHz, CDCl3): δ 217.0 (e), 141.5 (e), 
136.8 (e), 134.3 (o), 127.4 (o), 127.3 (o), 124.79 (o), 124.78 (o), 117.7 (o), 52.6 (o), 
43.3 (e), 35.6 (e), in agreement with previously reported data32. 
 
Compound 264. Synthesised according to representative procedure I at 90 oC, from 
compound 221 (198 mg, 0.66 mmol)  to afford compound 264 as a 
yellow oil (94 mg, 0.42 mmol, 67%). 1H NMR (500 MHz, CDCl3): 
δ 7.25-7.17 (m, 6H); 7.08-7.06 (m, 2H); 6.95 (d, J = 7.2 Hz, 1H); 
3.79-3.76 (m, 1H); 3.48 (d, J = 22.5 Hz, 1H); 3.34 (dd, J = 13.7, 4.7 Hz, 1H); 3.26 (d, 
J = 22.8 Hz, 1H); 2.99 (dd, J = 13.7, 8.1 Hz, 1H); 13C NMR (125 MHz, CDCl3): δ 
217.1 (e), 141.3 (e), 138.0 (e), 136.9 (e), 129.4 (o, 2C), 128.2 (o, 2C), 127.5 (o), 127.1 
(o), 126.4 (o), 125.1 (o), 124.7 (o), 54.4 (o), 43.2 (e), 37.9 (e); IR (neat): ~ = 3070 (w), 
3028 (w), 2922 (w), 1744 (s), 1602 (w), 1533 (w), 1495 (m), 1479 (m), 1454 (m), 1391 
(m), 1343 (w), 1308 (w), 1280 (w), 1246 (w), 1234 (w), 1188 (w), 1139 (m), 1074 
(m), 1042 (w), 1026 (w), 968 (w), 950 (w), 901 (w), 867 (w), 837 (w), 821 (w), 802 
(w), 776 (w), 740 (s), 712 (m), 696 (s) cm-1; HRMS (CI(CH4)): m/z calcd for 
C16H14O+H+: 223.1117 [M+H]+; found 223.1120. 
 
Compound 265. Synthesised according to representative procedure I, from compound 
222 (200 mg, 0.68 mmol) to afford compound 265 as a colourless liquid 
(15 mg, 0.07 mmol, 8%). 1H NMR (500 MHz, CDCl3): δ 7.38-7.20 (m, 
4H), 3.46 (s, 2H), 3.31 (d, J = 3.8 Hz, 1H), 2.03-1.90 (m, 2H), 1.75-1.67 
(m, 2H), 1.63 (d, J = 10.7 Hz, 2H), 1.57 (d, J = 11.8 Hz, 1H), 1.34-1.15 
(m, 4H), 1.15-1.03 (m, 1H); 13C NMR (100 MHz, CDCl3): δ 218.0 (e), 141.3 (e), 137.5 
 Page | 183  
 
(e), 127.15 (o), 127.14 (o), 125.1 (o), 124.6 (o), 59.0 (o), 44.3 (e), 42.7 (o), 29.8 (e), 
29.6 (e), 26.6 (e), 26.4 (e), 26.0 (e); IR (neat): ~ = 3025 (w), 2922 (w), 2851 (w), 1745 
(s), 1478 (m), 1461 (w), 1449 (m), 1393 (w), 1348 (w), 1308 (w), 1260 (w), 1185 (m), 
1138 (m), 1073 (w), 1055 (w), 1026 (w), 968 (w), 948 (w), 898 (w), 844 (w), 802 (w), 
745 (m), 726 (w); HRMS (CI (NH3)): m/z calcd for C15H18O+H+ 232.1696 [M+NH4]+; 
found 232.1698.   
 
Compounds 266 and 267. Synthesised according to representative procedure I, from 
compound 223 (50 mg, 0.16 mmol) to afford compounds 266 and 
267 as a white amorphous solid. (28 mg, 0.12 mmol, 74%). 1H NMR 
(500 MHz, CDCl3): δ 7.39 (d, J = 7.2 Hz,  minor), 7.35-7.29 (m, 2H, 
major), 7.28-7.23 (m, 1H, major), 7.19 (d, J = 7.5 Hz, minor), 7.11 
(d, J = 7.9 Hz, 3H, major), 7.03 (d, J = 8.5 Hz, minor), 6.93 (s, 1H, 
major), 6.90-6.84 (m, 1H, major), 4.62 (s, 1H, major), 3.99 (s, 
minor), 3.85 (s, 3H, major), 3.79 (s, minor), 3.66 (s, minor), 3.64 (s, 
2H, major); 13C NMR (100 MHz, CDCl3): δ 214.0 (e, major), 159.5 
(e, major), 138.49 (e, major), 138.47 (e, major), 133.2 (e, major), 130.9 (o, minor), 
129.4 (o, minor), 128.7 (o, 2C, major), 128.8 (o, minor), 128.3 (o, 2C, major), 127.9 
(o, minor), 127.8 (o, minor), 127.2 (o, major), 126.9 (o, major), 126.0 (o, minor), 124.8 
(o, minor), 114.3 (o, major), 114.2 (o, minor), 109.8 (o, major), 59.1 (o, major), 58.9 
(o, minor), 55.4 (o, major), 55.2 (o, minor), 43.3 (e, major), 42.8 (e, minor);   IR (neat): 
~ = 3057 (w), 3031 (w), 2979 (w), 2946 (w), 2833 (w), 1746 (s), 1713 (w), 1653 (w), 
1608 (w), 1582 (w), 1490 (s), 1471 (s), 1452 (m), 1429 (w), 1397 (w), 1386 (w), 1351 
(w), 1351 (w), 1305 (m), 1288 (m), 1259 (s), 1221 (m), 1206 (w), 1182 (m), 1152 (w), 
1134 (s), 1115 (w), 1069 (m), 1027 (s), 1001 (w), 969 (w), 955 (w), 928 (w), 914 (w), 
873 (w), 856 (w), 841 (m), 823 (s), 808 (w), 786 (w), 776 (w), 743 (s), 697 (s), 665 
(w); HRMS (CI(CH4)): m/z calcd for C16H14O+H+ [M+H]+ 239.1067. Found: 
239.1072. 
Compound 272. Synthesised according to representative procedure I, from compound 
268 (188 mg, 0.66 mmol) to afford compound 272 as a yellow oil 
(110 mg, 0.53 mmol, 85%). 1H NMR (500 MHz, CDCl3): 6.83 (s, 
1H), 6.79 (s, 1H), 3.90 (s, 3H), 3.89 (s, 3H), 3.54 (d, J= 22.4 Hz, 
1H), 3.46 (d, J= 19.2 Hz, 1H), 3.44 (q, J= 8.0 Hz, 1H), 1.39 (d, J= 
7.5 Hz, 3H);  13C NMR (100 MHz, CDCl3): δ 218.1 (e), 149.0 (e), 148.8 (e), 135.2 (e), 
O
Ph
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127.9 (e), 107.8 (o), 107.2 (o), 56.1 (o), 56.0 (o), 47.8 (o), 42.8 (e), 15.6 (o); IR (neat): 
~ = 3139 (w), 2977 (w), 2941 (w), 2844 (w), 1723 (s), 1634 (w), 1607 (w), 1594 (w), 
1516 (s), 1446 (m), 1420 (w), 1397 (w), 1347 (w), 1332 (w), 1312 (w), 1301 (w), 1277 
(m), 1248 (m), 1236 (m), 1224 (s), 1189 (m), 1164 (m), 1143 (s), 1067 (w), 1022 (s), 
927 (w), 884 (w), 848 (m), 815 (w), 795 (w), 764 (w), 719 (s); HRMS (CI(CH4)): m/z 
calcd for C12H14O3+H+: 207.1016; found: 207.1012. 
 
Compound 273. Synthesised according to representative procedure I, from compound 
269 to afford compound 273 as an off-white powder (137 mg, 0.61 
mmol, 91%). m.p. = 82-85 oC; 1H NMR (500 MHz, CDCl3): 7.72 
(d, J=8.2 Hz, 1H), 7.62 (d, J=8.8 Hz, 1H), 7.38 (d, J=8.3 Hz, 1H), 
7.20-7.23 (m, 2H), 3.94 (s, 3H), 3.81 (d, J=4.0 Hz, 2H), 3.64 (q, 
J=7.5 Hz, 1H), 1.47 (d, J=7.5 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ 218.0 (e), 
157.5 (e), 138.2 (e), 134.1 (e), 132.5 (e), 127.0 (o), 125.9 (o), 125.2 (o), 122.6 (o), 
119.3 (o), 106.9 (o), 55.3 (o), 48.5 (o), 41.4 (e), 15.9 (o); IR (neat): ~ = 3040 (w), 3005 
(w), 2977 (w), 2959 (w), 2935 (w), 2898 (w), 2860 (w), 2840 (w), 1733 (s), 1625 (m), 
1598 (m), 1516 (w), 1479 (m), 1448 (w), 1428 (m), 1396 (w), 1362 (m), 1317 (w), 
1290 (w), 1274 (w), 1262 (m), 1243 (s), 1226 (m), 1194 (m), 1166 (m), 1150 (m), 
1135 (m), 1047 (s), 1028 (s), 998 (m), 961 (w), 936 (w), 905 (w), 896 (w), 873 (s), 
813 (s), 768 (w), 748 (w), 735 (w), 710 (w), 698 (w), 698 (w), 659 (w) cm-1; HRMS 
(CI (CH4)): m/z calcd for C15H13O2+H+ [M+H]+ 226.1067; found 227.1075 
 
Compound 274. Synthesised according to representative procedure I, from compound 
270 (230 mg, 0.66 mmol) to afford compound 274 as a cream 
powder (121 mg, 0.45 mmol, 69%). m.p. = 165-167oC; 1H 
NMR (500 MHz, CDCl3): 8.02 (d, J= 1.8 Hz, 1H), 7.98 (d, J= 
8.0 Hz, 1H), 7.42 (dd, J= 2.1, 8.7 Hz, 1H), 7.29 (d, J= 8.7 Hz, 1H), 7.16 (d, J= 8.0 Hz, 
1H), 4.06 (d, J= 4.3 Hz, 2H), 3.98 (s, 3H), 3.63 (q, J= 8.1 Hz, 1H), 1.50 (d, J= 7.5 Hz, 
3H); 13C NMR (100 MHz, CDCl3): δ 217.3 (e), 142.4 (e), 139.3 (e), 137.5 (e), 125.5 
(o), 124.6 (e), 123.8 (e), 121.3 (e), 119.9 (o), 119.3 (o), 117.2 (e), 115.3 (o), 109.4 (o), 
47.2 (o), 41.5 (e), 30.6 (o), 16.1 (o); IR (neat): ~ = 2932 (w), 1741 (s), 1622 (w), 1600 
(w), 1580 (w), 1490 (w), 1459 (s), 1433 (w), 1410 (w), 1372 (w), 1359 (w), 1342 (w), 
1305 (m), 1275 (s), 1229 (w), 1189 (w), 1157 (w), 1128 (w), 1102 (w), 1078 (w), 1055 
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(w), 1038 (w), 1002 (w), 940 (m), 917 (m), 886 (m), 806 (s), 795 (s), 770 (m), 738 
(w), 730 (w), 710 (w), 685 (w), 660 (m) cm-1; HRMS (CI (CH4)): m/z calcd for 
C17H1535ClNO [M+H]+ 283.0764; found 284.0833.  
 
Compound 275 and 276. Synthesised according to representative procedure I, except 
that reaction time was extended to 48 h, from compound 271 
(246 mg, 0.66 mmol) to afford compounds 275 and 276 as a 
slightly pink solid (120 mg, 0.30 mmol, 62%). 1H NMR (500 
MHz, CDCl3): 8.21 (dd, J= 1.4, 7.9 Hz, 1H), 8.18 (dd, J= 1.4, 
7.9 Hz, 1H), 7.62-7.61 (m, 3H), 7.45-7.42 (m, 2H), 7.38 (br s, 
1H), 7.35-7.31 (m, 2H), 7.12 (d, J= 7.9 Hz, 1H), 4.41 (s, 2H), 
4.37 (s, 2H), 3.77 (d, J= 22.5 Hz, 1H), 3.72 (d, J = 22.8 Hz, 1H), 
3.56 (d, J= 22.7 Hz, 1H), 3.51-3.44 (m, 3H); 1.41 (d, J= 3.7 Hz, 
3H), 1.39 (d, J= 3.62 Hz, 3H);  13C NMR (100 MHz, CDCl3): δ 
216.3 (e), 219.9 (e), 191.9 (e), 190.5 (e), 145.6 (e), 145.3 (e), 140.2 (e), 140.1 (e), 
137.0 (e), 136.7 (e), 136.1 (e), 136.0 (e), 135.5 (e), 133.8 (e), 133.7 (e), 133.6 (e), 
132.5 (o), 131.5 (o), 131.4 (o), 130.83 (o), 130.81 (o), 130.6 (o), 127.6 (o), 126.9 (o), 
126.8 (o), 125.1 (o), 122.7 (o), 51.0 (e), 48.3 (o), 48.0 (e), 47.7 (o), 42.4 (e), 42.0 (e), 
15.4 (o), 15.3 (o); IR (neat): cm-1 3055 (w), 2971 (w), 2923 (w), 2901 (w), 1746 (s), 
1664 (s), 1586 (m), 1473 (w), 1455 (m), 1430 (m), 1395 (m), 1334 (w), 1282 (s), 1236 
(m), 1214 (m), 1189 (m), 1155 (m), 1135 (m), 1110 (m), 1072 (m), 1042 (w), 1025 
(w), 993 (w), 966 (w), 945 (w), 906 (w), 871 (w), 860 (w), 818 (m), 752 (s), 720 (m), 
698 (w), 686 (w), 662 (w); HRMS (CI (CH4)): m/z calcd for C18H14O2S+H+ [M+H]+ 
294.0715; found  295.0750.  
 
Compound 283. Synthesised according to representative procedure I, from compound 
277 (40 mg, 0.1 mmol) to afford compound 283 as an off white powder 
(21 mg, 0.06 mmol, 64%). M.p. = 143-145 oC; 1H NMR (500 MHz, 
CDCl3): δ 7.92 (dt, J = 0.8, 8.6 Hz, 1H), 7.78 (d, J = 8.3 Hz, 2H), 7.63 
(d, J = 3.7 Hz, 1H), 7.26-7.22 (m, 3H), 6.65 (dd, J = 0.9, 3.8 Hz, 1H), 
3.66 (q, J = 7.4 Hz, 1H), 3.62-3.59 (m, 2H), 2.35 (s, 3H), 1.49 (d, J = 7.5 Hz, 3H); 13C 
NMR (100 MHz, CDCl3): δ 217.7 (e), 145.0 (e), 135.5 (e), 135.2 (e), 134.5 (e), 130.9 
(e), 129.9 (o, 2C), 127.1 (o), 126.8 (o, 2C), 120.9 (o), 112.8 (o), 106.4 (o), 47.5 (o), 
42.8 (e), 21.6 (o), 15.7 (o); IR (neat): ~ = 3147 (w), 3113 (w), 3061 (w), 3027 (w), 
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2981 (w), 2940 (w), 2876 (w), 1745 (s), 1654 (w), 1594 (m), 1529 (w), 1489 (w), 1463 
(w), 1427 (m), 1363 (s), 1339 (m), 1295 (m), 1275 (m), 1241 (w), 1218 (w), 1178 (s), 
1155 (s), 1137 (s), 1118 (s), 1085 (m), 1063 (m), 1023 (m), 1016 (m), 987 (m), 907 
(w), 895 (m); 874 (w), 841 (w), 815 (m), 799 (m), 776 (m), 735 (m), 703 (m), 679 (s) 
cm-1; HRMS (ESI): m/z calcd for C19H17NO3S+Na+ [M+Na]+ 362.0821; found 
362.0821.  
 
Compound 284. Synthesised according to representative procedure I, from compound 
278 (30 mg, 0.11 mmol) to afford compound 284 as an off-white powder 
(14 mg, 0.07 mmol, 65%). M.p. = 105-107 oC; 1H NMR (500 MHz, 
CDCl3): δ 7.28-7.24 (m, 1H), 7.17 (d, J = 8.4 Hz, 1H), 7.11 (d, J = 3.1 
Hz, 1H), 6.46 (dd, J = 0.8, 3.1 Hz, 1H), 3.82 (s, 3H), 3.76 (q, J = 7.6 Hz, 
1H), 3.68-3.64 (m, 2H), 1.56 (d, J = 7.5 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ 
219.6 (e), 136.5 (e), 134.6 (e), 129.4 (o), 126.5 (e), 124.7 (e), 118.0 (o), 108.8 (o), 98.7 
(o), 47.8 (o), 43.1 (o), 33.0 (o), 15.5 (o); IR (neat): ~ = 3117 (w), 3096 (w), 2976 (w), 
2934 (w), 2901 (w), 2869 (w), 2824 (w), 1872 (w), 1735 (s), 1603 (w), 1508 (w), 1482 
(m), 1455 (w), 1442 (w), 1421 (s), 1396 (w), 1386 (w), 1365 (w), 1337 (m), 1300 (m), 
1287 (m), 1256 (m), 1239 (s), 1218 (m), 1176 (m), 1165 (m), 1146 (m), 1090 (m), 
1065 (w), 1020 (w), 999 (w), 978 (w), 940 (w), 923 (w), 897 (w), 872 (w), 799 (s), 
778 (s), 760 (w), 734 (s), 690 (w) cm-1; HRMS (CI (CH4)): m/z calcd for 
C13H13NO+H+ [M+H]+ 200.1070; found 200.1067. 
 
Compound 300. Synthesised according to represenatative procedure I, from 
compound 286 (240 mg, 0.66 mmol) to afford compound 300 as 
an amorphous white solid (152 mg, 0.57 mmol, 85%), alongside 
compound 301 (28 mg, 0.1 mmol, 15%). 1H NMR (500 MHz, 
CDCl3): δ 7.07 (s, 1H), 6.82 (s, 1H), 6.68 (q, J = 1.4 Hz, 1H), 6.17 (t, J = 3.6 Hz, 1H), 
6.15 (dd, J = 3.6, 1.5 Hz, 1H), 4.13 (t, J = 7.2 Hz, 1H), 3.93 (s, 3H), 3.92 (s, 3H), 3.89-
3.83 (m, 2H), 3.57 (t, J = 2.1 Hz, 2H), 2.89 (tt, J = 7.3, 2.5 Hz, 2H); 13C NMR (100 
MHz, CDCl3): δ 148.4 (e), 146.7 (e), 137.6 (e), 134.9 (e), 132.4 (e), 130.3 (e), 129.7 
(e), 121.1 (o), 108.7 (o), 108.2 (o), 103.4 (o), 102.0 (o), 56.4 (o), 56.2 (o), 44.1 (e), 
35.8 (e), 22.2 (e); IR (neat): ~ = 3096 (w), 3056 (w), 3002 (w), 2932 (w), 2905 (w), 
2834 (w), 1733 (w), 1703 (w), 1601 (w), 1580 (w), 1535 (w), 1515 (w), 1488 (s), 1463 
(s), 1431 (m), 1412 (w), 1382 (s), 1328 (s), 1313 (s), 1266 (s), 1229 (s), 1210 (s), 1189 
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(s), 1172 (s), 1144 (m), 1123 (s), 1086 (w), 1065 (s), 1047 (m), 1026 (m), 1002 (s), 
968 (w), 914 (w), 886 (w), 845 (m), 830 (m), 799 (w), 789 (w), 761 (w), 745 (w), 716 
(s), 680 (w), 661 (w) cm-1; HRMS (CI (CH4)): m/z calcd for C17H17NO2+H+ [M+H]+ 
268.1338; found 268.1441. 
 
Compound 301. 1H NMR (500 MHz, CDCl3): δ 6.82 (d, J = 8.2 Hz, 1H), 6.72 (dd, J 
= 2.0, 8.3 Hz, 1H), 6.69 (d, J = 2.0 Hz, 1H), 6.66 (dd, J = 1.9, 2.6 
Hz, 1H), 6.10 (t, J = 3.3 Hz, 1H), 6.06-6.05 (m, 1H), 4.25 (t, J = 
5.3 Hz, 2H), 3.90-3.88 (m, 1H), 3.86 (s, 3H), 3.85 (s, 3H), 3.76 
(d, J = 15.8 Hz, 1H), 2.46-2.39 (m, 1H), 2.33-2.26 (m, 1H); 13C 
NMR (100 MHz, CDCl3): δ 206.4 (e), 148.7 (e), 148.2 (e), 130.3 (e), 124.5 (e), 121.3 
(o), 120.5 (o), 111.9 (o), 111.0 (o), 108.4 (o), 107.3 (o), 56.7 (o), 55.81 (o), 55.79 (o), 
46.3 (e), 42.4 (e), 35.7 (e); IR (neat): ~ = 3101 (w), 2998 (w), 2916 (w), 2841 (w), 
1706 (m), 1594 (w), 1537 (m), 1518 (w), 1488 (w), 1449 (w), 1384 (m), 1353 (w), 
1328 (m), 1301 (m), 1283 (w), 1249 (m), 1236 (m), 1173 (s), 1136 (m), 1090 (m), 
1065 (w), 1024 (s), 958 (w), 883 (w), 857 (m), 822 (w), 800 (w), 762 (w), 722 (s), 680 
(w) cm-1; HRMS (ESI): m/z calcd for C17H19NO3+Na+ [M+Na]+ 308.1257; found 
308.1262. 
 
Compound 312. Synthesised according to representative procedure I, from compound 
306 (100 mg, 0.5 mmol) to afford compound 312 as a colourless oil (21 
mg, 0.07 mmol, 15%). 1H NMR (400 MHz, CDCl3): δ 6.74 (t, J = 2.2 
Hz, 2H), 6.33 (t, J = 2.2 Hz, 2H), 5.65 (s, 1H), 3.93 (hept, J = 5.7 Hz, 
1H, 2.34 (s, 3H); 13C NMR (100 MHz, CDCl3): δ 197.5, 121.6 (q, J = 285.8 Hz), 120.5 
(2C), 120.4 (q, J = 282.7), 111.7 (2C), 89.1, 71.1 (hept, J = 33.4 Hz), 25.9; 19F NMR 
(400 MHz, CDCl3): δ -72.2 (q, J = 9.1 Hz, 3F), -73.6 (q, J = 9.2 Hz, 3F); IR (neat): ~ 
= 3110 (w), 2937 (w), 1740 (m), 1568 (w), 1482 (w), 1419 (w), 1364 (m), 1277 (s), 
1220 (s), 1193 (s), 1117 (s), 1103 (s), 1088 (s), 1061 (w), 1034 (w), 959 (w), 907 (w), 
882 (w), 769 (w), 728 (s), 687 (s) cm-1; HRMS (CI (NH3)): m/z calcd for 
C10H9F6NO2+H+ [M+H]+ 290.0616; found 290.0620. 
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Compound 313. Synthesised according to representative procedure I, from compound 
307 (140 mg, 0.66 mmol) to afford compound 313 as a colourless oil 
(84 mg, 0.28 mmol, 42%). 1H NMR (500 MHz, CDCl3): δ  6.75 (t, J 
= 2.2 Hz, 2H), 6.30 (t, J = 2.2 Hz, 2H), 3.59 (sept, J = 5.9 Hz, 1H), 
2.40 (s, 3H), 1.93 (s, 3H); 13C NMR (100 MHz, CDCl3): δ 202.3 (e), 120.9 (q, J = 280 
Hz), 120.7 (q, J = 283 Hz), 119.6 (2C), 111.0 (2C), 93.5, 69.9 (hept, J = 33.7 Hz), 
25.3, 22.1; 19F NMR: -72.6 (q, J = 9.1 Hz, 3F), -73.0 (q, J = 9.4 Hz, 3F); IR (neat): ~ 
= 2944 (w), 1737 (s), 1477 (w), 1421 (w), 1359 (s), 1283 (s), 1258 (m), 1227 (s), 1194 
(s), 1101 (s), 1080 (s), 1044 (w), 1000 (w), 970 (w), 949 (w), 897 (s), 805 (w), 730 
(s), 687 (s), 687 (s), 663 (w) cm-1; HRMS (CI (NH3)): m/z calcd for C11H11F6NO2+H+ 
[M+H]+ 304.0767; found 304.0766. 
 
Compound 314: Synthesised according to representative procedure I, from compound 
308 (158 mg, 0.66 mmol) to afford compound 314 as a pale brown 
oil (97 mg, 0.29 mmol, 44%). 1H NMR (400 MHz, CDCl3): δ 6.76 
(t, J = 2.1 Hz, 2H), 6.32 (t, J = 2.1 Hz, 2H), 5.79-5.65 (m, 1H), 
5.26-5.16 (m, 2H), 3.24-3.01 (m, 3H), 2.36 (s, 3H); 13C NMR (100 
MHz, CDCl3): δ 202.1, 128.9, 121.3, 121.1 (q, J = 266.4 Hz), 121.0 (q, J = 284.1 Hz), 
120.0 (2C), 111.3 (2C), 95.5, 70.0 (hept, J = 33.7 Hz), 40.7, 27.2; 19F NMR (376 MHz, 
CDCl3): δ -72.8 (q, J = 10.1 Hz, 3F), -72.9 (q, J = 9.4 Hz, 3F); IR (neat): ~ = 3142 
(w), 3089 (w), 3018 (w), 2945 (w), 1728 (s), 1647 (w), 1586 (w), 1533 (w), 1475 (m), 
1441 (w), 1415 (m), 1358 (s), 1318 (w), 1287 (m), 1256 (s), 1226 (s), 1212 (s), 1195 
(s), 1164 (m), 1123 (s), 1095 (s), 1070 (s), 1024 (m), 987 (m), 955 (w), 938 (m), 896 
(s), 887 (s), 858 (w), 834 (w), 738 (s), 700 (m), 682 (s), 655 (s) cm-1; HRMS (CI 
(CH4)): m/z calcd for C13H13F6NO2+H+ [M+H]+ 330.0923; found 330.0938. 
 
Compound 315. Synthesised according to representative procedure I, from compound 
309 (182 mg, 0.66 mmol) to afford compound 315 as a purple liquid 
(135 mg, 0.37 mmol, 56%). 1H NMR (500 MHz, CDCl3): δ 7.61 (m, 
2H), 7.44 (m, 3H), 6.69 (s, 2H), 6.29 (m, 2H), 2.68 (hept, J= 6.0 Hz, 
1H), 2.25 (s, 3H); 13C NMR (100 MHz, CDCl3): δ 200.2, 135.2, 130.0, 
128.8 (2C), 127.1 (2C), 122.8 (2C), 121.4 (q, J = 278.8 Hz), 120.9 (q, J = 280.0 Hz), 
111.0 (2C), 96.9, 69.7 (hept, J = 33.6 Hz), 24.7; IR (neat): ~ = 3147 (w), 3098 (w), 
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3059 (w), 2948 (w), 1732 (s), 1698 (w), 1676 (w), 1592 (w), 1555 (w), 1523 (w), 1468 
(m), 14158 (w), 1357 (s), 1317 (w), 1289 (s), 1280 (s), 1255 (m), 1237 (s), 1218 (s), 
1189 (s), 1175 (s), 1117 (s), 1083 (s), 1060 (m), 1035 (w), 1009 (w), 976 (m), 906 (m), 
895 (s), 884 (s), 847 (w), 805 (w) cm-1; HRMS (ESI): m/z calcd for C16H13F6NO2+Na+ 
388.0743; found 388.0744. 
 
Compound 333. Synthesised according to representative procedure I, from compound 
321 (100 mg, 0.38 mmol) to afford compound 333 as an off-white 
solid (61 mg, 0.33 mmol, 87%). m.p.: 58–61 °C; 1H NMR (500 MHz, 
CDCl3): δ 7.53 (d, J = 8.0 Hz, 1H), 7.49 (d, J = 8.0, 1H), 7.33-7.26 
(m, 2H), 3.56-3.48 (m, 2H), 3.44 (d, J = 21.1 Hz, 1H), 1.46 (d, J = 7.4 Hz, 3H); 13C 
NMR (125 MHz, CDCl3): δ 214.0 (e), 160.5 (e), 157.5 (e), 125.2 (e), 124.0 (o), 123.2 
(o), 119.6 (e), 114.6 (e), 112.0 (o), 43.6 (e), 38.2 (e), 14.3 (o); IR (neat): ~ = 3040 (w), 
2960 (w), 2941 (w), 2917 (w), 1750 (s), 1728 (m), 1677 (w), 1616 (w), 1500 (w), 1479 
(w), 1445 (s), 1430 (m), 1415 (m), 1359 (w), 1312 (w), 1280 (w), 1227 (s), 1199 (w), 
1174 (m), 1145 (m), 1113 (m), 1078 (m), 1043 (s), 1013 (s), 996 (m), 959 (w), 934 
(w), 913 (w), 895 (w), 865 (w), 823 (w), 774 (w), 748 (vs), 726 (m), 711 (m) cm-1; 
HRMS (CI(CH4)): m/z calcd for C12H10O2+H+: 187.0754 [M+H]+; found 187.0750. 
Compound 334. Synthesised according to representative procedure I, from compound 
322 (50 mg, 0.19 mmol) to afford compound 334 as a cream-coloured 
amorphous solid (3.5 mg, 0.02 mmol, 13%) alongside compound 335 
as a cream-coloured solid (26 mg, 0.14 mmol, 75%). 1H NMR (500 
MHz, CDCl3): δ 7.56–7.46 (m, 2H), 7.34–7.21 (m, 2H), 3.66–3.54 (m, 
2H), 3.52 (d, J = 22.6 Hz, 1H), 1.15 (d, J = 7.3 Hz, 3H); 13C NMR (125 MHz, CDCl3): 
δ 214.0, 157.6 (e), 154.6 (e), 125.1 (e), 124.0 (o), 123.2 (o), 121.9 (e), 119.1 (o), 112.0 
(o), 45.1 (e), 38.3 (o), 15.5 (o); IR (neat): ~ = 3052 (w), 2992 (w), 2932 (w), 2904 (w), 
2873 (w), 1955 (w), 1914 (w), 1751 (w), 1622 (m), 1478 (w), 1445 (m), 1431 (w), 
1417 (w), 1369 (w), 1349 (m), 1308 (m), 1288 (w), 1263 (w), 1225 (m), 1188 (m), 
1167 (m), 1144 (m), 1132 (m), 1110 (m), 1056 (w), 1015 (w), 979 (m), 935 (w), 910 
(w), 859 (w), 828 (m), 761 (s), 752 (s), 723 (w), 703 (m), 688 (w), 656 (w) cm-1; 
HRMS (CI(CH4)): m/z calcd for C12H10O2+H+: 187.0754 [M+H]+; found 187.0751, 
 Page | 190  
 
Compound 335. m.p.: 75–77 °C; 1H NMR (500 MHz, CDCl3): δ 7.59 (dd, J = 7.7, 
1.1 Hz, 1H), 7.44-7.38 (m, 1H), 7.06 (td, J = 7.6, 1.0 Hz, 1H), 7.01-
6.97 (m, 1H), 5.53 (ddq, J = 5.9, 4.0, 2.6 Hz, 1H), 3.06 (dd, J = 16.2, 
5.8 Hz, 1H), 2.80 (dd, J = 16.4, 4.1 Hz, 1H), 1.99 (d, J = 2.8 Hz, 3H); 
13C NMR (125 MHz, CDCl3): δ 203.9 (e), 169.6 (e), 165.1 (e), 133.5 
(o), 130.3 (e), 124.5 (o), 122.3 (e), 122.0 (o), 112.1 (o), 85.6 (o), 44.1 (e), 8.6 (o); IR 
(neat): ~ = 3087 (w), 3056 (w), 3015 (w), 2990 (w), 2933 (w), 2908 (w), 1705 (s), 
1657 (s), 1603 (s), 1476 (w), 1453 (s), 1445 (s), 1411 (w), 1376 (m), 1346 (m), 1335 
(s), 1285 (s), 1270 (m), 1233 (m), 1208 (s), 1181 (w), 1155 (m), 1114 (m), 1100 (m), 
1057 (s), 1014 (w), 985 (m), 972 (s), 946 (m), 891 (m), 870 (w), 849 (m), 801 (m), 
767 (s), 756 (s), 731 (m), 691 (w), 655 (w) cm-1; HRMS (CI(CH4)): m/z calcd for 
C12H10O2+H+: 187.0754 [M+H]+; found 187.0752. 
Compounds 336 and 337. Synthesised according to representative procedure I, from 
compound 323 (100 mg, 0.36 mmol) to afford an inseparable mixture 
of compound 336 and 337 (30 mg, 0.15 mmol, 30%). 1H NMR (500 
MHz, CDCl3): δ 7.58 (dt, J = 8.0, 1.0 Hz, 1H, 337), 7.53 (d, J = 7.9 
Hz, 1H, 336), 7.35 (dt, J = 8.2, 0.9 Hz, 1H, 336), 7.31 (dt, J = 8.2, 0.8 
Hz, 1H, 337), 7.25-7.21 (m, 1H, both), 7.17-7.12 (m, 1H, both), 4.00 
(q, J = 7.1 Hz, 1H, 337), 3.78 (s, 3H, 337), 3.74 (s, 3H, 336), 3.67 (q, 
J = 7.4 Hz, 1H, 336), 3.56 (d, J = 22.0 Hz, 1H, 336), 3.50 (d, J = 21.9 
Hz, 1H, 336), 2.09 (s, 3H, 337), 1.49 (d, J = 7.3 Hz, 3H, both). 
Compound 336 was also synthesised under the iridium catalysed conditions, and full 
characterisation is described in the following section. 
Compound 338. Synthesised according to representative procedure I, from compound 
324 (40 mg, 0.1 mmol) to afford compound 338 as an off-white 
powder (16.1 mg, 0.05 mmol, 50%) alongside compound 339 as a 
pale pink powder (10 mg, 0.03 mmol, 31%). m.p.: 140–143 °C; 1H 
NMR (500 MHz, CDCl3): δ 8.11 (dt, J = 8.4, 0.9 Hz, 1H); 7.74 (d, J 
= 8.4 Hz, 2H); 7.44 (d, J = 7.8 Hz, 1H); 7.37-7.30 (m, 1H); 7.27 (dd, J = 7.7, 1.1 Hz, 
1H); 7.24 (d, J = 7.8 Hz, 2H); 3.78 (s, 2H); 3.52 (q, J = 7.4 Hz, 1H); 2.36 (s, 3H); 1.44 
(d, J = 7.3 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ 215.0 (e), 145.2 (e), 137.8 (e), 
135.6 (e), 135.3 (e), 130.1 (o, 2C), 126.7 (e), 126.6 (o, 2C), 125.5 (e), 124.5 (e), 123.7 
(o), 114.4 (o), 44.4 (o), 40.6 (e), 21.6 (o), 15.4 (o); IR (neat): ~ = 3054 (w), 2971 (w), 
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2911 (w), 1749 (s), 1594 (m), 1491 (w), 1478 (w), 1446 (m), 1417 (w), 1397 (w), 1364 
(s), 1345 (m), 1328 (m), 1303 (w), 1294 (w), 1266 (w), 1239 (m), 1218 (w), 1197 (W), 
1185 (s), 1164 (s), 1141 (m), 1120 (m), 1103 (w), 1086 (s), 1047 (m), 1008 (m), 955 
(w), 931 (w), 913 (m), 808 (m), 796 (m), 759 (m), 745 (s), 700 (w), 666 (s) cm-1; 
HRMS (ESI): m/z calcd for C19H17NO3S+Na+: 362.0821 [M+Na]+; found 362.0823.  
Compound 339. m.p.: 88–90 °C; 1H NMR (500 MHz, CDCl3): δ 7.86 (d, J = 8.4 Hz, 
1H), 7.78 (d, J = 8.2 Hz, 2H), 7.53 (d, J = 7.8 Hz, 1H), 7.49-7.43 (m, 
1H), 7.29 (d, J = 8.2 Hz, 2H), 7.15 (td, J = 7.6, 0.9 Hz, 1H), 4.65 (ddq, 
J = 5.8, 4.2, 2.7 Hz, 1H), 3.15 (dd, J = 17.2, 5.6 Hz, 1H), 2.96 (dd, J 
= 17.0, 4.2 Hz, 1H), 2.39 (s, 3H), 1.94 (d, J = 2.7 Hz, 3H); 13C NMR (100 MHz, 
CDCl3): δ 205.0 (e), 163.9 (e), 146.9 (e), 145.1 (e), 132.8 (o), 132.5 (e), 130.6 (e), 
130.0 (o, 2C), 127.8 (o, 2C), 124.8 (o), 124.4 (o), 115.6 (o), 66.0 (o), 45.1 (e), 21.6 
(o), 8.5 (o); IR (neat): ~ = 3675 (w), 2987 (m), 2901 (m), 1752 (w), 1704 (s), 1655 (s), 
1597 (m), 1492 (w), 1452 (s), 1412 (m), 1394 (w), 1375 (w), 1354 (s), 1335 (s), 1302 
(m), 1286 (m), 1273 (m), 1233 (s), 1203 (m), 1167 (s), 1155 (s), 1117 (s), 1104 (s), 
1081 (s), 1058 (s), 1038 (s), 1014 (s), 976 (w), 955 (m), 905 (m), 867 (w), 830 (w), 
914 (m), 814 (s), 763 (m), 742 (s), 705 (m), 656 (w), 661 (s) cm-1; HRMS (ESI): m/z 
calcd for C19H17NO3S+Na+: 362.0821 [M+Na]+; found 362.0826.  
Compound 396. Synthesised according to representative procedure I, from compound 
394 (199 mg, 0.66 mmol), to afford compound 396 as a pale brown 
amorphous solid (20.1 mg, 0.09 mmol, 14%) along with compound 397 
as a pale brown amorphous solid (54.6 mg, 0.24 mmol, 38%). 1H NMR 
(400 MHz, CDCl3): δ 8.68 (d, J = 4.9 Hz, 1H), 7.77 (td, J = 7.9, 2.0 Hz, 
1H), 7.57 (d, J = 4.1 Hz, 1H), 7.56 (d, J = 4.3 Hz, 1H), 7.42 (t, J = 7.5 
Hz, 1H), 7.34 (d, J = 7.5 Hz, 1H), 7.25-7.21 (m, 1H), 3.91 (d, J = 23.3 Hz, 1H), 3.81 
(d, J = 23.3 Hz, 1H), 3.54 (q, J = 7.6 Hz, 1H), 1.45 (d, J = 7.5 Hz, 1H). This compound 
was synthesised for preliminary results only, and so was not fully characterised. 
Compound 397. 1H NMR (400 MHz, CDCl3): δ 8.71 (d, J = 4.8 Hz, 1H), 7.96 (s, 1H), 
7.87 (d, J = 8.0 Hz, 1H), 7.80-7.72 (m, 2H), 7.41 (d, J = 8.0 Hz, 1H), 
7.26-7.21 (m, 1H), 3.66 (d, J = 22.6 Hz, 1H), 3.61-3.52 (m, 2H), 1.49 
(d, J = 7.5 Hz, 3H). This compound was synthesised for preliminary 
results only, and so was not fully characterised. 
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3.5 Iridium Catalysed Cyclisation of Sulfoxonium Ylides 
 
Representative Procedure J: To a flame dried microwave vial under N2 was added 
compound 306 (60 mg, 0.3 mmol, 1.0 equiv) and [Ir(cod)Cl]2 (2 mg, 0.003 mmol, 1 
mol%), and the vial was evacuated and backfilled with N2 three times. Dry 1,2-DCE 
(15 mL, 0.02 M)  was added, and the solution was degassed with an argon balloon for 
30 mins. The vial was then sealed and heated at 80 oC in the microwave (Anton Paar 
Microwave Synthesis Reactor Monowave 300) for 2 hours. The vial was cooled to rt 
under a stream of nitrogen, and the solvent was removed in vacuo. The residue was 
purified by FCC (petroleum ether/EtOAc =  9:1) to afford compound 341 as a dark 
green powder (27 mg, 0.22 mmol, 74%). 
 
Compound 341. 1H NMR (500 MHz, CDCl3): δ 6.77 (dd, J = 2.8, 1.2 Hz, 1H); 6.27 
(t, J = 3.1 Hz, 1H); 6.02 (dq, J = 3.5, 1.2 Hz, 1H); 4.40 (s, 2H); 3.54 (d, J 
= 1.0 Hz, 2H); 13C NMR (100 MHz, CDCl3): δ 209.6 (e), 130.2 (e), 115.4 
(o), 111.2 (o), 101.8 (o), 54.4 (e), 37.4 (e), in agreement with previously 
reported data33. 
 
Compound 342. Synthesised according to representative procedure J, from compound 
307 (64 mg, 0.3 mmol) to afford compound 342 as a dark green powder 
(26 mg, 0.19 mmol, 64%). m.p.: 46–48 °C; 1H NMR (500 MHz, CDCl3): 
δ 6.80-6.71 (m, 1H), 6.32-6.21 (m, 1H), 6.05-5.95 (m, 1H), 4.39 q, J = 6.9 
Hz, 1H), 3.62-3.45 (m, 2H), 1.54 (d, J = 7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ 
212.5 (e), 128.2 (e), 114.0 (o), 111.1 (o), 101.4 (o), 59.8 (o), 36.5 (e), 17.3 (o); IR 
(neat): ~ = 3500 (w), 3042 (w), 2998 (w), 2978 (w), 2934 (w), 2901 (w), 2873 (w), 
1755 (s), 1717 (w), 1625 (w), 1568 (w), 1551 (w), 1468 (w), 1455 (w), 1447 (w), 1399 
(w), 1366 (m), 1312 (m), 1294 (m), 1255 (s), 1229 (w), 1193 (w), 1181 (w), 1116 (w), 
1103 (w), 1073 (m), 1064 (m), 1032 (m), 1025 (m), 1003 (w), 977 (w), 937 (w), 904 
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(m), 898 (m), 874 (w), 857 (w), 815 (w), 770 (w), 724 (m), 704 (s) cm-1; HRMS 
(CI(CH4)): m/z calcd for C8H9NO+H+: 136.0757 [M+H]+; found 136.0762. 
 
Compound 340. Synthesised according to representative procedure J, from compound 
325 (28 mg, 0.1 mmol),  to afford compound 340 as a pale-pink 
powder (17 mg, 0.08 mmol, 85%). 1H NMR (500 MHz, CDCl3): δ 
7.51 (d, J = 7.6 Hz, 1H), 7.30 (d, J = 8.3 Hz, 1H), 7.25-7.20 (m, 1H), 
7.16-7.11 (m, 1H), 3.64–3.61 (m, 5H), 3.14-3.09 (m, 2H), 2.78 (t, J 
= 6.7 Hz, 2H); 13C NMR (125 MHz, CDCl3): δ 208.0 (e), 137.6 (e), 131.8 (e), 126.0 
(e), 121.4 (o), 119.3 (o), 118.0 (o), 108.4 (e), 39.5 (e), 37.5 (e), 29.2 (o), 19.8 (e); IR 
(neat): ~ = 3051 (w), 2978 (w), 2933 (w), 2856 (w), 1906 (w), 1871 (w), 1705 (s), 
1615 (w), 1586 (w), 1567 (w), 1470 (s), 1418 (w), 1375 (m), 1345 (w), 1314 (m), 1291 
(w), 1273 (w), 1239 (s), 1203 (w), 1178 (m), 1144 (w), 1129 (w), 1034 (m), 1010 (w), 
983 (w), 964 (w), 935 (w), 920 (w), 877 (w), 786 (w), 757 (s), 736 (s), 664 (w); 
elemental analysis calcd (%) for C13H13NO: C 78.36, H 6.58, N 7.03; found: C 78.30, 
H 6.60, N 6.98. 
 
Compound 344. Synthesised according to representative procedure J, from compound 
309 (28 mg, 0.10 mmol) to afford compound 344 as yellow gum (17 mg, 
0.08 mmol, 90%). 1H NMR (500 MHz, CDCl3): δ 7.39-7.33 (m, 3H), 7.10-
7.05 (m, 2H), 6.71 (dd, J = 2.7, 1.1 Hz, 1H), 6.35 (t, J = 3.1 Hz, 1H), 6.12 
(dq, J = 3.5, 1.1 Hz, 1H), 5.38 (s, 1H), 3.63 (s, 2H); 13C NMR (125 MHz, CDCl3): δ 
208.5 (e), 135.9 (e), 129.2 (e), 129.0 (o,, 128.6 (o), 126.2 (o,, 115.3 (o), 111.7 (o), 
101.6 (o), 68.1 (o), 36.2 (e); IR (neat): ~ = 3085 (w), 3068 (w), 3028 (w), 2901 (w), 
1956 (w), 1759 (s), 1601 (w), 1582 (w), 1555 (w), 1523 (w), 1495 (m), 1470 (m), 1454 
(m), 1438 (w), 1401 (m), 1350 (m), 1296 (m), 1279 (m), 1249 (m), 1222 (m), 1193 
(w), 1185 (m), 1129 (w), 1094 (m), 1078 (m), 1057 (m), 1030 (w), 1013 (w), 986 (w), 
967 (w), 934 (w), 901 (m), 845 (w), 826 (w), 781 (w), 770 (m), 759 (m), 740 (m), 724 
(s), 715 (m), 700 (s) cm-1; HRMS (CI(CH4)): m/z calcd for C13H11NO+H+: 198.0913 
[M+H]+; found 198.0922. 
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Compound 346. Synthesised according to representative procedure J, from compound 
310 (29 mg, 0.10 mmol) to afford compound 346 as purple gum (20 mg, 
0.09 mmol, 95%). 1H NMR (500 MHz, CDCl3): δ 7.26-7.20 (m, 3H), 6.99 
(dd, J = 6.4, 2.8 Hz, 2H), 6.50 (d, J = 1.9 Hz, 1H), 6.20 (t, J = 3.1 Hz, 
1H), 5.87-5.94 (m, 1H), 4.69-4.61 (m, 1H), 3.44-3.33 (m, 2H), 3.00-3.10 (m, 2H); 13C 
NMR (125 MHz, CDCl3): δ 211.7 (e), 135.1 (e), 129.2 (o, 2C), 128.7 (e), 128.3 (o, 
2C), 126.9 (o), 114.6 (o) , 110.8 (o), 101.1 (o), 65.0 (o) , 38.5 (o), 36.7 (o); IR (neat): 
~ = 3138 (w), 3113 (w), 3062 (w), 2901 (w), 1970 (w), 1758 (s), 1600 (w), 1585 (w), 
1552 (w), 1496 (w), 1468 (m), 1455 (m), 1403 (m), 1380 (w), 1343 (w), 1295 (m), 
1267 (w), 1250 (m), 1214 (w), 1187 (m), 1166 (m), 1128 (w), 1085 (m), 1052 (m), 
1028 (w), 1010 (w), 998 (w), 974 (w), 946 (w), 921 (w), 871 (w), 853 (m), 836 (w), 
779 (m), 765 (m), 747 (m): 715 (s): 700 (s) cm-1; HRMS (CI(CH4)): m/z calcd for 
C14H13NO+H+: 212.1070 [M+H]+; found 212.1080. 
 
 Compound 348. Synthesised according to representative procedure J, from 
compound 311 (91 mg, 0.3 mmol) using 2.5 mol% of [Ir(cod)Cl]2 at 
100 °C to afford compound 348 as yellow oil (54 mg, 0.24 mmol, 
79%).1H NMR (500 MHz, CDCl3): δ 7.29-7.26 (m, 2H), 7.22-7.18 (m, 
1H), 7.14-7.12 (m, 2H), 6.80 (dd, J = 2.7, 1.2 Hz, 1H), 6.32-6.30 (m, 
1H), 6.04-6.02 (m, 1H), 4.39 (td, J = 5.4, 1.0 Hz, 1H), 3.52 (d, J = 22.9 Hz, 1H), 3.39 
(dt, J = 22.8, 1.1 Hz, 1H), 2.67-2.56 (m, 2H), 2.35-2.24 (m, 2H); 13C NMR (125 MHz, 
CDCl3): δ 212.4 (e), 140.2 (e), 129.0 (e), 128.48 (o, 2C), 128.50 (o, 2C), 126.3 (o), 
114.4 (o), 111.4 (o), 101.6 (o), 63.5 (o), 37.1 (e), 33.9 (e), 30.6 (e); IR (neat): ~ = 3026 
(w), 2923 (w), 1759 (s), 1602 (w), 1558 (w): 1496 (w), 1470 (m), 1454 (m), 1403 (m), 
1403 (m), 1257 (m), 1193 (w), 1180 (w), 1099 (m), 1080 (w), 1058 (m), 1029 (w), 
903 (m), 846 (w), 776 (m), 748 (m), 699 (s) cm-1; HRMS (CI(CH4)): m/z calcd for 
C15H15NO+H+: 226.1226 [M+H]+; found 226.1232. 
 
Compound 297. Synthesised according to representative procedure J, from compound 
285 (105 mg, 0.3 mmol) to afford compound 297 as pale-brown 
amorphous solid (76 mg, 0.28 mmol, 94%).1H NMR (500 MHz, 
CDCl3): δ 6.81 (d, J = 8.3 Hz, 1H), 6.69 (br s, 1H), 6.61 (dd, J = 
8.3, 2.2 Hz, 1H), 6.41 (d, J = 2.1 Hz, 1H), 6.19 (t, J = 3.2 Hz, 1H), 
6.00 (d, J = 2.8 Hz, 1H), 4.49 (dd, J = 13.1, 5.4 Hz, 1H), 4.39 (dd, J = 13.1, 7.2 Hz, 
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1H), 3.87-3.74 (m, 3H), 3.85 (s, 3H), 3.78 (s, 3H); 13C NMR (125 MHz, CDCl3): δ 
205.6 (e), 149.2 (e), 148.6 (e), 128.4 (e), 124.8 (e), 120.4 (o), 119.6 (o), 111.4 (o), 
111.0 (o), 108.8 (o), 106.0 (o), 55.84 (o), 55.81 (o), 55.1 (o), 48.8 (e), 37.8 (e); IR 
(neat): ~ = 3135 (w), 3007 (w), 2967 (w), 2938 (w), 2876 (w), 2841 (w), 1724 (s), 
1633 (w), 1605 (w), 1592 (w), 1550 (w), 1515 (s), 1487 (m), 1464 (m), 1445 (m), 1418 
(w), 1400 (w), 1373 (w), 1345 (w), 1328 (w), 1299 (w), 1275 (s), 1245 (s), 1235 (s), 
1223 (s), 1187 (m), 1162 (m), 1143 (s), 1128 (m), 1067 (w), 1021 (s), 982 (w), 945 
(w), 925 (w), 886 (w), 849 (m), 831 (w), 814 (m): 793 (w), 780 (w), 763 (w), 719 (s) 
cm-1; HRMS (ESI): m/z calcd for C16H17NO3+Na+: 294.1101 [M+Na]+; found 
294.1102.                 
Compound 301. Synthesised according to representative procedure J from compound 
286 (109 mg, 0.3 mmol) to afford compound 301 as pale-brown 
amorphous solid (77 mg, 0.27 mmol, 90%).1H NMR (500 MHz, 
CDCl3): δ 6.82 (d, J = 8.2 Hz, 1H), 6.72 (dd, J = 8.3, 2.0 Hz, 1H), 
6.69 (d, J = 2.0 Hz, 1H), 6.66 (dd, J = 2.6, 1.9 Hz, 1H), 6.10 (t, J 
= 3.3 Hz, 1H), 6.06-6.05 (m, 1H), 4.28–4.22 (m, 2H), 3.92-3.86 (m, 2H), 3.86 (s, 3H), 
3.85 (s, 3H), 3.76 (d, J = 15.8 Hz, 1H), 2.46-2.39 (m, 1H), 2.33-2.26 (m, 1H). 
Compound 301 was also synthesised by the HFIP mediated electrocyclisation, and full 
characterisation was described in the previous section. 
 Compound 299. Synthesised according to representative procedure J, from 
compound 287 (95 mg, 0.3 mmol) using 5 mol% of [Ir(cod)Cl]2 to 
afford compound 296 as pale-brown amorphous solid (40 mg, 0.17 
mmol, 56%). 1H NMR (500 MHz, CDCl3): δ 7.32-7.27 (m, 2H), 7.25-
7.20 (m, 3H), 6.69–6.65 (m, 1H), 6.22 (t, J = 3.0 Hz, 1H), 6.08–6.04 
(m, 1H), 4.08 (ddd, J = 15.3, 8.2, 2.7 Hz, 1H), 3.83 (ddd, J = 15.4, 7.9, 3.1 Hz, 1H), 
3.80 (s, 2H), 3.75 (dd, J = 11.1, 2.7 Hz, 1H), 2.14-2.05 (m, 1H), 2.04-1.87 (m, 2H), 
1.82-1.72 (m, 1H); 13C NMR (100 MHz, CDCl3): δ 211.2 (e), 140.1 (e), 128.4 (o, 2C), 
128.0 (o, 2C), 127.0 (o), 126.3 (e), 121.2 (o), 108.9 (o), 108.6 (o), 55.6 (o), 45.9 (e), 
41.6 (e), 32.2 (e), 30.6 (e); IR (neat): ~ = 2927 (w), 1707 (s), 1600 (w), 1484 (m), 1452 
(m), 1398 (w), 1352 (w), 1304 (m), 1277 (w), 1208 (w), 1102 (w), 1075 (m), 1030 
(w), 971 (w), 939 (w), 910 (w), 878 (w), 826 (w), 795 (m); 758 (m), 698 (s) cm-1; 
HRMS (ESI): m/z calcd for C16H17NO+Na+: 262.1208 [M+Na]+; found 262.1209. 
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Compound 355. Synthesised according to representative procedure J from compound 
351 (41 mg, 0.1 mmol) using 5 mol% of [Ir(cod)Cl]2 for 3 
hours to afford compound 355 as a purple powder (20.5 mg, 
0.06 mmol, 61%). m.p.: 115–116 °C; 1H NMR (500 MHz, 
CDCl3): δ 6.49 (d, J = 3.9 Hz, 1H), 6.07 (d, J = 3.8 Hz, 1H), 4.67 (s, 2H), 3.89–3.71 
(m, 4H), 3.52-3.49 (m, 6H), 1.48 (s, 9H); 13C NMR (100 MHz, CDCl3): δ 208.7 (e), 
162.2 (e), 154.6 (e), 134.4 (e), 121.6 (e), 115.4 (o), 102.7 (o), 80.3 (e), 55.9 (e), 44.9 
(e)*, 43.8 (e)*, 37.2 (e), 28.4 (o, 3C) (peaks marked by an asterisk are very broad due 
to slow rotation of Boc group); IR (neat): ~ = 2978 (w), 2903 (w), 1766 (s), 1690 (s), 
1617 (s), 1552 (w), 1475 (s), 1409 (s), 1368 (m), 1283 (m), 1242 (s), 1164 (s), 1132 
(s), 1069 (m), 1041 (m), 995 (m), 977 (m), 862 (m), 839 (w), 822 (w), 809 (w), 767 
(m), 735 (s), 669 (w) cm-1; HRMS (ESI): m/z calcd for C17H23N3O4+Na+: 356.1581 
[M+Na]+; found 356.1585. 
 
Compound 359. Synthesised according to representative procedure J, from compound 
358 (118 mg, 0.3 mmol) using 2.5 mol% [Ir(cod)Cl]2 at 100 oC for 
3 h to afford compound 359 as a turquoise solid (80.3 mg, 0.26 
mmol, 85%). [α]D = -61.28 (MeOH, l = 0.25 dm, c = 8.6); Chiral 
HPLC analysis (Chiralpak AD-H), 10% isopropanol/hexane  at 
0.75 mL/min. flow rate, 254 nm; tR (major) 28.29 min., tR (minor) 23.32 min., 57% 
enantiomeric excess; 1H NMR (500 MHz, CDCl3): δ 7.49 (d, J= 7.9 Hz, 1H), 7.29 (d, 
J= 8.2 Hz, 1H), 7.23 (t, J= 7.3 Hz, 1H), 7.13 (t, J= 7.4 Hz, 1H), 5.61 (br s, 1H), 4.72 
(q, J = 7.4 Hz, 1H), 3.86-3.81 (m, 2H), 3.73 (d, J= 19.7 Hz, 1H), 3.63 (s, 3H), 2.70 (t, 
J= 12.2 Hz, 1H), 1.49 (s, 9H); 13C NMR (125 MHz, CDCl3): δ 204.0 (e), 155.4 (e), 
137.7 (e), 130.2 (e), 125.9 (e), 121.7 (o), 119.6 (o), 109.0 (o), 106.4 (e), 79.9 (e), 57.3 
(o), 37.5 (e), 28.4 (o, 3C), 28.2 (e); IR (neat): ~ = 3368 (w), 2974 (w), 2928 (w), 2869 
(w), 1737 (s), 1686 (s), 1616 (w), 1584 (w), 1569 (w), 1510 (s), 1471 (s), 1443 (m), 
1409 (w), 1394 (w), 1365 (m), 1338 (m), 1308 (w), 1290 (m), 1235 (s), 1170 (s), 1156 
(s), 1114 (w), 1076 (m), 1046 (m), 1010 (m), 1001 (m), 917 (w), 865 (w), 838 (w), 
826 (m), 780 (m), 736 (s), 695 (w) cm-1; HRMS (ESI): m/z calcd for C18H22N2O3+Na+ 
[M+Na]+ 337.1527; found 337.1523. 
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Compound 336. Synthesised according to representative procedure J from compound 
323 (83 mg, 0.3 mmol) using 2.5 mol% of [Ir(cod)Cl]2 at 100 °C to 
afford compound 336 as cream-coloured solid (49 mg, 0.25 mmol, 
82%). m.p.: 91–93 °C; 1H NMR (500 MHz, CDCl3): δ 7.53 (d, J = 7.9 
Hz, 1H), 7.35 (dt, J = 8.2, 0.9 Hz, 1H), 7.25-7.21 (m, 1H), 7.17-7.12 
(m, 1H), 3.74 (s, 3H), 3.67 (q, J = 7.4 Hz, 1H), 3.56 (d, J = 22.0 Hz, 1H), 3.50 (d, J = 
21.9 Hz, 1H), 1.49 (d, J = 7.3 Hz, 3H); 13C NMR (125 MHz, CDCl3): δ 216.5 (e), 
139.2 (e), 137.6 (e), 124.2 (e), 121.3 (o), 119.6 (o), 118.6 (o), 117.4 (e), 109.6 (o), 45.3 
(o), 37.4 (e), 31.1 (o), 16.4 (o); IR (neat): ~ = 3048 (w), 2973 (w), 2931 (w), 2896 (w), 
2858 (w), 2827 (w), 1739 (s), 1612 (w), 1558 (w), 1484 (m),1469 (m), 1448 (w), 1420 
(w), 1402 (w), 1382 (m), 1264 (w), 1226 (m), 1182 (w), 1143 (w), 1132 (w), 1113 
(w), 1070 (w), 1060 (w), 1011 (m), 958 (w), 930 (w), 904 (w), 856 (w), 805 (w), 746 
(s), 669 (w) cm-1; HRMS (CI(CH4)): m/z calcd for C13H13NO+H+: 200.1070 [M+H]+; 
found 200.1077. 
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Compound 368: Synthesised according to representative procedure J from compound 
366 (68 mg, 0.3 mmol) to afford compound 368 as a slightly yellow 
solid (23.3 mg, 0.16 mmol, 53%). 1H NMR (400 MHz, CDCl3): δ 7.32-
7.22 (m, 2H), 7.04 (t, J = 7.06 Hz, 1H), 6.82 (d, J = 8.23 Hz, 1H), 3.52 
(s, 2H), 3.21 (s, 3H); HRMS (CI(CH4)): m/z calcd for C9H9NO+H+ [M+H]+ 148.0757; 
found 148.0757, in agreement with previously reported data34. 
 
Compound 115. Synthesised according to representative procedure J, from compound 
220 (75 mg, 0.3 mmol) to afford compound 115 as a pale yellow liquid 
(42.3 mg, 0.25 mmol, 82%). 1H NMR (500 MHz, CDCl3): δ 7.34-7.27 (m, 
3H), 7.23-7.15 (m, 2H), 3.58-3.53 (m, 1H), 2.80-2.70 (m, 1H), 2.37-2.31 
(m, 1H),  2.13-2.04 (m, 1H), 1.97-1.92 (m, 1H), 1.19-1.11 (m, 1H), 1.01-0.96 (m, 1H), 
in agreement with previously reported data32. 
 
Compound 371. Synthesised according to representative procedure J from compound 
308 (72 mg, 0.3 mmol) to afford compound 371 as a dark green amorphous 
solid (26.2 mg, 0.16 mmol, 54%) alongside compound 323 as a dark green 
oil (18.9 mg, 0.12 mmol, 39%). (500 MHz, CDCl3): δ 6.82-6.78 (m, 1H), 
6.26 (t, J = 3.2 Hz, 1H), 6.03-5.98 (m, 1H), 5.70-5.57 (m, 1H), 5.18-5.09 (m, 2H), 4.42 
(t, J = 5.5 Hz, 1H), 3.53 (d, J = 22.8 Hz, 1H), 3.43 (d, J = 22.7 Hz, 1H), 2.84-2.76 (m, 
1H), 2.66-2.55 (m, 1H); 13C NMR (125 MHz, CDCl3): δ 211.8 (e), 131.6 (o), 128.8 
(e), 119.7 (e), 114.7 (o), 111.1 (o), 101.4 (o), 63.8 (o), 37.1 (e), 36.6 (e); IR (neat): ~ 
= 3080 (w), 2905 (w), 1761 (s), 1642 (w), 1559 (w), 1470 (m), 1435 (w), 1404 (w), 
1337 (w), 1296 (m), 1276 (w), 1250 (w), 1213 (w), 1180 (w), 1092 (w), 1055 (w), 996 
(w), 923 (m), 773 (w), 701 (s); HRMS (CI (NH3)): m/z calcd for C10H11NO+H+ 
[M+H]+ 162.0913; found 162.0916. 
 
Compound 372. 1H NMR (500 MHz, CDCl3): δ 6.65 (t, J = 2.1 Hz, 2H), 6.23 (t, J = 
2.1 Hz, 2H), 3.19 (dd, J = 18.8, 7.5 Hz, 1H), 2.68-2.62 (m, 2H), 2.51-
2.45 (m, 2H), 1.41-1.34 (m, 1H), 1.28-1.23 (m, 1H); 13C NMR (125 
MHz, CDCl3): δ 208.3 (e), 120.0 (o, 2C), 108.5 (o, 2C), 59.3 (o), 30.6 
(e), 25.2 (o), 19.9 (o), 14.8 (e), IR (neat): ~ = 3099 (w), 2937 (w), 1734 (s), 1688 (s), 
1618 (m), 1514 (w), 1492 (s), 1451 (w), 1426 (w), 1384 (w), 1329 (w), 1309 (w), 1285 
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(s), 1253 (w), 1221 (w), 1205 (w), 1190 (w), 1124 (w), 1092 (s), 1068 (m), 1037 (w), 
1015 (w), 997 (w), 975 (w), 948 (w), 926 (w), 881 (w), 843 (w), 829 (w), 781 (w), 766 
(w), 718 (vs), 665 (w); HRMS (CI (CH4)): m/z calcd for C10H11NO+H+ [M+H]+ 
162.0913; found 162.0921. 
 
Compound 376: Synthesised according to representative procedure J from compound 
375 (50 mg, 0.2 mmol) to afford compound 376 as a colourless oil (9.0 
mg, 0.05 mmol, 26%) along with compound 377 as a pale brown 
amorphous solid (25.1 mg, 0.14 mmol, 74%). 1H NMR (400 MHz, 
CDCl3): δ 3.56 (s, 2H), 4.27-4.29 (m, 2H), 5.20-5.27 (m, 2H), 5.79-5.89 (m, 1H), 6.80 
(d, J = 8.2 Hz, 1H), 7.03 (t, J = 7.3 Hz, 1H), 7.21-7.25 (m, 2H); in agreement with 
previously reported data34. 
 
Compound 377. 1H NMR (500 MHz, CDCl3): δ 7.52 (d, J = 7.8 Hz, 2H), 7.31-7.36 
(m, 2H), 7.11 (tt, J = 7.7, 1.5 Hz, 1H), 4.05 (dd, J = 5.8, 10.0 Hz, 1H), 
3.75 (dd, J = 1.5, 10.0 Hz, 1H), 2.13-2.07 (m, 1H), 2.02-1.95 (m, 1H), 
1.23-1.17 (m, 1H), 0.80 (q, J = 4.3 Hz, 1H); 13C NMR (100 MHz, CDCl3): 
δ 174.3 (e), 139.4 (e), 128.8 (o, 2C), 124.2 (o), 119.7 (o, 2C), 50.3 (e), 21.7 (o), 12.7 
(e), 11.3 (o);  IR (neat): ~ = 3081 (w), 3063 (w), 3008 (w), 2965 (w), 2939 (w), 2889 
(w), 1679 (s), 1597 (s), 1584 (s), 1494 (s), 1481 (s), 1457 (w), 1443 (w), 1390 (s), 
1353 (m), 1320 (s), 1284 (s), 1233 (s), 1219 (m), 1179 (w), 1171 (w), 1157 (w), 1145 
(m), 1097 (w), 1075 (w), 1054 (m), 1025 (s), 1008 (m), 997 (w), 963 (m), 910 (w), 
895 (w), 835 (m), 828 (m), 808 (m), 769 (s), 744 (s), 690 (s), 662 (s) cm-1; HRMS (CI 
(NH3)): m/z calcd for C11H11NO+H+ [M+H]+ 174.0913; found 174.0920. 
 
Compound 385. Synthesised according to representative procedure J from compound 
381 (75 mg, 0.30 mmol), to afford compound 385 as a pale-brown 
powder (42 mg, 0.25 mmol, 82%). 1H NMR (500 MHz, CDCl3): δ 
7.63 (d, J = 7.9 Hz, 1H), 7.26-7.19 (m, 2H), 7.18-7.13 (m, 1H), 6.38 
(q, J = 1.1 Hz, 1H), 4.46 (s, 2H), 3.71 (s, 2H); 13C NMR (100 MHz, CDCl3): δ 208.6 
(e), 136.5 (e), 133.5 (e), 130.5 (e), 121.5 (o), 120.8 (o), 120.3 (o), 109.6 (o), 95.7 (o), 
52.2 (e), 37.5 (e), HRMS (CI(CH4)): m/z calcd for: C11H9NO+H+ [M+H]+ 172.0757; 
found 172.0765, in agreement with previously reported data35. 
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Compound 413. Synthesised according to representative procedure J, from compound 
412 (83 mg, 0.3 mmol) to afford compound 413 as a dark green solid (7.7 
mg, 0.03 mmol, 13%) along with compound 414 as a dark green solod (4.2 
mg, 0.02 mmol, 7%). 1H NMR (400 MHz, CDCl3): δ 8.54 (d, J = 4.9 Hz, 
1H), 7.65 (t, J = 7.7 Hz, 1H), 7.47 (d, J = 7.6 Hz, 1H), 7.30-7.24 (m, 1H), 
7.08 (t, J = 6.7 Hz, 1H), 6.77 (d, J = 8.7 Hz, 1H), 4.59 (s, 2H), 3.49 (s, 2H). This 
compound was synthesised for preliminary results only, so was not fully characterised. 
 
Compound 414. 1H NMR (400 MHz, CDCl3): δ 8.52 (d, J = 4.9 Hz, 1H), 7.65 (t, J = 
7.8 Hz, 1H), 7.44 (d, J = 7.0 Hz, 1H), 7.30-7.25 (m, 1H), 6.80 (s, 1H), 6.06 
(s, 1H), 4.65 (s, 2H), 3.66 (s, 2H). This compound was synthesised for 
preliminary results only, and so was not fully characterised. 
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